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Abstract 
 
Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder 
associated with the Philadelphia chromosome (Ph) that arises from a reciprocal 
translocation between chromosomes 9 and 22, thereby resulting in the formation of the 
chimeric BCR-ABL oncogene encoding a constitutively activated tyrosine kinase. BCR-
ABL tyrosine kinase inhibitors (TKIs) induce a complete hematologic and cytogenetic 
response in the majority of chronic phrase CML patients. However, TKIs cannot 
efficiently eradicate leukemia stem cells (LSCs) because of the insensitivity of LSCs to 
TKIs. Therefore, developing new strategies to target LSCs is necessary and critical for 
curing CML, and success of this approach depends on further understanding the 
molecular mechanisms by which LSCs survive and are maintained. 
In Chapter I, I briefly introduce CML disease, BCR-ABL oncoprotein, and TKIs.  
I also describe the identification and features of LSCs. Several key pathways in LSCs 
including Wnt/ß-catenin, hedgehog, FoxO, Bcl6 and HIF1, are discussed.  I also propose 
our strategy to identify unique molecular pathways that are important for LSCs but not 
their normal stem cell counterparts. 
In Chapter II, I describe our finding about the function of the positive regulator, 
HIF1α, in CML development and LSC survival. I show that loss of HIF1α impairs the 
maintenance of CML through impairing cell cycle progression and inducing apoptosis of 
LSCs, and I also report that p16Ink4a and p19Arf mediate the effect of HIF1α on LSCs, as 
knockdown of p16Ink4a and p19Arf rescues the defective colony-forming ability of HIF1α-/- 
LSCs. 
  v 
As detailed in Chapter III and IV, through comparing the global gene expression 
profiles of LSCs and HSCs, I find two novel regulators, Blk and Scd1, which act as 
tumor suppressors in CML development. In Chapter III, I show that Blk is markedly 
down-regulated by BCR-ABL in LSCs, and that c-Myc and Pax5 mediate this down-
regulation. Deletion of Blk accelerates CML development; conversely, Blk 
overexpression significantly delays the development of CML and impairs the function of 
LSCs. I also demonstrate that p27, as a downstream effector, is involved in the function 
of Blk in LSCs. Blk also functions as a tumor suppressor in human CML stem cells, and 
inhibits the colony-forming ability of human CML cells. In Chapter IV, I investigate the 
function of another negative regulator, Scd1, in CML LSCs, and find that expression of 
Scd1 is down-regulated in mouse LSCs and human CML cells. We report that Scd1 acts 
as a tumor suppressor in CML, as loss of Scd1 causes acceleration of CML development 
and overexpression of Scd1 delays CML development. Using a colony-forming assay, I 
demonstrate that Scd1 impairs the maintenance of LSCs due to the change of expression 
of Pten, p53 and Bcl2. Importantly, I find that both Blk and Scd1 do not affect normal 
hematopoietic stem cells (HSCs) or hematopoiesis. 
Taken together, our findings demonstrate that HIF1α is required for the 
maintenance of CML LSCs, and conversely that Blk and Scd1 suppress the function of 
LSCs, suggesting that combining TKI treatment with specific targeting of LSCs will be 
necessary for curing CML. 
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CHAPTER I 
INTRODUCTION 
 
1. Chronic myeloid leukemia and the Philadelphia chromosome 
Chronic myeloid leukemia (CML) is a myeloproliferative disease that originates 
from an abnormal hematopoietic stem cell (HSC) harboring the Philadelphia (Ph) 
chromosome (Figure 1A)1-3. CML is a rare disease with an incidence of 1 or 2 cases per 
100,000 people every year in United States4. It occurs most commonly in the middle-
aged and elderly, and accounts for 15-20% of all cases of adult leukemia4. In general, 
CML has three distinct clinical stages: the initial indolent chronic phase, the accelerated 
phase and the blast crisis1,4. The chronic phase is characterized by the accumulation of 
myeloid precursors in the bone marrow and mature granulocytes in peripheral blood4. 
The accelerated phase is characterized by an increase in disease burden and in the 
frequency of progenitor cells. Blast crisis is characterized by arrested hematopoietic 
differentiation and the accumulation of immature blast cells resembling acute leukemia4. 
About 70% of CML patients develop acute myeloblastic leukemia (AML), and 
approximately 20-30% develop acute lymphoblastic leukemia (ALL)1.  
The discovery of the Philadelphia chromosome by Nowell and Hungerford in 
1960 through analyzing leukemic cells from seven chronic phase CML patients5, 
provided a major clue to the pathogenesis of CML. This chromosomal abnormality is 
generated by a reciprocal translocation between chromosome 9 and 22 [t (9; 22)(q34; 
q11)], which results in the formation of the chimeric BCR-ABL protein that functions as 
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a constitutively active tyrosine kinase1,6. This aberrant BCR-ABL oncoprotein constitutes 
the molecular basis of CML.  
 
2. BCR-ABL oncoprotein 
The product of the Philadelphia chromosome was identified by diverse 
experimental approaches7-10, showing that the ABL proto-oncogene on chromosome 9 
translocates into the 5’ sequence of the breakpoint cluster region (BCR) gene on 
chromosome 22, thereby generating the fusion oncogene BCR-ABL, which encodes the 
BCR-ABL oncoprotein7,9. Furthermore, advances in chromosome mapping and molecular 
biology enabled the discovery of additional forms of BCR-ABL, including p185BCR-ABL, 
p210BCR-ABL, and p230BCR-ABL, which are generated due to different breakpoints in the 
BCR gene (Figure 1B)8. The first breakpoint is the minor breakpoint cluster (m-bcr), 
which results in a smaller 7.0 kb mRNA that generates p185BCR-ABL; the major breakpoint 
cluster (M-bcr) results in an 8.5 kb mRNA encoding p210BCR-ABL; another minor 
breakpoint is µ-bcr which exists at the end of the BCR gene and generates an 9.0 kb 
mRNA coding for p230BCR-ABL1,8. It is known that these distinct forms are associated with 
relatively specific human leukemias: p185BCR-ABL is mainly associated with 66% of adult 
B-ALL1; the majority of CML cases are caused by p210BCR-ABL; p230BCR-ABL is mainly 
identified in neutrophilic CML as well as some CML cases1. 
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Figure 1. The Philadelphia chromosome and three different forms of the chimeric 
BCR-ABL oncogene. (A) Schematic diagram of the Philadelphia chromosome. CML 
originates from an abnormal hematopoietic stem cell harboring the Philadelphia 
chromosome, resulting from reciprocal translocation between chromosome 9 and 
chromosome 22, which generates the fusion oncogene BCR-ABL (Modified from ref. 3 
and http://www.cancer.gov/cancertopics/pdq/treatment/CML/Patient/page1). (B) Three 
distinct forms of the chimeric BCR-ABL oncogene formed due to the different 
breakpoints in the BCR gene1. 
 
       
ABL kinase belongs to the non-receptor tyrosine kinase family and has three 
highly conserved domains, including an SRC-homology 3 (SH3), an SH2 and a tyrosine 
kinase domain6. In the carboxy-terminus, ABL has an actin binding domain (ABD), a 
DNA binding domain (DBD), three nuclear localization signals (NLSs), and four proline-
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rich SH3 binding sites (PPs)6. These domains assemble ABL into a dynamic protein that 
can switch between inactive and active conformations6. The N-terminal myristoyl group 
or hydrophobic residues in the cap domain of ABL bind to the deep hydrophobic pocket 
in the kinase domain, which contributes to the maintenance of an inactive conformation 
of ABL11. Previous studies demonstrated that loss of myristoylation in ABL dramatically 
increased the tyrosine kinase activity of ABL by promoting the switch of an inactive 
conformation to an active state11,12. These findings suggested that myristoylation of ABL 
inhibits its kinase activity. The latching of the N terminus of ABL to its kinase domain 
places the SH3 and SH2 domains on the backside of the small and large lobes of the 
tyrosine kinase domain respectively, resulting in the clamping of these structures and 
stabilization of the inactive conformation of ABL1. This was confirmed by the findings 
that mutations in the SH3/SH2 regions abolished the clamping and resulted in the 
activation of ABL13.  Additionally, the activation loop of the kinase domain is 
sequestered in this clamping structure, thus preventing the phosphorylation of tyrosine 
412 that is required for full activation of the kinase6. Therefore, the crystal structure of 
ABL implies that disruption of these inhibitory processes might be the mechanism by 
which chimeric oncoprotein BCR-ABL attains constitutive kinase activity6.  
As a component of the fusion protein, BCR is a serine/threonine kinase protein6. 
BCR contains several domains, including a coiled-coil (CC) oligomerization domain, A 
and B boxes, a serine/threonine kinase domain, a Dbl/CDC24 guanine-nucleotide 
exchange factor homology domain, a pleckstrin homology domain, a putative calcium-
dependent lipid binding site (CaLB) and a RAC guanosine triphosphatase-activating 
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protein (RAC-GAP) domain6. These domains have been shown to activate tyrosine 
kinase activity and increase the transforming capability of BCR-ABL14,15. First, the CC 
oligomerization domain of BCR contributes to the activation of BCR-ABL14. McWhirter 
et al. demonstrated that disruption of the CC oligomerization domain of BCR by 
insertional mutagenesis inactivates the kinase activity and the transformation ability of 
BCR-ABL14. This finding suggested that the CC oligomerization domain of BCR 
correlates with the activation of the tyrosine kinase of BCR-ABL. Mice transplantation 
experiments also showed that mutant BCR-ABL without the BCR CC domain failed to 
induce myeloid leukemia, suggesting a critical role for this domain15. Second, the A and 
B boxes are required for BCR-ABL activation and cellular transformation16,17, as 
perturbations through deletions or substitutions can disrupt their binding to the SH2 
domain of ABL, which is required for maintaining BCR-ABL in an active 
conformation16,17. Additionally, previous data also showed that 
phosphoserine/phosphothreonine but not phosphotyrosine residues on BCR are required 
for interaction with the ABL SH2 domain17. Therefore, BCR encoded domains activate 
the tyrosine kinase and the transforming potential of BCR-ABL through specifically 
interfering with negative regulation of the ABL-encoded tyrosine kinase. Finally, the 
tyrosine at residue Tyr177 (Y177) located in the first exon of BCR is critical for BCR-
ABL binding to growth factor receptor bound protein 2 (GRB2) and induction of the 
downstream RAS signaling pathway15. Mutant Y177 blocks this binding function and 
fails to induce myeloid leukemia15. 
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3. CML mouse models 
A good animal model of CML will help us study the pathogenesis of CML and 
characterize leukemic and normal stem cells, and contribute to the evaluation of 
experimental therapeutic strategies for this disease. Several CML mouse models have 
been established. The most widely used model is the 
retroviraltransduction/transplantation model (Figure 2A)18-22. In this model, murine bone 
marrow cells are infected with a retrovirus encoding p210BCR-ABL and transplanted into 
irradiated syngeneic recipients18,20. Over time, the recipients develop a CML-like 
myeloproliferative syndrome. Originally, this early system was limited because of 
difficulties in generating high-titer BCR-ABL retroviruses, which subsequently caused a 
low efficiency of generating diseased animals18,20. Additionally, serial transfer of the 
myeloproliferative disease also occurred at a low frequency18,20-22. These deficiencies 
hampered the use of this CML mouse model in a functional assay. Through modification 
of the original bone marrow transduction protocol, an efficient and rapid induction of a 
CML-like mouse model was established23,24. In this improved system, in order to enrich 
hematopoietic stem cells, donor mice were primed by intravenous injection with 5-
fluorouracil (5-FU) 4 days before collecting bone marrow cells23,24. Cells were cultured 
with cytokines including interleukin-3 (IL-3), IL-6, and stem cell factor (SCF)23,24. To 
increase transduction efficiency, virus and cells were co-sedimented. In our lab, using 
this model, we are able to obtain 100% incidence of the CML-like syndrome in recipient 
mice by 2-4 weeks after transfer of p210BCR-ABL-transduced bone marrow cells23. 
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Therefore, this consistent and rapid CML disease model allows us to study the molecular 
mechanisms of CML development and the maintenance of CML stem cells.  
The transgenic mouse is an alternative and useful approach to investigate BCR-
ABL induced leukemia in vivo.  Several BCR-ABL transgenic mice strains have been 
created using different regulatory elements to drive BCR-ABL expression25,26. The 
transgenic mice expressing p210BCR-ABL driven by the metallothionein (MT) promoter 
developed T-cell leukemia25. Huettner et al. generated an inducible transgenic strain in 
which BCR-ABL expression was controlled by tetracycline transactivator (tTA) through 
the mammary tumor virus long terminal repeat (MMTV-LTR)26. Withdrawal of 
tetracycline administration in this transgenic strain allowed expression of BCR-ABL and 
resulted in the development of acute B-cell leukemia in 100% of the mice within 3-6 
weeks26. These studies demonstrate that the phenotype of BCR-ABL transgenic mice is 
dependent on the expression pattern and cell-type specificity of the regulatory elements: 
in the MT-BCR-ABL transgenic model, as the tumorigenicity of BCR-ABL chimeric 
protein is restricted to the hematopoietic tissues in vivo, the MT promoter only drives 
BCR-ABL expression in the hematopoietic tissues, thymus and spleen, thus accounting 
for the T-cell phenotype25; in the MMTV-LTR/tTA-BCR-ABL inducible model, the 
MMTV-LTR directs expression of tTA to early B-cell progenitors within murine bone 
marrow, thus accounting for the B-cell phenotype26. Given that CML is a stem cell 
disorder, it is reasonable that the regulatory elements derived from HSC-specific genes 
should cause a more accurate model of human CML. The SCL (stem cell leukemia) gene 
encodes a basic helix-loop-helix transcription factor, which mainly expresses in 
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hematopoietic cells, endothelial cells, and embryonic skeleton, and is critical for cell fate 
determination and differentiation27-29. An enhancer fragment within the 3’ region of SCL 
has been identified to restrict expression of the LacZ transgene in adult HSCs, progenitor 
cells and megakaryocytes30,31. Based on these findings, Koschmierder et al. generated the 
SCLtTA/TRE-BCR-ABL transgenic model32 (Figure 2B), in which tTA was driven by 
the SCL 3’ enhancer. Induction of BCR-ABL resulted in neutrophilia, splenomegaly, and 
myeloid invasion, which models the major features of human CML disease32, and also 
altered the biology of stem cell and progenitor cell populations33. Therefore, this 
inducible transgenic model represents a valuable alternative for CML study. 
The ideal model for investigating CML is the xenograft model in which primary 
cells from human CML patients are transplanted into SCID mice to mimic human CML 
disease (Figure 2C). However, many efforts have proved that this model is more difficult 
to establish due to the failure of engraftment of CML cells34,35. This failure of 
engraftment may be a result of the rare CML stem cells in most chronic phase CML 
patients, or the lack of a suitable immunodeficient mouse strain. Recently, Eisterer et al36 
used only patient samples in which the long-term culture-initiating cells were 
predominantly Ph+, and then transplanted Lin- or Lin-CD34+ cells from these samples into 
sublethally irradiated NOD/SCID and NOD/SCID-ß2microglobulin-/- mice36. The 
average engraftment level ranged from 0.02% to 10% after transplantation, and the 
highest frequencies of human cells were typically seen after 3 weeks36. In our lab, we 
sorted Lin-CD34+ bone marrow cells from human CML patients in the chronic phase and 
transplanted these cells into NOD/SCID/IL2Rγ-/- mice which supports engraftment of 
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human CD34+ hematopoietic stem cells37,38. The highest frequencies  (about 5-10%) of 
human cells (human CD45+) were typically observed after 2 weeks, and about 1% of 
human cells were persistent for 2-3 months in most recipients (unpulished data). 
Therefore, these findings demonstrate the efficacy of the xenograft model of human 
CML.  
 
Figure 2. CML mouse models. (A) Retroviral transduction/transplantation model. Bone 
marrow cells from 5-FU (200mg/kg) pretreated donor mice are transduced with BCR-
ABL retrovirus twice. These cells are then transplanted into lethally irradiated recipients 
for induction of CML23. (B) BCR-ABL transgenic model. The SCL 3’ enhancer drives the 
expression of tetracycline dependent transcription factor (tTA) in hematopoietic 
stem/progenitor cells31. The presence of tetracycline blocks the binding of tTA to the Tet 
promoter, thus shutting off BCR-ABL expression. Conversely, tTA binding to the Tet 
promoter in the absence of tetracycline activates transcription of BCR-ABL in 
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hematopoietic stem/progenitor cells, leading to the induction of CML disease33. (C) 
Xenograft model. Lin-CD34+ cells from human CML patients are sorted by magnetic-
activated cell sorting (MACS) and injected into NOD/SCID mice. 
 
 
4. BCR-ABL tyrosine kinase inhibitors 
The discovery of the molecular basis of CML provided the foundation for 
designing therapeutic drugs and led to the development of the BCR-ABL tyrosine kinase 
inhibitor (TKI), imatinib, the first TKI found to be highly effective in CML treatment39-41.  
Imatinib can bind to the ABL kinase domain through forming hydrogen bonds, and 
impair ATP binding, which block the substrate activation42. Therefore, targeting therapy 
with imatinib induces a complete hematologic and cytogenetic response in more than 
80% of chronic phrase CML patients43. However, resistance to TKI has been frequently 
observed, especially in patients with advanced-stage disease44. One critical reason is the 
occurrence of point mutations in the kinase domain of BCR-ABL45. Using a PCR strategy 
to determine the sequence of the ATP binding pocket and activation loop of the kinase 
domain of ABL coming from relapsed patient samples, Gorre et al. identified a single 
nucleotide C to T change, which results in a threonine to isoleucine substitution at 
position 315, that is, the well-known T315I mutation44. This substitution of theronine 
precludes the formation of a hydrogen bond with TKI but does not interfere with ATP 
binding45. To date, more than 50 point mutations have been found, including mutations of 
contact residues, mutations in the ATP binding loop and the regulatory motifs46. These 
mutations prevent ABL from adopting the specific conformation required for high-
affinity imatinib binding46.  
   
11 
To override this resistance, secondary-generation TKIs, such as dasatinib and 
nilotinib, have been developed. Dasatinib is a dual ABL and Src family kinases (SFKs) 
kinase inhibitor47. Previous studies proved that dasatinib overcame imatinib resistance 
conferred by most ABL kinase mutations, as dasatinib is able to bind both the inactive 
and active states of ABL with higher affinity48-51. Similarly, nilotinib has a higher affinity 
for the inactive conformation of BCR-ABL by 20 to 30 fold52, which makes it highly 
efficacious in patients with CML following failure of imatinib therapy53. However, both 
inhibitors cannot inhibit the gatekeeper residue mutant T315I. With the development of 
structural biology and computational biology, an alternative strategy to target other BCR-
ABL motifs that are remote from the kinase domain has been developed54-56. This 
strategy would be unaffected by kinase mutations that confer the ability of TKI-
resistance. Through a high-throughput screen, GNF-2, a highly selective non-ATP 
competitive inhibitor of BCR-ABL, was identified54. A recent study using nuclear 
magnetic resonance (NMR) spectroscopy and X-ray crystallography confirmed that 
GNF-2 bound to the C-terminal myristoyl pocket of ABL, leading to changes in the 
structural dynamics of the ATP-binding site55. GNF-5, an analogue of GNF-2 with an 
improved pharmacokinetic feature, can act cooperatively with an ATP competitive 
inhibitor to inhibit both wild type and T315I BCR-ABL activity55.  Additionally, using 
structure-based drug design, Chan et al developed an inhibitor, DCC-2036, which 
potently inhibits both unphosphorylated and phosphorylated ABL1 by inducing an 
inactive conformation56. This inhibitor exhibited efficacy against the T315I mutant in 
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vivo56. The development of these inhibitors provides the possibility of overcoming TKI 
resistance caused by kinase mutations. 
  
5. Beyond TKIs---cancer stem cells in chronic myeloid leukemia 
Although the majority of CML patients achieve a complete hematological 
response, and up to 90% can achieve a complete cytogenetic response to TKI therapy 
with at least 2 years follow-up49,50,57,58, clinical relapse eventually occurs once treatment 
is interrupted59. Additionally, only a very low percentage of complete molecular response 
is achieved from therapy with imatinib, or new generation TKIs48,53,60, which suggests 
that a population of residual malignant cells is unaffected by TKIs. Now, it is accepted 
that these TKI-refractory malignant cells are leukemia stem cells (LSCs).  The existence 
of cancer stem cells (CSCs) in CML has been experimentally proved in a series of 
studies61-63.   Using carboxy-fluorescein diacetate succinimidyl diester (CFSE) to track 
cell division, Graham et al showed that imatinib treatment eradicated almost all the 
dividing CD34+ cells from patients with CML in the chronic phase, leaving behind the 
non-proliferating quiescent cells, implying that quiescent CML stem cells are insensitive 
to imatinib62. Further study demonstrated that Ph+CD34+ cells persisted in CML patients 
who achieved complete cytogenetic response (CCR) with imatinib treatment61, and 
analysis using colony forming cell (CFC) assay and long-term bone marrow culture-
initiating cells (LTC-IC) confirmed that these cells retained primitive progenitor ability61. 
In our lab, using the retroviral transduction/transplantation CML mouse model, we found 
that treatment with imatinib and the secondary generation of TKI, dasatinib, dramatically 
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prolonged the survival of CML mice; however, all treated CML mice eventually died of 
this disease63. Fluorescence-activated cell sorting (FACS) analysis showed that TKIs 
reduced the numbers of BCR-ABL-expressing HSCs but failed to eliminate these cells 
completely in CML mice63. A recent study also demonstrated that targeting BCR-ABL 
could not eliminate CML stem cells, although drug treatment inhibited BCR-ABL 
activity and killed the proliferating CML progenitor cells64. Together these studies 
indicate TKIs cannot eradicate LSCs, which forces us to reassess the notion of LSCs and 
their role in the disease, in order to understand the molecular mechanisms of LSC 
maintenance and to design new strategies to eradicate them.  
 
6. Cancer stem cell and chronic myeloid leukemia stem cell 
The cancer stem cell model is not a new idea65, but it has attracted broad interest 
recently due to its promising clinical implications in cancer therapy. Like normal stem 
cells, cancer stem cells can be defined as a specific cell population inside cancer that can 
self-renew and has the ability to initiate cancer development65-68. Bonnet and Dick first 
identified and characterized LSCs from human AML samples69. They isolated 
CD34+CD38- cells and transplanted them into NOD/SCID mice. They found that these 
cells could not only initiate AML in NOD/SCID mice but also differentiate in vivo into 
leukemic blasts69. More importantly, serial transplantation demonstrated that these cells 
had a capacity to self-renew and transferred AML disease into secondary recipients69. 
Therefore, this study showed for the first time that LSCs were exclusively CD34+CD38- 
cells, which have the same cell-surface phenotype as normal human primitive cells. 
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Subsequently, similar approaches were applied to solid tumors. Cancer stem cells have 
been identified in many kinds of solid tumors, including breast70, brain71, pancreas72, 
colon73, lung74, and prostate75. These studies indicate that CSCs are a rare phenotypically 
distinct subpopulation of cancer cells in most of cancers, and these rare CSCs represent 
the driving force of tumor malignancy. Therefore, targeting CSCs might be an attractive 
and potentially effective strategy for cancer treatment. These types of therapies would 
require an understanding of the molecular mechanisms of CSC self-renewal and survival. 
Considerable evidence shows that CSCs and normal stem cells share similar mechanisms 
for self-renewal and survival, and many pathways, such as Wnt-β-catenin and hedgehog 
pathways76,77.  
Many efforts have been undertaken to identify cancer stem cells in CML. The 
myeloid progenitors, common myeloid progenitor (CMP) and granulocyte-macrophage 
progenitors (GMP), transduced with BCR-ABL retrovirus did not serially replate, 
indicating these cells lack the ability of self-renewal78. Using the SCLtTA/TRE-BCR-
ABL transgenic mouse model, Reynaud et al confirmed that BCR-ABL-expressing 
progenitors including CMP, GMP and common lymphoid progenitor (CLP), failed to 
transfer CML disease into secondary recipients79. Therefore, these data demonstrate that 
BCR-ABL cannot confer properties of self-renewal to committed myeloid progenitors. 
To identify CML stem cells, we tested whether BCR-ABL-expressing HSCs function as 
LSCs. Using a BCR-ABL induced CML mouse model, we sorted BCR-ABL expressing 
Lin-Sca-1+c-Kit+ (LSK) cells from primary CML mice and transplanted them into lethally 
irradiated secondary recipients, and found that these BCR-ABL-expressing LSK cells 
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induced CML disease in the secondary recipients63, suggesting that BCR-ABL expressing 
LSK cells function as LSCs. We further characterized the ability of this stem cell 
population to transfer CML to secondary recipient mice. We divided BCR-ABL-
expressing (GFP+) Lin- cells into four populations: Lin-Sca-1+c-Kit- (LSK-), Lin-Sca-1+c-
Kit+ (LSK), Lin-Sca-1-c-Kit- (LS-K-), and Lin-Sca-1-c-Kit+ (LS-K) (Figure 3A). We 
serially diluted sorted GFP+LSK cells from CML mice and transplanted 1x104, 5x103, 
1x103 or 1x102 cells into a lethally irradiated mice along with 2x105 normal bone marrow 
cells. FACS analysis showed that myeloid leukemia cells (GFP+Gr-1+) were detected in 
the peripheral blood of mice receiving 1x104, 5x103 or 1x103 GFP+LSK cells at 10 days 
after BMT, whereas almost no leukemia cells were found in mice receiving 1x102 
GFP+LSK cells (Figure 3B). At day 15 after bone marrow transplantation (BMT), 
leukemia cells almost disappeared from mice receiving 1x103 GFP+LSK cells (Figure 
3B). Eventually, mice receiving 1x104 (100% of the mice) or 5x103 (50% of the mice) 
GFP+LSK cells developed CML, and lower cell doses (1x103 or 1x102) did not induce 
CML (Figure 3B). We also tested the other GFP+ cell populations (LS-K, LSK-, and LS-
K- cells) for their ability to induce CML in secondary recipient mice. We transplanted 
3x104 cells along with 2x105 normal bone marrow cells into lethally irradiated mice and 
found that leukemia cells were barely detectable in peripheral blood of recipient mice 
(Figure 3C), indicating these populations are incapable of inducing leukemia. Similarly, 
Naka et al. also confirmed that BCR-ABL-expressing LSK cells from CML mice could 
efficiently induce CML development in recipient mice. In contrast, no other CML cell 
populations expressing differentiation markers induced CML80. Therefore, these studies 
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suggest that BCR-ABL-expressing LSK cells function as CML LSCs, which exhibit 
characteristic similar to those of normal HSCs. The identification of CML LSCs allows 
us to understand the mechanisms by which CML stem cells survive and maintain 
themselves, which will contribute to the design of new strategies aimed at targeting CML 
stem cells as a curative therapy for CML. 
 
Figure 3. Identification of chronic myeloid leukemia stem cells. (A) Four populations 
of cells (LSK-; LSK; LS-K-; LS-K) were sorted from BCR-ABL induced CML mice and 
transplanted into lethally irradiated recipients at different doses.  (B and C) Only LSK 
cells can function as LSCs and transfer CML disease into secondary recipients. 
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7. LSCs are independent of BCR-ABL kinase activity 
Resistance to TKIs by CML stem cells is a common mechanism among nearly all 
CML patients62,63. As mentioned earlier, primitive Ph+CD34+ cells from CML patients 
exhibit insensitivity to TKIs62. Understanding the mechanisms by which LSCs survive 
under treatment with TKIs will be critical to designing strategies targeting LSCs. 
However, it is still unclear why and how LSCs in CML evade TKIs. The development of 
BCR-ABL mutations renders resistance, but resistance to TKIs is frequently present in 
the absence of a detectable mutation in BCR-ABL64. Therefore the most interesting 
characteristic of the resistant CML cells is its relationship with BCR-ABL.  
It is widely accepted that Ph+ leukemia cells are addicted to BCR-ABL kinase 
activity, and BCR-ABL activates numerous downstream signaling pathways, such as 
RAS, phosphoinositide 3-kinases (PI3K), and signal transducer and activator of 
transcription (STAT), which are critical in BCR-ABL induced leukemogenesis through 
regulating cell proliferation, survival and differentiation81-83. However, it remains unclear 
whether LSCs are dependent or independent of BCR-ABL kinase activity. Recent studies 
indicate that LSCs of CML are independent of BCR-ABL kinase activity64,84. Using 
multiple complementary methods, including immunocytochemistry, immunoblot and 
LTC-IC assay, Druker and colleagues confirmed this idea in in vitro cultured cells 64. 
Intracellular phosphotyrosine levels determined by FACS analysis showed similar 
degrees of BCR-ABL inhibition by TKIs in different immature cell subtypes, including 
CD34+CD38+ and CD34+CD38- populations from newly diagnosed CML patients64. 
Consistently, immunoblot analysis showed that imatinib equivalently completely 
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inhibited the phosphorylation of CRKL, a BCR-ABL specific substrate, and STAT5 in 
CML stem and progenitor cells64. Further, phospho-CRKL immunoblots of sorted 
quiescent (Ki67-) and cycling (Ki67+) cells showed equal inhibition of BCR-ABL activity 
in both fractions64. These data demonstrated that imatinib equally inhibits BCR-ABL in 
CML stem cells, progenitor cells, and quiescent cells. This inhibition is continuous and 
does not select a subpopulation with innate resistance, as a similar distribution of cell 
types in untreated versus imatinib treated cultures was observed64. Finally, when 
cytokines were added, these cells remained capable of in vitro proliferation despite 
continuous imatinib treatment, and an LIT-IC assay showed quiescent primitive cells 
were only slightly reduced by imatinib treatment64. Therefore, these data suggested that 
the survival of primitive CML cells was independent of BCR-ABL activity. This study 
also excluded the possibility that drug efflux/influx affects TKI sensitivity of CML stem 
cells, as comparable inhibition was observed in CML stem cells and progenitors64. 
Consistently, a study from another group also indicated that CML stem cells are not 
dependent on BCR-ABL kinase activity for their survival84. Human CML CD34+ cells 
were cultured in serum-free SFM media and treated with dasatinib. Immunoblot analysis 
showed the complete inhibition of phosphor-CRKL by dasatinib treatment84, suggesting 
the inhibition of BCR-ABL kinase activity. However, although fewer cells (10% of input) 
were achieved after 12-days of treatment, these cells displayed similar proliferation 
abilities compared to untreated cells when cytokines were supplied84. They also retained 
their self-renewal ability84. Together, these results suggest that CML stem cells utilize 
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signaling pathways that are independent of BCR-ABL kinase activity for their 
maintenance and survival.  
This notion raises various questions related to what the BCR-ABL kinase 
independent pathways are and how they regulate the survival of CML stem cells. In our 
lab, we have found several pathways that are independent of BCR-ABL kinase 
activity85,86.  
1) BCR-ABL/Src pathway in B-ALL. Src family kinases are critical for the 
cellular transformation by BCR-ABL87,88. In B-lymphoid cells imatinib markedly 
inhibited BCR-ABL kinase activity but did not result in a decrease in Src activation86. 
Given the fact that BCR-ABL activates Src kinases, these results suggest that the 
activation of Src kinases by BCR-ABL is independent of its kinase activity63. Using the 
retroviral transduction/transplantation CML mouse model discussed above, we find 
another Src kinase, B lymphoid kinase (Blk), is significantly down-regulated by BCR-
ABL in LSCs, and imatinib treatment fails to restore this down-regulation (the detailed 
information will be described in CHAPTER III), suggesting that the down-regulation of 
Blk expression in LSCs is independent of BCR-ABL kinase activity.  
2) BCR-ABL/Alox5 pathway. Another example is arachidonate 5-lipoxygenase 
(Alox5), which is dramatically induced by BCR-ABL in CML LSCs85; however, 
inhibition of BCR-ABL kinase by imatinib cannot suppress this up-regulation of Alox585, 
suggesting that Alox5 expression in LSCs is independent of BCR-ABL kinase activity.  
Therefore, these findings of BCR-ABL kinase independent pathways provide an 
alternative explanation for the resistance of LSCs to TKIs. It is deduced from these 
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findings that completely different strategies, such as targeting the pathways of stem cell 
self-renewal or targeting the BCR-ABL kinase independent pathways, are needed to 
eliminate LSCs. 
 
8. Molecular pathways regulating the maintenance of LSCs  
The finding that CML LSCs are resistant to TKI treatment leads us to ponder why 
LSCs evade BCR-ABL kinase inhibitor treatment. What is the nature of LSCs? How do 
LSCs survive whereas other CML cells are eliminated by TKI therapy? To answer these 
questions requires a full understanding of the biology of LSCs. As LSCs share functional 
properties (self-renewal, and pluripotency) with normal HSCs 65,89,90, it is reasonable to 
consider that signaling pathways involved in the regulation of normal stem cells should 
also be essential for LSCs. As described in the following section, many studies 
demonstrate that Wnt/β-catenin91, hedgehog92, TGF-FOXO80, BCL693, and HIF1α94 
signaling pathways that are essential for normal HSC self-renewal are also required for 
CML LSCs.  
 
The Wnt/β-catenin pathway 
The Wnt/β-catenin signaling pathway, an important developmental pathway, is 
necessary for stem cell self-renewal95. The canonical Wnt pathway is initiated by binding 
of Wnt ligands to their receptors Frizzled and LRP5/695. This consequently destabilizes 
the multiprotein destruction complex that contains Axin, glycogen synthase kinase 3β 
(GSK3β), casein kinase 1 (CK1) and adenomatous polyposis coli (APC)95. This disrupts 
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the binding of GSK3β with β-catenin and leads to the dephosphorylation of β-catenin95. 
Unphosphorylated β-catenin accumulates and translocates into the nucleus, where it 
interacts with the lymphoid enhancer factor/T-cell factor transcription factors and 
regulates the transcription of genes such as c-myc and cyclin D195-98. Dysregulated 
Wnt/β-catenin signaling has been found in certain human leukemia and LSCs98,99 (Figure 
4). In acute myeloid leukemia, activated Wnt/β-catenin signaling is required for the self-
renewal of LSCs derived from HSCs or more differentiated granulocyte-macrophage 
progenitors (GMP) induced either by coexpression of Hoxa9 and Meis1a or by MLL-AF9 
99. Similarly, self-renewal of BCR-ABL+ CML cells is also sustained by a nuclear 
activated serine/threonine unphosphorylated β-catenin100.  GMP cells from CML patients 
in blast crisis have accumulated nuclear β-catenin and exhibit enhanced self-renewal 
ability in vitro100. Using a CML mouse model, Zhao et al demonstrate that loss of β-
catenin impairs the development of BCR-ABL induced CML due to a defect in cancer 
stem cell self-renewal without β-catenin91. The mechanism underlying β-catenin 
deregulation in CML has been investigated. BCR-ABL physically interacts with β-
catenin, and phosphorylates β-catenin at tyrosine residues at position 486 and 654. This 
subsequently induces β-catenin stabilization by interrupting binding to Axin101. Unlike 
the essential role of β-catenin in LSCs91, the β-catenin pathway function in adult HSCs is 
controversial. Activation of Wnt signaling by retrovirus-mediated expression of 
constitutively active β-catenin in HSCs or exposure to purified Wnt3a can increase self-
renewal of murine HSCs in vitro and enhance their ability to reconstitute the 
hematopoietic system in vivo102,103. However, several studies demonstrate that deficiency 
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of β-catenin, γ-catenin, or both, does not perturb hematopoiesis104,105, suggesting that 
Wnt-dependent effects on adult HSCs might be subtle. Given the critical role of Wnt/β-
catenin pathway in LSCs, a drug that can target this pathway could offer a new treatment 
approach for targeting LSCs. A recent study confirmed the feasibility of this approach, as 
treatment with indomethacin, a reversible COX inhibitor that blocks activation of the 
Wnt pathway by inhibiting β-catenin expression, reduced LSCs in AML mice99.  
 
 
Figure 4. Wnt/β-catenin and hedgehog pathway in leukemia stem cells. 
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The hedgehog pathway 
Hedgehog (Hh) is a developmental signaling pathway in which Hh ligands, 
including Sonic hedgehog (Shh), Indian hedgehog (Ihh), and Desert hedgehog (Dhh), 
bind the seven-transmembrane domain receptor Patched (Ptch)106. This leads to the 
release of Ptch binding from Smoothened (Smo)107. Subsequently, Smo activates Hh 
pathway target genes like Gli1, Ptch1, cyclin D1, and Bcl2 using the Gli transcription 
factors107 (Figure 4). The role of Hh signaling in normal and malignant hematopoiesis is 
controversial. To understand the role of Hh signaling in normal HSCs, Hofmann et al108 
and Gao et al109 in parallel studies examined the effects of the conditional Smo deletion in 
the hematopoietic system. They demonstrated that deletion of Smo had no apparent effect 
on adult HSC self-renewal and function, including colony-forming potential and long-
term repopulating activity in a competitive repopulation assay, suggesting that Hh 
signaling is dispensable for normal HSC function108,109. In leukemogenesis, deletion of 
Smo does not affect MLL-AF9 induced AML, which is shown by a similar in vitro 
replating potential and in vivo leukemia development between MLL-AF9 transduced WT 
and Smo-/- cells108. However, these findings do not exclude the possibility that Hh 
signaling is required for other types of leukemia. Most attention has been focused on the 
role of Hh signaling in CML. Interestingly, Hh signaling is activated in LSCs of CML, 
which show up-regulation of Smo92,110. Loss of Smo impaired BCR-ABL induced CML 
development and caused depletion of CML LSCs, as LSCs failed to transfer CML disease 
into secondary recipients92,110. These findings suggest thatHh signaling is essential for 
maintenance of CML LSCs (Figure 4). Pharmacological inhibition of Hh signaling with 
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cyclopamine reduced the colony-forming potential of LSCs and increased the time to 
relapse after the end of treatment110. Importantly, LSCs with mutated BCR-ABL bearing 
the mutation T315I were also sensitive to Smo inhibition110. Given the fact that Hh 
signaling is dispensable for normal HSCs109, it is reasonable to think that combining 
targeting of this essential pathway and administration of TKIs might be an effective 
treatment strategy to specifically reduce the LSC pool in CML. 
 
The FoxO pathway 
The forkhead O transcription factors (FoxO1, FoxO3, FoxO4, FoxO6), as the 
important downstream targets of PI3K-Akt signaling, are involved in various cellular 
processes, such as cell cycle arrest, differentiation, apoptosis, stress resistance and 
metabolism111. Akt directly phosphorylates FoxO1, FoxO3 and FoxO4112,113. This leads 
to the binding of the 14-3-3 chaperone proteins to FoxOs that interfere with the DNA 
binding domain of FoxOs and induce the export of FoxOs from the nucleus to the 
cytoplasm112,113. This translocation of FoxOs results in their proteasomal degradation in 
the cytoplasm112,113. Therefore, while FoxO inactivation by Akt increases cell survival, 
proliferation and stress sensitivity, activation of FoxO residing in the nucleus causes cell 
cycle arrest by regulating the expression of p27, p21, cyclin D, cyclin G2, and cyclin 
B114. It is widely accepted that BCR-ABL activates the PI3K-Akt pathway, leading to 
inactivation of FoxO transcription factors that lead to increases in CML cell proliferation 
and survival115. Unexpectedly, using a retroviral transduction/transplantation CML mouse 
model, Naka et al. identified a converse role for Akt-FoxO in LSCs of CML80. Unlike 
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leukemia progenitor cells showing enhanced Akt phosphorylation and higher cytoplasmic 
localization of FoxO3a, CML LSCs exhibited decreased Akt phosphorylation and 
enriched nuclear localization of FoxO3a80 (Figure 5). Furthermore, FoxO3a deletion 
impaired CML development in a serial transplantation assay, suggesting FoxO3a is 
essential for the long-term maintenance of CML LSCs80. Consistently, FoxO also has a 
surprisingly essential role in the maintenance of the undifferentiated status of LSCs in 
AML116. LSCs from MLL-AF9 induced AML have decreased Akt activation and active 
FoxOs. Deletion of FoxO1/FoxO3/FoxO4 decreased colony-forming ability, promoted 
myeloid maturation and diminished LSC function in vivo116. Moreover, about 40% of 
AML patients displayed active FoxOs, which is consistent with a previous observation 
that high expression of FoxO3 is associated with adverse prognosis in AMLs with normal 
cytogenetics117. These data demonstrate an opposite role for FoxOs in LSCs that is 
counter to their established function as tumor suppressors in many cancers. The study of 
FoxOs in normal HSCs might provide key insight into what is observed in LSCs. 
Deletion of FoxO1/FoxO3/FoxO4 in the adult hematopoietic system led to a marked 
decrease of HSC numbers and resulted in the defective long-term reconstitution ability114. 
The effects of FoxOs on HSCs correlated with the modulations of their target genes in the 
cell cycle, including p21, p27, cyclin D2, and cyclin G2114. FoxO deficiency also caused 
increased apoptosis of HSCs. Therefore, FoxOs are required for the maintenance of 
HSCs. Further, Naka et al also demonstrated that the TGF-ß-Smad2/3 pathway regulated 
the retention of FoxO3a in the nucleus in CML LSCs, and that TGF-ß inhibition caused 
the nuclear exclusion of FoxO3a80. A combination of TGF-ß inhibition and imatinib 
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treatment led to more efficient depletion of CML in vivo80. Thus targeting FoxOs and 
related signaling pathways might represent a new therapeutic way for eliminating LSCs.  
 
The BCL6 pathway 
B cell lymphoma 6 (BCL6) is a known proto-oncogene encoding a BTB/POZ-
zinc-finger transcriptional repressor118,119. It is known that BCL6 is necessary for 
germinal-center formation and is involved in the pathogenesis of B-cell lymphoma118. 
Therefore, the majority of previous studies about BCL6 focus on B cells and B 
lymphoma. BCL6 suppresses p53 transcription by binding the promoter of p53 and 
modulates DNA damage-induced apoptotic responses in germinal-center B cells119. 
Constitutive expression of BCL6 protects B cell lines from apoptosis induced by DNA 
damage, suggesting that deregulated BCL6 expression contributes to lymphomagenesis in 
part by functional inactivation of p53119.  Recent studies indicate that BCL6 plays a 
critical role in a protective feedback signaling mechanism by LSCs in response to TKI 
treatment93,120. Duy et al. first demonstrated that TKI treatment induced BCL6 up-
regulation mediated by decreased phosphorylation of STAT5 and enhanced FoxO4 
expression in Ph+ acute lymphoblastic leukemia (ALL) cells120. The target genes of 
BCL6 in TKI-treated Ph+ ALL cells, including p53, Arf, p21, and p27, were identified by 
a ChIP on chip and comparative gene expression assay120 (Figure 5). Furthermore, BCL6-
/- BCR-ABL-transduced B lymphoblast failed to induce leukemia in immunodeficient 
mice, which was suggestive of a defect in the self-renewal of BCL6-/- LSCs120. 
Interestingly, deletion of BCL6 restored the sensitivity of B-ALL cells to imatinib, 
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indicating a protective role for BCL6 in LSCs of Ph+ ALL treated with TKIs120. Muschen 
and colleagues also extended their findings to LSCs in CML93. They demonstrated that 
human primary CD34+ CML cells exhibited enhanced BCL6 expression upon TKI 
treatment and that the Pten-Akt-FoxO pathway was responsible for this up-regulation of 
BCL693, which is validated by our recent study121. We found that Pten was down-
regulated by BCR-ABL, conditional deletion of Pten accelerated CML development, and 
overexpression of Pten delayed CML development because of the impaired function of 
LSCs121. Additionally, deletion of BCL6 impaired the colony-forming potential in vitro of 
LSCs and failed to induce CML93, suggesting BCL6 is required for the maintenance of 
LSCs in CML. Further, p53 was identified as a key transcriptional target of BCL6 in 
CML93. Most importantly, both studies showed that a combination of TKIs and inhibition 
of BCL6 by the retro-inverso peptide inhibitor RI-BPI, which blocks the repressor 
activity of BCL6, effectively eradicated LSCs in CML and Ph+ALL93,120.  These exciting 
findings regarding BCL6 up-regulation after TKI treatment provide one possible 
explanation for why and how LSCs persist in patients despite long-term TKI treatment 
and make it a potential target in TKI resistant LSCs in both CML and Ph+ ALL. 
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Figure 5. Akt-FoxO-Bcl6 pathway in leukemia stem cells. 
 
 
The hypoxia inducible factor pathway 
HIF1 belongs to the family of basic helix-loop-helix (bHLH) transcription 
factors122. It forms a heterodimer that consists of a constitutively expressed HIF1β 
subunit and a HIF1α subunit, and mediates cellular adaptation to hypoxia122. The 
expression of HIF1α is regulated in multiple ways. Under normoxic conditions, HIF1α is 
degraded rapidly, which is triggered by the oxygen-hydroxylation of proline residues 402 
and 564 by a proline hydroxylase (PHD)123. The hydroxylated HIF1α is recognized by 
the Von Hippel-Lindau protein (pVHL), which is the recognition component of an E3 
ubiquitin-protein ligase 123,124. HIF1α expression is also regulated by growth factors, 
cytokines and other signaling pathways such as PI3K and MAPK pathways 125. It is 
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widely accepted that HIF1α plays an important role in cancer progression by activating 
transcriptional programs for self-renewal and multipotency of cancer stem cells 126-128. 
Recent studies from our group and another group have added HIF1α as one of the key 
pathways in LSCs of hematological maligancies94. Wang et al. demonstrated that cancer 
stem cells in lymphoma from transgenic mice with an insertional mutation of the Epm2a 
gene had a high level of HIF1α under normoxia94. Both knockdown of HIF1α by shRNA 
and inhibiting HIF1α activity by the inhibitor, echinomycin, which blocks HIF1α DNA 
binding activity, reduced the colony forming ability in vitro and abrogated lymphoma 
development in vivo94, suggesting HIF1α is essential for maintenance of CSCs of 
lymphoma. Furthermore, similar to the findings in the lymphoma CSCs, higher HIF1α 
activity was only observed in CD34+CD38- LSCs of human AML94. Using a xenogeneic 
mouse model, the authors showed that echinomycin treatment effectively prevented the 
engraftment of LSCs from AML patients in a serial transplantation assay94. To our 
interest, BCR-ABL induces HIF1a expression at the transcriptional level in leukemia cell 
lines, which is mediated by PI3K and mTOR but not MAPK pathways, as this up-
regulation was only inhibited by the addition of either PI3K inhibitor LY294002 or 
mTOR inhibitor rapamycin129. These findings suggest that HIF1α might contribute to the 
pathogenesis of CML. Using a retroviral transduction/transplantation CML mouse model, 
we found, which will be mentioned in CHAPTER II, that an active HIF1α signaling 
pathway was maintained in LSCs of CML comparing to normal HSCs. HIF1α-/- LSCs 
gave rise to less colonies in vitro and failed to induce CML disease in the secondary 
recipients130, suggesting that HIF1α is required for self-renewal of LSCs in CML. 
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Further, we showed that HIF1α-/- LSCs have enhanced levels of p16Ink4a and p19Arf and 
that deletion of p16Ink4a and p19Arf by lentivirus-mediated shRNA rescued the defective 
colony-forming potential of LSCs due to the absence of HIF1α130. Importantly, 
microarray analysis showed significant changes of HIF1α target genes in HIF1α-/- LSCs, 
compared to HIF1α-/- HSCs, suggesting that LSCs of CML are more dependent on 
HIF1α activity than HSCs130. Given the higher specificity and sensitivity of CSCs in 
lymphoma and human AML to HIF1α inhibitor echinomycin94, it is reasonable to 
hypothesize that it is possible to eradicate LSCs in CML by targeting HIF1α, although 
the efficiency of echinomycin or other HIF1α inhibitors on LSCs of CML will need to be 
validated in a future study.  
 
9. Current strategies for identifying therapeutic targets in LSCs 
Understanding the mechanisms of the survival and self-renewal of LSCs and 
designing new strategies to target LSC are necessary and critical for curing CML. The 
identification of the above molecular mechanisms in LSCs makes this goal possible80,91-
94, however, the critical roles of most of these pathways in normal stem cells limit their 
utilization for curing CML. Therefore, developing strategies to uniquely target LSCs is 
crucial. One strategy is to identify agents that specifically eliminate LSCs. The study 
from Weinberg and colleagues prove the feasibility of this strategy131. They screened 
specific inhibitors of epithelial cancer stem cells using a high-through screen method and 
found that one compound, salinomcin, selectively killed breast CSCs and inhibited 
mammary tumor growth through inducing differentiation131. Importantly, global gene 
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expression analyses showed reduced expression of CSC-associated genes after treatment, 
implying the existence of unique genes that are associated with this specific phenotype of 
CSCs131. In our lab, our strategy is to identify genes that play key roles in LSCs but not 
their normal stem cell counterparts, as we hypothesize that relative to their normal stem 
cell counterparts, LSCs utilize a unique molecular network to regulate their functions and 
that it is possible to identify these genes for developing targeted therapies. For these 
reasons, comparing the global gene profiling of normal HSCs and LSCs in CML will 
provide us a straightforward method to identify the key differences between LSCs and 
their normal counterparts. Towards this goal, using BCR-ABL-induced CML as a disease 
model, we have performed a microarray to explore the gene expression profiling of CML 
stem cells (Figure 6A), analyzed these microarray data via bioinformatics methods. 
Based these information and literatures, we picked up several candidates and assessed the 
biological functions of candidates using a series of experimental approaches (Figure 6B 
and C). We have previously identified the Alox5 gene as a key regulatory gene in LSCs 
but not normal HSCs85. This study proves the principle that it is realistic and feasible to 
find the specific genes in LSCs. Two more genes, Blk and Scd1, were identified. Blk 
belongs to the Src family kinases (SFKs). Since our previous studies have indicated that 
SFKs play dynamic roles in leukemogenesis, this promotes us to further investigate 
functional role of Blk in leukemogenesis using CML mouse model. Interestingly through 
analyzing our microarray data, we observed that many lipogenesis-related genes were 
significantly altered in LSCs compared to normal stem cells. Scd1 is a rate-limiting 
enzyme involved in converting saturated fatty acids into unsaturated fatty acids. 
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Therefore we chose Scd1 as our target gene to study out of hundreds of lipogenesis 
related candidate genes. The detailed experimental results will be described in 
CHAPTER III and IV respectively. 
 
Figure 6. Strategy for understanding the signature of LSCs 
 
LSC-specific regulator---Alox5 
The Alox5 gene encoding arachidonate 5-lipoxygenase (5-LO) is involved in 
numerous physiological and pathological processes, including oxidative stress response, 
inflammation and cancer 132-139. 5-LO is responsible for producing leukotrienes, a group 
of inflammatory substances that cause human asthma 140. Altered arachidonate 
metabolism by leukocytes and platelets was reported in association with 
myeloproliferative disorders almost 30 years ago 141. Several selective 5-LO inhibitors 
were found to reduce proliferation of and induce apoptosis of CML cells in vitro 142,143, 
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although potential off-target effects of these inhibitors were not excluded in these studies. 
However, the function of Alox5 in LSCs needs to be tested. Our microarray analysis 
showed that the Alox5 gene was upregulated by BCR-ABL in CML LSCs and that this 
upregulation was not inhibited by imatinib treatment 85, providing a possible explanation 
why LSCs are not sensitive to inhibition by BCR-ABL kinase inhibitors 63,64. 
Furthermore, recipients of BCR-ABL transduced bone marrow cells from Alox5-/- donor 
mice were resistant to the induction of CML by BCR-ABL 85. FACS analysis of CML 
cells from the peripheral blood and bone marrow of recipients receiving BCR-ABL-
transduced Alox5-/- donor bone marrow cells showed that myeloid leukemia cells 
proliferated initially, peaking around 2 weeks, then started to decline, and eventually 
disappeared after 7 weeks85. Alox5 deficiency mainly affected growth of BCR-ABL-
expressing but not non-BCR-ABL-expressing donor bone marrow cells85, suggesting that 
Alox5 signaling is much more critical for the function of LSCs than for normal HSCs. 
The effect of Alox5 on LSC function was further demonstrated and supported by the 
failure of BCR-ABL-expressing Alox5-/- bone marrow cells to induce CML in secondary 
recipient mice 85. Together, these results suggest that Alox5 could be a specific target 
gene in CML LSCs.  
 
Src family kinases in leukemogenesis 
The Src family kinases (SFKs) are non-receptor intracellular tyrosine kinases and 
are comprised of nine members: Src, Fyn, Yes, Blk, Yrk, Fgr, Hck, Lck and Lyn144. SFKs 
display diverse roles in leukemogenesis86,145,146,147. Enhanced phosphorylation levels of 
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Src have been found in primitive and committed progenitor cells isolated from CML 
patients88, and BCR-ABL interacts with and activates Hck and Lyn in myeloid cells 
through multiple binding domains145,87,148. Our previous data also show that BCR-ABL 
can activate the SFKs Lyn, Hck and Fgr in B-lymphoid cells86. These data suggest that 
SFKs are involved in the proliferation of BCR-ABL induced leukemia.  This is supported 
by the fact that the activation of Hck phosphorylates Tyr177 in the BCR moiety of BCR-
ABL, which promotes the binding of Grb2 leading to the activation of downstream 
pathways145. In addition, Hck also mediates BCR-ABL-dependent activation of STAT5 
149. Lyn-/- mice are hyperresponsive to myeloid growth factors and develop a 
myeloproliferative disorder, showing splenomegaly and increased numbers of myeloid 
progenitors150. Loss of two SFKs, Lyn and Hck, results in more HSCs with increased 
proliferation, reduced apoptosis and skewed differentiation to macrophages. In addition, 
Lyn-/-Hck-/- mice exhibit clinical signs indicative of a myeloproliferative disease by 2 
months of age151. However, deletion of three SFKs, Lyn, Hck and Fgr, does not affect 
hematopoiesis, and these mutant mice show no signs of myeloproliferative disease152. 
The role of SFKs in leukemogenesis also has been challenged by recent findings. Our 
previous data showed that deletion of Lyn, Hck and Fgr is dispensable for BCR-ABL 
induced CML but is required for B-cell acute lymphoblastic leukemia (B-ALL). These 
data indicate that SFKs might play a different role in hematopoiesis and leukemogenesis. 
The studies on another SFK, Blk, mainly focus on B cell development, and its role in 
leukemogenesis remains unknown. The absence of Blk modestly affects B cell 
development153; however, combined deficiency of the three Src kinase, Blk, Fyn, and 
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Lyn, impairs pre-B cell receptor mediated NF-kB activation, and results in blocking of B 
cell development154. As will be described in CHAPTER III, we find that Blk plays an 
inhibitory role in BCR-ABL-induced CML. Deletion of Blk accelerates CML 
development; conversely, overexpression of Blk suppresses the development of CML 
through its effects on the function of LSCs. Interestingly, we show that Blk is dispensable 
for normal hematopoiesis. Our data demonstrate an unexpected and critical role for Blk in 
leukemia stem cells. 
 
Scd1 and leukemogenesis 
Scd is an endoplasmic reticulum enzyme that belongs to a family of ∆9-fatty acid 
desaturase isoforms. Four mouse Scd isoforms (Scd1-4) and two human Scd isoforms 
(hScd1 and 5) have been identified155,156. Although these isoforms exhibit diverse tissue 
distribution patterns, they share the same enzymatic function that catalyzes the 
biosynthesis of monounsaturated fatty acids (MUFA) from saturated fatty acids (SFA) 
157. Scd1 expression is detected in almost all tissues with a predominant expression in 
liver156,158. Several transcriptional factors, including liver X receptor (LXR), sterol 
response element binding protein 1c (SREBP-1c), peroxisome proliferator activated 
receptor (PPAR), and estrogen receptor, are involved in the regulation of Scd1 
expression155. Serial biochemical assays showed SREBP1c induces Scd1 expression via 
binding to the sterol regulatory element (SRE) in the promoter of Scd1159. Treatment with 
the LXR agonist T0901317 induces SREBP-1c expression, suggesting that LXR directly 
activates SREBP-1 gene transcription, which subsequently induces Scd1 expression160. 
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However, the LXR agonist increases hepatic Scd1 expression in the absence of SREBP-
1c, suggesting the ability of LXR to regulate Scd1 also occurs via an SREBP-1c 
independent pathway. An LXR response element is identified in the promoter of Scd1, 
which mediates the direct transcriptional regulation of Scd1 by LXR161.  Additionally, 
diabetes patients treated with the PPAR gamma agonist, rosiglitazone, show higher Scd 
activity and expression162. Another PPAR gamma agonist, pioglitazone, could also 
increase the levels of Scd1 mRNA and protein in adipose tissue162. However, the exact 
mechanism of how PPAR regulates Scd1 expression is still unclear, although SREBP-1c 
seems to mediate this regulation. Furthermore, at the post-translational level, Scd1 can be 
degraded via an ubiquitin-dependent proteasome mechanism163.  
Scd1 is involved in regulating metabolic pathways related to preadipocyte 
differentiation, insulin sensitivity, metabolism, and tumorigenesis 157,164-167. Deletion of 
Scd1 leads to decreased synthesis of lipids, especially triglycerides, and causes the 
resistance to leptin-deficient-induced and diet-induced obesity via increased insulin 
sensitivity168. Scd1-/- mice have decreased expression of genes of lipogenesis and 
increased expression of lipid oxidative genes. Scd1 has been implicated in the pathology 
of several cancers. Increased Scd expression has been detected in human colonic 
carcinoma, and inhibition of Scd1 impairs proliferation, survival and invasiveness of lung 
cancer cells 165, suggesting that Scd1 plays a supporting role in lung cancer cells. The 
level of Scd1 expression also correlates with predisposition to liver carcinogenesis 166. 
However, prostate carcinoma displays lower Scd expression compared to normal prostate 
epithelium, suggesting that Scd might play an inhibitory role in cancer169. However, the 
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role of Scd1 in leukemogenesis and hematopoiesis remains unknown, although previous 
studies suggest that fatty acid metabolism plays a role in leukemogenesis and 
hematopoiesis 170,171. Using a BCR-ABL induced chronic myeloid leukemia mouse 
model, we find that deletion of Scd1 accelerates CML development through affecting the 
function of LSCs but not normal HSCs and that enforced expression of Scd1 dramatically 
delays the development of CML172. These findings suggest that Scd1 plays a tumor 
suppressor role in BCR-ABL leukemogenesis. It is known that Scd1 affects insulin 
signaling. Rahman et al. found that the phosphorylation levels of Akt, insulin receptor 
(IR) and insulin receptor substrates 1 and 2 (IRS1/2) were elevated in the absence of 
Scd1173. Conversely, stable overexpression of Scd1 in muscle cells decreased the 
phosphorylation of IRS1 and Akt and was sufficient to impair glucose uptake and insulin 
signaling. We find that deletion of Scd1 results in higher Akt phosphorylation in CML 
leukemia cells, and Scd1-/- LSCs also display dysregulated Pten, p53 and Bcl2 
expression172, suggesting these molecular changes downstream of Scd1 might be 
involved in the regulation of CML development by Scd1. Therefore, our study suggests a 
novel role for Scd1 in leukemogenesis. 
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CHAPTER II 
HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells 
 
The work described in this chapter has been published (Zhang et al., Blood 2012 119(11): 
2595-2607. 
 
Abstract 
Hypoxia-inducible factor-1α (HIF1α), a master transcriptional regulator of the 
cellular and systemic hypoxia response, is essential for the maintenance of self-renewal 
capacity of normal hematopoietic stem cells (HSCs). It is still unknown whether HIF1α 
has a role in survival regulation of leukemia stem cells (LSCs) in chronic myeloid 
leukemia (CML). Using a mouse model of CML, here we report that HIF1α plays a 
crucial role in survival maintenance of LSCs. Deletion of HIF1α impairs the propagation 
of CML through impairing cell cycle progression and inducing apoptosis of LSCs. 
Deletion of HIF1α results in elevated expression of p16Ink4a and p19Arf in LSCs, and 
knockdown of p16Ink4a and p19Arf rescues the defective colony-forming ability of HIF1α-/- 
LSCs. Compared to normal HSCs, LSCs appear to be more dependent on the HIF1α 
pathway. Together, these results demonstrate that HIF1α represents a critical pathway in 
LSCs and inhibition of the HIF1α pathway provides a therapeutic strategy for eradicating 
LSCs in CML. 
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Introduction 
Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder 
associated with the Philadelphia chromosome resulting from a reciprocal translocation 
between chromosomes 9 and 22. The molecular basis of this chromosomal translocation 
is the formation of the chimeric BCR-ABL protein that functions as a constitutively 
activated tyrosine kinase 1,2,174. Although BCR-ABL kinase inhibitors are highly effective 
in treating chronic phase CML patients 39, they do not efficiently kill leukemia stem cells 
(LSCs) 62.  It is generally accepted that eradication of LSCs is required for curing CML. 
On the one hand, LSCs share similar mechanisms for self-renewal and survival with 
normal hematopoietic stem cells (HSCs). For example, some developmental genes 
essential for normal HSCs, including Wnt, Hedgehog, Bmi-1, and p53, are involved in the 
regulation of both LSCs and HSCs 89-92. On the other hand, LSCs utilize pathways 
relatively specific for LSCs 85, providing a novel strategy for targeting LSCs while 
sparing normal HSCs. The challenge lies in the identification of genes that play a critical 
role in survival regulation of LSCs.  
Mammalian bone marrow provides a relatively hypoxic niche essential for 
maintaining the self-renewal and survival of primitive HSCs175,176. It is widely accepted 
that gradients of O2 from below 1% in the hypoxic niche to 6% in the sinusoidal cavity 
exist in human bone marrow 175. The hypoxic niche is crucial for bone marrow function 
because in vitro culture of hematopoietic progenitors under hypoxic conditions displays a 
decrease in cellular proliferation accompanied by accumulation of the cells at the G0 
phase of the cell cycle 177,178. Although the molecular mechanisms by which hypoxia 
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regulates HSCs remains largely unknown, accumulating evidence suggests that hypoxia-
inducible factor 1 (HIF1) plays a critical role in mediating the effect of hypoxia on HSCs 
177,179,180. In addition, it has been shown that cyclin-dependent kinase inhibitors that are 
regulated by HIF1α are associated with the function of hypoxia in HSCs 180. A recent 
study on HSCs in an animal model showed that regulation of the HIF1α level is essential 
for the survival of HSCs 181. In this study, it was found that normal HSCs maintain 
intracellular hypoxia and stabilize HIF1α protein, and HIF1α deficiency resulted in the 
loss of cell cycle quiescence in a p16Ink4a/p19Arf dependent manner, and subsequently 
impaired the reconstitution ability of HSCs during various stress settings including serial 
transplantation, myelosuppression and aging.  
HIF1 belongs to the family of basic helix-loop-helix (bHLH) transcription factors, 
and is a heterodimer that consists of a constitutively expressed HIF1β subunit and a 
HIF1α subunit 122. The expression of HIF1α is regulated in multiple ways. Under 
normoxic conditions, HIF1α is degraded rapidly, which is triggered by the oxygen-
hydroxylation of proline residues 402 and 564 by a proline hydroxylase (PHD). The 
hydroxylated HIF1α is recognized by the Von Hippel-Lindau protein (pVHL), which is 
the recognition component of an E3 ubiquitin-protein ligase 123,124. HIF1α expression is 
also regulated by growth factors, cytokines and other signaling pathways such as PI3K 
and MAPK pathways 125.  
Recent studies demonstrate that HIF1α plays a role in cancer progression by 
activating transcriptional programs for maintaining the ability of self-renewal and 
multipotency of cancer stem cells in a hypoxic environment 126-128, and that HIF1α was 
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required for stem cell functions of mouse lymphoma and human acute myeloid leukemia 
182. However, it is still unknown whether HIF1α plays a role in LSCs in CML. In this 
study we show that HIF1α is up-regulated in BCR-ABL-expressing LSCs and is required 
for survival maintenance of LSCs in CML.  
 
Results 
Hypoxia-responsive genes are up-regulated by BCR-ABL in LSCs 
We have shown that BCR-ABL-expressing HSCs (Lin-Sca-1+c-Kit+ cells, LSK 
cells) function as LSCs in CML mice, because this cell population isolated from primary 
CML mice effectively transfers the disease into lethally irradiated secondary recipient 
mice 63. This provides us with an assay system to examine whether BCR-ABL alters 
expression of hypoxia-responsive genes. We conducted a DNA microarray analysis to 
compare the gene expression profiles between LSCs and normal HSCs in our bone 
marrow transplantation (BMT) mouse model of CML (GEO submission: GSE10912). 
We retrovirally transduced bone marrow cells from C57BL/6J (B6) mice with BCR-
ABL-GFP or GFP alone (as a normal HSC control) and transplanted the transduced cells 
into lethally irradiate B6 recipient mice to induce CML. Two weeks after BMT, we 
sorted GFP+LSK cells from bone marrow of the mice, and total RNA was extracted from 
the sorted cells for the Affymetrix microarray analysis. We intended to determine the 
global status of HIF1α activity in LSCs, and found that the HIF1α and its targets were up-
regulated by BCR-ABL in LSCs as compared to the LSK cells transduced with GFP 
alone (Fig. 1A, B), which is enriched for normal HSCs. We next examined expression of 
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genes known to be specifically regulated by HIF1α, and found that expression of VEGF, 
GLUT1 and TGFα, except for PGK1, were significantly higher in LSCs than in normal 
HSCs (Fig. 1C). Real time RT-PCR assay confirmed the up-regulation of HIF1α and 
hypoxia-responsive genes by BCR-ABL in LSCs (Fig. 1D). PGK1 was also significantly 
up-regulated in LSCs (Fig. 1D). Together, these results suggest that HIF1α is involved in 
functional regulation of LSCs and CML development. 
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Figure 1. Hypoxia-responsive genes are up-regulated in LSCs. LSCs and control 
HSCs were sorted from mice receiving BCR-ABL or empty vector-transduced bone 
marrow cells for DNA microarray analysis. (A) The heatmap compares the activation of 
the HIF1α signaling pathway in LSCs and control HSCs. (B) Gene set enrichment 
analysis (GSEA) displays the expression profiling of HIF1α targets in LSCs (P<0.001). 
(C) Microarray data showed higher expression of HIF1α, vascular endothelial growth 
factor (VEGF), glucose transporter type 1 (GLUT1), and transforming growth factor 
alpha (TGFα) in LSCs comparing to normal HSCs. (D) Real time RT-PCR was 
performed with primers specific for HIF1α, VEGF, GLUT1, TGFα, and 
phosphoglycerate kinase 1 (PGK1). The results were normalized using actin as a control, 
and shown as mean±s.d. * P<0.05; ** P<0.01. 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Figure 1. Hypoxia-responsive genes are up-regulated in LSCs. 
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HIF1α is essential for CML development 
To determine the role of HIF1α in BCR-ABL leukemogenesis, we asked whether 
HIF1α is required for CML development. Because deletion of the HIF1α gene is 
embryonic lethal 183, we crossed mice carrying a loxP-flanked HIF1α allele with Cre 
transgenic mice in which expression of Cre is driven by the Vav regulatory element (Fig. 
2A). Since Vav is an adaptor protein expressed predominantly in hematopoietic cells 
including the HSC population 184, the use of the Vav regulatory element causes the 
deletion of the HIF1α gene mainly in the hematopoietic system, allowing Vav-Cre-
HIF1αflox/flox mice to survive after HIF1α deletion. To examine whether HIF1α was 
efficiently deleted in Vav-Cre-HIF1αflox/flox mice, we sorted LSK cells from bone marrow 
and analyzed HIF1 α expression by RT-PCR. We did not detect HIF1α expression in 
LSK cells of Vav-Cre-HIF1αflox/flox mice as compared to HIF1αflox/flox mice (Fig. 2A). For 
simplicity, Vav-Cre-HIF1αflox/flox mice will be referred to as HIF1α-/- mice and 
HIF1αflox/flox mice as wild type (WT) mice.  
We first studied the role of HIF1α in CML development using HIF1α-/- mice in 
our bone marrow transplantation (BMT) model. Bone marrow cells from 5-FU-treated 
wild type (WT) or HIF1α-/- mice were transduced with empty vector (GFP alone) or 
BCR-ABL-GFP retrovirus, and then transplanted into lethally irradiated recipient mice. 
While recipients of empty vector transduced WT or HIF1α-/- bone marrow cells did not 
develop CML disease, recipients of BCR-ABL-transduced WT or HIF1α-/- bone marrow 
cells developed and succumbed to CML within 4 weeks after BMT; however, no 
significant difference in survival was observed in WT and HIF1α-/- CML mice (Fig. 2B), 
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which correlated with similar percentages at day 14 post BMT (Fig. 2C) and total 
numbers of myeloid leukemia cells in peripheral blood (PB) of CML mice as analyzed at 
day 8 and 11 post BMT (Fig. 2D). However, we noticed that at day 14 post BMT, the 
number of PB leukemia cells in mice receiving the BCR-ABL transduced HIF1α-/- bone 
marrow cells was significantly less than that in mice receiving the BCR-ABL transduced 
WT marrow cells (Fig. 2D). This observation suggests a possibility that HIF1α plays a 
role in functional regulation of LSCs in CML. We also examined the spleens and bone 
marrow of CML mice, and found both WT and HIF1α-/- CML mice displayed similar 
percentages of leukemia cells in the spleens and bone marrow at 2 weeks after BMT (Fig. 
S1A).  Additionally, there was no significant difference in the degree of splenomegaly 
between the two groups of the CML mice (Fig. 2E).  
Therefore, we decided to do a secondary transplantation assay to biologically 
assess the effect of HIF1α on LSCs. We induced primary CML by transducing bone 
marrow cells from WT or HIF1α-/- mice, followed by transplantation of the transduced 
cells into WT recipient mice. We then conducted a secondary BMT by transferring bone 
marrow cells from primary CML mice at day 14 to secondary recipient mice. Prior to the 
transplantation, we analyzed and normalized LSCs (GFP+LSK) from bone marrow of 
primary CML mice receiving BCR-ABL transduced WT or HIF1α-/- donor bone marrow 
cells to ensure that equal numbers of LSCs were injected for the two transplantation 
groups. For control, we also transplanted equal numbers of normal GFP+LSK cells from 
primary control mice receiving empty vector transduced WT or HIF1α-/- donor bone 
marrow cells into secondary recipient mice; to match up with the time frames for CML 
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transplantation, we did secondary transplantation on day 14 after primary transplantation 
and analyzed the secondary recipient mice within a month. HIF1α-/- LSCs failed to 
induce CML in the secondary recipient mice, whereas WT LSCs efficiently induced 
CML and all secondary recipient mice died within 4 weeks post BMT (Fig. 2B). The 
defective CML phenotype in the absence of HIF1α was consistent with a gradual 
decrease of the percentages and total numbers of leukemia cells in peripheral blood (Fig. 
2C, D). Unlike CML secondary transplantation (Fig. 2C), we observed that the 
percentages and total numbers of GFP+ cells in peripheral blood of non-BCR-ABL mice 
gradually decreased to low levels in secondary recipients of WT or HIF1α-/- bone marrow 
cells (Fig. 2C, D), presumably because serial BMT within a short time period 
significantly increases the replicative stress, affecting the cycling ability of control 
HSCs185. Additionally, recipients of HIF1α-/- LSCs displayed much less severe 
splenomegaly than did recipients of WT LSCs (Fig. 2E, F). Consistently, histological 
analysis showed no or modest infiltration of leukemia cells in the lung and spleen of the 
secondary recipient mice receiving HIF1α-/- LSCs from primary CML mice (Fig. 2G). 
These results indicate that HIF1α is required for CML development. 
 Constitutive expression of Cre may be toxic186 . It is possible that Vav-driven 
expression of Cre causes damage on HSCs prior to BCR-ABL transduction, resulting in 
the defective CML development. In addition, 5FU is more detrimental to HIF1α -/- HSCs 
181, potentially causing a defect in CML development. To examine these possibilities, we 
constructed BCR-ABL-iCre-GFP retroviral construct to allow co-expression of BCR-
ABL and iCre in the same cell187. We transduced bone marrow cells from both WT and 
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HIF1αflow/flow mice with BCR-ABL-iCre-GFP retrovirus, and transplanted into recipient 
mice. If Cre and 5-FU are toxic to bone marrow cells, both WT and HIF1αflow/flow cells 
should be equally affected, allowing us to assess the additional effect of HIF1α deletion 
on CML development. Recipients of BCR-ABL-iCre transduced WT and HIF1αflow/flow 
bone marrow cells similarly developed CML, consistent with the findings for primary 
CML using WT and HIF1α-/- mice (Fig. 2B). The secondary BMT confirmed the failure 
of CML development after deletion of HIF1α (Fig. 2H, I). 
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Figure 2. HIF1α is essential for CML development. (A) Deletion of HIF1α in 
hematopoietic cells. Mice carrying the floxed HIF1α allele were crossed with Vav-Cre 
transgenic mice in which the Vav promoter drives the expression of the Cre recombinase. 
RT-PCR analysis showed that HIF1α was undetectable in sorted HSCs (Lin-Sca-1+c-Kit+) 
from HIF1αflox/flox-Vav-Cre mice. (B) Kaplan-Meier survival curves for primary and 
secondary recipients of empty vector or BCR-ABL-transduced bone marrow cells from 
WT or HIF1α-/- donor mice. For secondary bone marrow transplantation, bone marrow 
cells from primary control and CML recipient mice which received empty vector or BCR-
ABL-transduced WT and HIF1α-/- bone marrow cells were analyzed by FACS, and bone 
marrow cells containing equal number of WT or HIF1α-/- GFP+Lin-Sca-1+c-Kit+ cells 
along with 2x105 WT BM cells (CD45.1) were transplanted into each lethally irradiated 
secondary recipient mouse. (C) FACS analysis of GFP+Gr-1+ cells in peripheral blood of 
primary and secondary recipients of empty vector or BCR-ABL-transduced bone marrow 
cells from WT or HIF1α-/- donor mice (n=5). Mean values (± s.d.) are shown. (D) The 
total numbers of GFP+Gr-1+ cells in peripheral blood of primary and secondary recipients 
of empty vector or BCR-ABL-transduced bone marrow cells from WT or HIF1α-/- donor 
mice (n=5). Mean values (± s.d.) are shown. * P<0.05; ** P<0.01; *** P<0.001. (E) The 
spleen weight of primary and secondary recipients of empty vector or BCR-ABL-
transduced bone marrow cells from WT or HIF1α-/- donor mice (n=12). Mean values (± 
s.d.) are shown. *** P<0.001. (F) Gross appearance of the lungs and spleens showed 
severe lung hemorrhages and splenomegaly in secondary recipients of WT LSCs but not 
HIF1α-/- LSCs at day 14 after BMT, compared to those from recipients of WT and 
HIF1α-/- HSCs. (G) Hematoxylin/eosin staining of tissue sections from lung and spleen 
of secondary recipients. The scale bar represents 50 µm. (H) Kaplan-Meier survival 
curves for the secondary bone marrow transplantation. Bone marrow cells from WT or 
HIF1αflox/flox mice were transduced with BCR-ABL-iCre-GFP retrovirus, and transplanted 
into lethally irradiated recipient mice. CML cells without HIF1α failed to induce CML 
disease in the secondary BMT. (I) The percentages of leukemia cells in peripheral blood 
at day 14 in WT and HIF1α-/- secondary CML mice. 
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Figure 2. HIF1α is essential for CML development. 
   
51 
Deletion of HIF1α does not affect transfection efficiency and the homing ability of 
leukemia cells 
The failure of CML induction in the secondary recipients could also be related to 
a change in retroviral transduction efficiency caused by the deletion of HIF1α. To rule 
out this possibility, we compared GFP expression between empty GFP vector or BCR-
ABL-GFP transduced WT and HIF1α-/- bone marrow cells by FACS prior to BMT, and 
found that the percentages of GFP+ cells were similar between the transduced WT and 
HIF1α-/- cells (Fig. 3A). These results indicate that HIF1α deletion does not affect 
retroviral transduction efficiency. In addition, a failure of cell homing potentially resulted 
from the loss of HIF1α may cause the failure of CML induction. To rule out this 
possibility, we performed an in vivo homing analysis comparing the ability of WT and 
HIF1α-/- bone marrow cells. Equal number of WT or HIF1α-/- bone marrow cells was 
injected into lethally irradiated CD45.1 mice. 3 hours after BMT, FACS analysis showed 
that the percentages of WT and HIF1α-/- donor-derived cells representing by CD45.2 
were similar (Fig. 3B). To confirm this result in BCR-ABL-expressing leukemia cells, 
we transplanted equal number of leukemia cells from bone marrow of primary CML mice 
receiving BCR-ABL-transduced WT or HIF1α-/- bone marrow cells into recipients. 3 
hours after BMT, we did not observe a defective homing ability of BCR-ABL transduced 
HIF1α-/- cells (Fig. 3C). Furthermore, using the same strategy, we compared the homing 
ability of WT or HIF1α-/- LSCs with that of WT or HIF1α-/- normal stem cells, and did 
not observe a reduced homing ability of HIF1α-/- LSCs and normal stem cells (Fig. 3D).  
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Figure 3. Effects of HIF1α deletion on retroviral transduction efficiency and the 
homing ability of normal and BCR-ABL transduced total bone marrow cells or 
LSK cells. (A) HIF1α  deletion does not affect retroviral transduction efficiency. WT and 
HIF1α -/- bone marrow cells were transduced with empty vector or BCR-ABL-GFP 
retrovirus, and 2 days later, the percentages of GFP+ cells were determined by FACS. (B) 
FACS analysis showed the similar homing ability of WT and HIF1α -/- bone marrow 
cells. 3×106 bone marrow cells from WT or HIF1α -/- mice (CD45.2) were transplanted 
into lethally irradiated recipients (CD45.1). The donor-derived bone marrow cells 
(CD45.2) were detected by FACS in 3 hours after BMT (n=4). Mean values (± s.d.) are 
shown. NS, no significance. (C) HIF1α deletion does not cause a reduction of the homing 
ability of BCR-ABL transduced bone marrow cells. 2×106 leukemia cells (GFP+) from 
CML mice transplanted with BCR-ABL-transduced WT or HIF1α -/- bone marrow cells 
were transplanted into lethally irradiated recipients (CD45.1). 3 hours later, donor-
derived leukemia cells (GFP+) in the bone marrow were detected by FACS (n=4 for each 
group). Mean values (± s.d.) are shown. **P<0.01. (D) HIF1α deletion does not cause a 
reduction of the homing ability of control or BCR-ABL transduced stem cells. Bone 
marrow cells were transduced with GFP vector or BCR-ABL-GFP, and 2×104 sorted 
normal HSCs and LSCs (GFP+Lin-Sca-1+c-Kit+) were transplanted into lethally irradiated 
recipients (CD45.1). 3 hours later, donor-derived leukemia cells (GFP+) in the bone 
marrow were detected by FACS (n=3 for each group). Mean values (± s.d.) are shown. 
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Figure 3. Effects of HIF1α deletion on retroviral transduction efficiency and the 
homing ability of normal and BCR-ABL transduced total bone marrow cells or 
LSK cells. 
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HIF1α is essential for survival maintenance of LSCs 
Because CML is derived from a stem cell 2, an inhibitory effect of HIF1α 
deficiency on LSCs is likely a cause for the defect of CML development (Figure 2). To 
test this idea, we first examined LSCs in primary CML mice, and did not observe 
significant differences in the percentages and total numbers of LSCs (GFP+LSK and 
GFP+CD48-CD150+LSK) between WT and HIF1α-/- CML mice (Fig. S1B, C), consistent 
with the similar survival of WT and HIF1α-/- primary CML mice (Fig. 2B). We further 
analyzed LSCs in the secondary recipient mice receiving WT or HIF1α-/- LSCs from 
primary CML mice (Fig. 4A). Two weeks post the secondary BMT, the percentages and 
numbers of LSCs (GFP+LSK and GFP+CD48-CD150+LSK) in the bone marrow were 
dramatically lower in the absence of HIF1α (Fig. 4B, C), indicating that HIF1α is 
required for survival maintenance of LSCs. 
           To investigate whether HIF1α affects self-renewal of LSCs, we carried out an in 
vitro serial colony-forming assay. We sorted normal stem cells and LSCs (GFP+LSK) 
from control or CML mice receiving empty vector or BCR-ABL-transduced WT or 
HIF1α -/- bone marrow cells, and plated the cells in vitro. We observed that comparing to 
WT LSK cells, HIF1α -/- LSK cells generated similar colonies in the 1st and 2nd plating, 
and less colonies in the 3rd plating. In contrast, comparing to WT LSCs, HIF1α -/- LSCs 
gave rise to less colonies in all three plating, indicating that deletion of HIF1α results in a 
more significant reduction of self-renewal ability of LSCs (Fig. 4D). 
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Figure 4. HIF1α deletion suppresses LSCs. (A) FACS analysis of LSCs in bone 
marrow of secondary recipients of WT or HIF1α-/- bone marrow cells from primary CML 
mice. (B, C) The percentages and total numbers of stem cells (GFP+Lin-Sca-1+c-Kit+ 
cells and GFP+CD48-CD150+Lin-Sca-1+c-Kit+ cells) in bone marrow of secondary 
recipient mice receiving bone marrow cells from WT or HIF1α-/- control and CML mice 
were analyzed by FACS. * P<0.05; ** P<0.01. (D) The loss of HIF1α causes a decrease 
in the colony-forming ability of LSCs. Sorted normal HSCs and LSCs (GFP+Lin-Sca-1+c-
Kit+ cells) were plated into methycellulose medium, colonies were counted and cells 
were serially replated. Data showed results from representative experiments. Mean values 
(± s.e.m) are shown. *P<0.05; ***P<0.001. 
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      Figure 4. HIF1α deletion suppresses LSCs. 
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HIF1α is required for survival maintenance of LSCs 
To understand the mechanism by which HIF1α maintains the survival of LSCs, 
we analyzed the effect of HIF1α on cell cycle progression and apoptosis of LSCs. We 
found that deletion of HIF1α resulted in an accumulation of cells in the G0-G1 phase and 
a concomitant reduction in the S phase of the cell cycle (Fig. 5A), suggesting that HIF1α 
deficiency impaired cell cycle progression of LSCs. HIF1α is important for maintaining 
the quiescence of HSCs, and loss of HIF1α promotes cell cycle entry180,181. Therefore, we 
further examined the cell cycle kinetics of HIF1α -/- LSCs using Ki67. A reduction in the 
Ki67- G0 fraction and an increase in the Ki67+ G1 fraction were observed in HIF1α -/- 
LSCs, as compared to WT LSCs (Fig. 5B). These results indicate that HIF1α regulates 
cell cycle progression of LSCs. Furthermore, by staining the cells with annexin V and 
7AAD, we found that HIF1α-/- LSCs had a higher apoptotic rate than WT LSCs (Fig. 
5D). To further demonstrate the induction of apoptosis of LSCs by HIF1α deficiency, we 
examined active caspase 3 in WT and HIF1α -/- leukemia progenitors. We observed an 
increase in the number of active caspase 3-positive cells among HIF1α-/- leukemia 
progenitor cells, as compared to WT cells (Fig. 5E). We also examined the effect of 
HIF1α on cell cycle and apoptosis of normal HSCs, and unlike the observed effects on 
cell cycle progression and apoptosis of LSCs (Fig. 5A, D; top panels), we did not 
observe any significant differences between WT HSCs and HIF1α-/- HSCs (Fig. 5A, D; 
bottom panels).  
 To understand the molecular mechanism by which HIF1α regulates the function 
of LSCs, we compared the gene expression profiling between HIF1α-/- LSCs and WT 
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LSCs (Table 1 and 2) and found that the cyclin-dependent kinase inhibitors p16Ink4a and 
p19Arf were up-regulated in HIF1α-/- LSCs. Real-time PCR confirmed higher levels of 
expression of p16Ink4a and p19Arf in HIF1α-/- LSCs (Fig. 5C). Expression of another 
cyclin-dependent kinase inhibitor p57 was also higher in HIF1α-/- LSCs than in WT LSCs 
(Fig. 5C). Elevated expression of p16Ink4a and p19Arf was also observed in HIF1α-/- 
normal HSCs (Fig. 5C), which is consistent with previous studies181. However, 
expression of p57 was unchanged in HIF1α-/- normal HSCs (Fig. 5C), indicating that loss 
of HIF1α might not alter an identical set of genes in LSCs and normal HSCs. To test 
whether p16Ink4a and p19Arf mediate the function of HIF1α in LSCs, we knocked down 
the expression of p16Ink4a and p19Arf in LSCs using lentivirus-mediated shRNA to 
evaluate whether repression of p16Ink4a and p19Arf rescues the defective LSCs function 
caused by HIF1α deletion. Because the transcripts of p16Ink4a and p19Arf share the exons 2 
and 3, we designed a single shRNA to simultaneously knockdown expression of both 
genes in p53-/-MEF cells that express higher levels of p16Ink4a and p19Arf (Fig. 5G). In a 
colony-forming assay, we infected WT or HIF1α-/- CML bone marrow cells with the 
p16Ink4a/p19Arf shRNA, and found that HIF1α-/- CML bone marrow cells formed less 
numbers of colonies than did WT cells, and knockdown of p16Ink4a and p19Arf allowed the 
formation of more colonies in secondary and third replating. This result indicates that 
reduced function of HIF1α-/- LSCs was restored by repressing expression of p16Ink4a and 
p19Arf, demonstrating that the regulatory function of HIF1α in LSCs is at least in part 
mediated by p16Ink4a and p19Arf.  
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           Because elevated p16Ink4a and p19Arf are related to the induction of stem cell 
senescence188,189, we examined the senescent status of HIF1α-/- LSCs and normal HSCs. 
Sorted LSCs and normal HSCs from WT and HIF1α-/- CML mice and control mice were 
stained with β-galactosidase. We observed a similar frequency of β-galactosidase-
positive LSCs and normal HSCs (Fig. 5H), suggesting that senescence is not responsible 
for the impaired maintenance of HIF1α-/- LSCs. In addition, we also observed an 
increased expression of the apoptotic gene p53 in HIF1α-/- LSCs (Fig. 5F), which 
supports our observation of increased apoptosis of HIF1α-/- LSCs (Fig. 5D).  
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Table 1. List of up-regulated genes (HIF1α-/- LSCs vs WT LSCs) 
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Table 2. List of down-regulated genes (HIF1α-/- LSCs vs WT LSCs) 
 
 
 
 
 
 
 
   
62 
Figure 5. HIF1α is required for survival maintenance of LSCs. (A) The cell cycle 
analysis of normal HSCs and LSCs. The percentages of HIF1α-/- LSCs were low in the S 
phase and higher in the G0-G1 phase, as compared to WT LSCs (n=6). However, normal 
WT and HIF1α-/- HSCs showed similar percentages of cells in G0-G1, S and G2-M 
phases.  (B) The cell cycle analysis of LSCs using Ki67 and Hoechst 33342 showed an 
accumulation of G1 phase of HIF1α-/- LSCs. (C) RT-PCR analysis showed elevated 
expression of cell cycle inhibitors p16Ink4a, p19Arf, and p57 in the sorted HSCs and LSCs 
from HIF1α-/- control and CML mice as compared to the sorted HSCs and LSCs from 
WT control and CML mice. Bone marrow cells from control and CML mice at day 14 
post BMT were collected, and HSCs and LSCs were sorted for extracting total RNA. 
Mean values (± s.d.) are shown ** P<0.01; *** P<0.001. (D) The apoptosis of normal 
HSCs and LSCs from bone marrow of control and CML mice (n=6). HIF1α deletion 
induced the apoptosis of LSCs, but did not affect the apoptosis of normal HSCs. (E) 
FACS analysis showed a higher percentage of active caspase positive HIF1α-/- leukemia 
progenitors. (F) RT-PCR analysis showed elevated expression of p53 in the sorted LSCs 
from HIF1α-/- CML mice comparing to the sorted LSCs from control CML mice. Mean 
values (± s.d.) are shown. ** P<0.01. (G) Simultaneous knockdown of p16Ink4a and p19Arf 
rescued the colony-forming ability of HIF1α-/- LSCs. Western blot analysis showed that 
protein levels of p16Ink4a and p19Arf in p53-/- MEF and CML leukemia cells were 
dramatically reduced by shRNA#1 that targets both p16Ink4a and p19Arf. Bone marrow 
cells from WT and HIF1α-/- normal or CML mice were infected by shRNA#1, and plated 
into methycellulose media after selection by puromycin. Colonies were counted and cells 
from the colonies were serially replated. Mean values (± s.d.) are shown ** P<0.01; *** 
P<0.001. (H) Loss of HIF1α did not affect the senescence of normal HSCs and LSCs. 
Sorted GFP+Lin-Sca-1+c-Kit+ cells from the bone marrow of WT or HIF1α-/- control and 
CML mice were stained by X-Gal, and the number of β-galactosidase expressing cells 
were counted. 
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Figure 5. HIF1α is required for survival maintenance of LSCs 
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Loss of HIF1α has different effects on LSCs and normal HSCs 
To further examine the involvement of HIF1α in functional regulation of LSCs, 
we examined whether deletion of HIF1α causes reduced expression of several HIF1α 
target genes. We found that as compared to WT LSCs, expression levels of VEGF and 
GLUT1 in HIF1α-/- LSCs were reduced by approximately 50% (Fig. 6A); however, there 
were no significant differences in the expression of TGF α and PGK1 between HIF1α-/- 
and WT LSCs (Fig. 6A). These results suggest that these hypoxia-responsive genes are 
responsive to HIF1α in LSCs. To determine whether loss of HIF1α also similarly affects 
normal HSCs, we sorted HSCs from bone marrow of WT and HIF1α-/- bone marrow 
cells, and compared expression of these HIF1α target genes by RT-PCR. We found that 
loss of HIF1α did not cause a significant reduction of expression of VEGF and GLUT1 in 
normal HSCs, although expression of these two genes was down-regulated in HIF1α-/- 
LSCs (Fig. 6A). Furthermore, we conducted a microarray assay to examine expression of 
HIF1α target genes in HIF1α-/- LSCs and HIF1α-/- HSCs and to evaluate the data using 
GSEA algorithm190,191. The enrichment plots showed that HIF1α targets were generally 
down-regulated in both LSCs and HIF1α-/- HSCs, but the extent of this downregulation 
was much more significant in HIF1α-/- LSCs than HIF1α-/- HSCs (P<0.001 vs. P<0.03) 
(Fig. 6B). Together, these results suggest that relative to normal HSCs, LSCs are more 
dependent on the HIF1α pathway. 
 The differential expression of the HIF1α target genes in LSCs and HSCs 
prompted us to further examine the biological effect of HIF1α on normal HSCs in our 
Vav-Cre-HIF1αflox/flox mice. It is also necessary to point out that in our Vav-Cre-
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HIF1αflox/flox mice, HIF1α was deleted by the Vav-Cre in contrast to the deletion of 
HIF1α by Mx1-Cre 181. We observed that the percentage of LSK cells (Lin-Sca-1+c-Kit+) 
in HIF1α-/- mice was significantly higher than that in WT mice (Fig. 6C). The higher 
percentage of LSK cells in HIF1α-/- mice was largely due to the effect of HIF1α deletion 
on MPP population (Lin-Sca-1+c-Kit+CD34+Flt3+) and ST-HSCs (Lin-Sca-1+c-
Kit+CD34+Flt3-), but not on LT-HSCs (Lin-Sca-1+c-Kit+CD34-Flt3-), as the percentage of 
LT-HSCs was only slightly lower in HIF1α-/- mice than in WT mice (Fig. 6C). 
Furthermore, a lower percentage of CD41-CD48-CD150+LSK was also found in HIF1α-/- 
mice as compared to WT mice (Fig. 6D). This is in line with previous study showing that 
HIF1α-null HSC are still able to support hematopoiesis in physiological conditions181. 
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Figure 6. Effects of HIF1α deficiency on normal HSCs. (A) RT-PCR analysis for the 
expression of HIF1α, VEGF, GLUT1, TGFα, and PGK1 in WT or HIF1α-/- normal HSCs 
and LSCs. (B) Gene set enrichment analysis of DNA microarray data displays gene 
expression profiling of HIF1α targets in WT or HIF1α-/- normal HSCs and LSCs. (C) 
FACS analysis of HSCs in bone marrow cells from WT or HIF1α-/- mice. The 
percentages of LSK cells (Lin-Sca-1+c-Kit+), LT-HSCs (Lin-Sca-1+c-Kit+CD34-CD135-) 
and ST-HSCs (Lin-Sca-1+c-Kit+CD34-CD135+) were similar in WT and HIF1α-/- mice; 
however, HIF1α-/- mice showed higher percentage of MPP (Lin-Sca-1+c-
Kit+CD34+CD135+) (n=5). (D) Similar percentages of CD41-CD48-CD150+ Lin-Sca-1+c-
Kit+ cells in bone marrow cells of WT or HIF1α-/- mice (n=3).  
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Figure 6. Effects of HIF1α deficiency on normal HSCs 
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Discussion 
HIF has been shown to be involved in cancer development122,128,192. In this study, 
we utilized mice with conditional deletion for HIF1α to provide the first evidence for an 
essential role of HIF1α in CML development and maintenance of LSCs. Because HIF1α 
deficiency results in elevated expression of cell cycle inhibitors p16Ink4a, p19Arf and p57 
and apoptotic gene p53 in LSCs, inhibition of the HIF1α pathway is likely to be effective 
in eradicating LSCs, providing a rationale for developing an anti-HIF1α therapy in 
treating CML.  
We demonstrate that HIF1α is required for survival regulation of LSCs in CML 
mice, and that HIF1α and its target genes are up-regulated in LSCs by BCR-ABL, which 
is consistent with BCR-ABL up-regulation of HIF1α mRNA expression in a leukemia 
cell line 129. The PI3K and mTOR pathways appear to be responsible for BCR-ABL-
dependent HIF1α expression in Ba/F3 cells129. Consistent with a previous report showing 
a higher level of VEGF expression in the plasma and serum of CML patients 193, we 
show that expression of VEGF is elevated in LSCs in CML mice. We also show a higher 
level of GLUT1 expression in LSCs, consistent with a previous observation that BCR-
ABL expression alters the distribution of GLUT1 in cell plasma membrane of TonB210 
cells 194. Interestingly, HIF1a deletion causes an increased homing ability of BCR-ABL-
expressing leukemia cells to bone marrow, consistent with increased expression of some 
homing-related genes such as MMP-14, CXCL10, CCL19 (data not shown). The 
underlying mechanisms need to be further studied in the future.  
Our study suggests that HIF1α deletion induces a tumor suppressor response in 
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LSCs through induction of expression of p16Ink4a, p19Arf, and p53. In addition, the 
elevated expression of p16Ink4a and p19Arf are not specific to LSCs, as HIF1α deficiency 
also induces their expression in normal HSCs 181. This is consistent with a previous study 
showing that the enforced expression of p16Ink4a and p19Arf in HSCs resulted in cell cycle 
arrest and p53-dependent apoptosis, and caused the exhaustion of HSCs90. Our data 
suggest that p16Ink4a and p19Arf contribute to the exhaustion of LSCs. On the other hand, it 
is known that HIF1α is essential for cell cycle arrest during hypoxia195. HSCs cultured in 
hypoxia in vitro increased their long-term reconstitution ability through maintaining 
quiescence of HSCs180. Because HIF1α deletion induces the loss of LSC quiescence and 
accumulation of the cells in the G1 phase, up-regulated expression of p16Ink4a and p19Arf 
induced by HIF1α deletion may inhibit the transition of G1/S phase of cell cycle through 
binding to cyclin D-dependent CDK4/6196. Indeed, we observed an increase of HIF1α -/- 
LSCs in G1 phase and a decrease of the cells in S phase. Furthermore, knockdown of 
p16Ink4a and p19Arf rescues the defect of HIF1α -/- LSCs to form colonies. It has been 
reported that Ink4a-Arf−/− HSCs retain their self-renewal capacity better than wild type 
HSCs in a long-term ex vivo culture197, and repression of p16Ink4a and p19Arf by 
overexpressing Bmi1 restores the reconstitution ability of HIF1α -/- HSCs181. However, 
other cell cycle regulators might also play a role in mediating the function of HIF1α in 
LSCs, because up-regulated expression of p21 and p27 in HIF1α-deficient cells is also 
associated with an increased number of cells in the G1 phase and a decreased number of 
cells in the S phase of the cell cycle126. Mechanistically, it is also possible that cellular 
senescence induced by HIF1α deficiency facilitates the exhaustion of HIF1α -/- LSCs and 
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HSCs, which is likely caused by the upregulation of p16ink4a and p19Arf. Although a 
previous work suggests that HIF1α plays a protective role against senescence181, a solid 
supporting evidence is still lacking. In fact, we observe that HIF1α deficiency causes 
decreased proliferation of LSCs, indicating a different mechanism.  
HIF1a appears to play a protective role under stress setting, such as in vitro 
culture, 5-FU treatment and oncogene transformation. In our study, we use the Vav 
promoter to drive Cre expression in order to delete the HIF1α gene predominantly in 
hematopoietic system. Another advantage of using Vav-driven Cre expression is to avoid 
the effect of IFN signaling on LSCs and HSCs in the popularly used Mx1-Cre expression 
system198,199. Furthermore, Vav-Cre-HIF1αflox/flox mice are viable and has a basically 
normal lifespan. Thus, our Vav-Cre-HIF1αflox/flox mice will provide a valuable model for 
in-depth study of the role of HIF1α in LSCs and BCR-ABL leukemogenesis for 
developing novel therapeutic strategies in CML treatment. 
 
Materials and Methods 
Mice. HIF1αflox/flox C57BL/6J, Vav1-Cre-C57BL/6J, C57BL/6J-CD45.1 and C57BL/6J-
CD45.2 mice were obtained from The Jackson Laboratory (Bar Harbor, Maine). All mice 
were bred and maintained in a temperature- and humidity-controlled environment and 
given unrestricted access to 6% chow diet and acidified water. 
Generation of retroviral stocks. The retroviral constructs MSCV-IRES-GFP, MSCV-
BCR-ABL-IRES-GFP were used to generate high-titer, helper-free, replication-defective 
ecotropic viral stocks by transient transfection of 293T cells as previously described 23. 
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The MSCV-BCR-ABL-iCre-GFP construct was made by cloning the iCre ORF into the 
MSCV-BCR-ABL vector, and cloning the IRES-GFP fragment after the iCre ORF, as 
described previously187. 
Bone marrow transduction/transplantation. 8 to 12 week-old C57BL/6 mice were 
used for bone marrow transduction/transplantation. Retroviral transduction and 
transplantation of mouse bone marrow cells for inducing CML by BCR-ABL had been 
described previously 23,86. For secondary transplantation, equal number of bone marrow 
cells from primary CML mice was transplanted into lethally irradiated recipient mice. 
Flow cytometry analysis. Hematopoietic cells were collected from bone marrow and 
peripheral blood of CML mice for FACS analysis. For stem cell analysis, bone marrow 
cells were incubated with biotin-labeled lineage antibody cocktail containing a mixture of 
antibodies against CD3, CD4, CD8, B220, Gr-1, Mac-1 and Ter119. After washing, the 
fluorochrome-labeled secondary antibody (APC-Cy7-conjugated Streptavidin) for 
recognizing biotin and PE-conjugated c-Kit and APC-conjugated Sca-1 antibodies were 
added to the cells. Long-term and short-term stem cells were distinguished by CD34 and 
CD135 or SLAM markers CD41, CD48, and CD150. All these antibodies were 
purchased from eBioscience. 
        Cell cycle analysis of LSCs was performed by staining cells with antibodies in 
combination with Hoechst 33342, followed by flow cytometric analysis. For Ki67 
staining, cells were fixed and permeabilized before staining with PerCP-Cy5.5-
conjugated anti-Ki67 antibody (from BD Biosciences). To analyze apoptosis of bone 
marrow cells, the cells were stained with Annexin V (from eBioscience). 7AAD was 
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added before flow cytometry analysis. For active caspase 3 staining, cells were first 
surface stained, fixed and permeabilized (Fixation and Permeabilization kit; 
eBioscience), and stained with PE-conjugated anti–active caspase 3 antibody (from BD 
Biosciences). 
In vitro methylcellulose colony formation assay. Normal stem cells or LSCs (GFP+Lin-
Sca-1+c-Kit+) from bone marrow of control and CML mice receiving empty vector or 
BCR-ABL-transduced WT or HIF1α-/- bone marrow cells were sorted by FACS, and 
were cultured in methylcellulose medium (Methocult GF M3434; Stem Cell 
Technologies) for 7 days. Colonies were counted under microscope. For the colony 
forming assay after shRNA-mediated knockdown of CDKN2A, CML bone marrow cells 
were cultured in methylcellulose media containing 2.5µg/mL puromycin for selection.  
Senescence-associated β-galactosidase staining. LSCs (GFP+Lin-Sca-1+c-Kit+) from 
bone marrow of CML mice were sorted by FACS, and cytospun on a poly-lysine coated 
slide and stained using the senescence-associated β-gal staining kit (#9860, Cell 
Signaling Technology). 
Lentiviral transduction and shRNA-mediated knockdown of p16Ink4a and p19Arf. 
Lentiviral shRNA vector pLKO.1 were purchased from OpenBiosystems. Sequences of 
CDKN2a (p16Ink4a and p19Arf) shRNA were as follows: shRNA#1: sense 5’- 
gtgatgatgatgggcaacgtt-3’: shRNA #1 antisense 5’-aacgttgcccatcatcatcac -3’; shRNA#2 
sense 5’-gctcggctggatgtgcgcgat -3’ #2 antisense 5’-atcgcgcacatccagccgagc -3’. For 
transduction of the CDKN2A shRNAs, p53-/-MEF or CML bone marrow cells were 
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transfected with lentirvirus-shRNA, and 24 hours later, were selected under puromycin 
(2.5µg/ml) for 48 hours before the next steps. 
Antibodies and western blot analysis. Antibodies against p16Ink4a, p19Arf and actin were 
purchased from Santa Cruz Biotechnology. Protein lysates were prepared by lysing cells 
in immunoprecipitation buffer, and Western blotting were carried out as shown 
previously200. 
Real Time-PCR. Total RNA was isolated from GFP+Lin-Sca-1+c-Kit+ bone marrow cells 
from mice using the RNeasy Mini kit (Qiagen, CA). cDNA was synthesized using the 
Ovation-Pico cDNA synthesis method. All real time PCR reactions were done using the 
Applied Biosystems 7500. 25µL reaction system was composed of 12.5µL SYBR Green, 
2.5µL 20uM primer mixture, 10ng cDNA and nuclease-free water. All experiments were 
performed in triplicate. Beta-actin was the internal control. The primer sequences are 
shown as following: HIF1a sense: tgagcttgctcatcagttgc; HIF1a antisense: 
ccatctgtgccttcatctca; VEGF sense: caggctgctgtaacgatgaa; VEGF antisense: 
tttcttgcgctttcgttttt; GLUT1 sense: gctgtgcttatgggcttctc; GLUT1 antisense: 
agaggccacaagtctgcatt; TGFa sense: agcatgtgtctgccactctg; TGFa antisense: 
tggatcagcacacaggtgat; PGK1 sense: caaggctttggagagtccag; PGK1 antisense: 
tgtgccaatctccatgttgt; p16Ink4a sense: cgaactctttcggtcgtaccc; p16Ink4a antisense: 
cgaatctgcaccgtagttgagc; p19Arf sense: gttcttggtcactgtgaggattcag; p19Arf antisense: 
ccatcatcatcacctggtccag; p53 sense: agagaccgccgaacagaaga; p53 antisense: 
ctgtagcatgggcatcctt; p57 sense: ctgacctcagacccaattc; p57 antisense: ctcagagaccggctcagttc. 
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DNA Microarray and Data Analysis. Normal HSCs and LSCs (GFP+Lin-Sca-1+c-Kit+; 
99% purity) were stored by FACS directly into RNAlater (Ambion, Austin, TX) and 
homogenized in RLT Buffer (RNeasy Micro Kit) (Qiagen, Valencia, CA). Total RNA 
was isolated by following the protocol for the RNeasy Micro Kit. RNA was amplified, 
labeled, and approximately 2.0µg of fragmented and biotin-labeled cDNA was then 
hybridized onto Mouse Genome 430 1.0 microarray (Affymetrix, Santa Clara, CA.). 
Gene expression values from Affymetrix cel files were background corrected and 
normalized using RMA algorithm, and were rank-ordered by the extent of differential 
expression using the moderated t-statistics from limma R package. To collectively assess 
HIF1α targets, the GSEA algorithm was used to evaluate the statistical significance of the 
expression of HIF1α targets122,190,191.  
Statistical analysis. Results are given as mean ± s.d. Statistical analysis was performed 
by Students’s t test. For survival curves, p values were obtained using a Log-rank test. 
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Figure S1. The phenotype of primary WT and HIF1α-/- CML mice. (A) FACS 
analysis showed the percentages of GFP+Gr-1+ cells in spleen and BM from primary 
recipients of BCR-ABL transduced WT and HIF1α-/- bone marrow cells at day 14. (B, C) 
The percentages and total numbers of LSCs (GFP+Lin-Sca-1+c-Kit+ cells and GFP+CD48-
CD150+Lin-Sca-1+c-Kit+ cells) in bone marrow of primary recipient mice receiving BCR-
ABL-transduced WT or HIF1α-/- bone marrow cells were analyzed by FACS (n=6). Total 
numbers of LSCs were calculated by the percentage of stem cells x total number of bone 
marrow cells. Mean values are shown. 
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CHAPTER III 
Tumor suppressor function of the Blk pathway in cancer stem cells  
of chronic myeloid leukemia 
 
The work described in this chapter is accepted by Nature Genetics. 
 
Abstract 
A therapeutic strategy for treating cancer is to target and eradicate cancer stem 
cells (CSCs) without harming their normal stem cell counterparts. The success of this 
approach relies on identification of molecular pathways that selectively regulate CSC 
function. Using BCR-ABL-induced chronic myeloid leukemia (CML) as a disease model 
for CSCs, we show that BCR-ABL down-regulates the B lymphoid kinase (Blk) gene 
through c-Myc in leukemia stem cells (LSCs) in CML mice and that Blk functions as a 
tumor suppressor in LSCs but does not affect normal hematopoietic stem cells (HSCs) or 
hematopoiesis. Blk suppresses LSC function through a pathway involving an upstream 
regulator, Pax5, and a downstream effector, p27. Inhibition of this Blk pathway 
accelerates CML development, whereas increased activity of the Blk pathway delays 
CML development. Our results demonstrate the feasibility of selectively targeting LSCs, 
an approach that should be applicable to other cancers.  
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Introduction 
Cancer stem cells (CSCs) are a cell population required for cancer initiation in 
many types of hematologic malignancies and some solid tumors, and must be eradicated 
to cure these cancers 65-68. A recent study identified specific inhibitors of epithelial CSCs 
by high-throughput screening 131, implying the existence of molecular pathways specific 
to CSCs that could serve as effective and selective therapeutic targets. We are interested 
in identifying genes that have essential roles in CSCs but not their normal stem cell 
counterparts. For example, previously we identified the Alox5 gene as an important 
regulatory gene in leukemia stem cells (LSCs) but not normal hematopoietic stem cells 
(HSCs) 85, demonstrating the feasibility of this approach.  
We have been using BCR-ABL-induced chronic myeloid leukemia (CML) as a 
disease model because CML is a stem cell disease and we have previously identified 
LSCs for CML in mice 63. CML is a clonal hematopoietic stem cell disorder associated 
with a reciprocal translocation between chromosomes 9 and 22 (t(9;22); also known as 
the Philadelphia chromosome); as a result, a chimeric BCR-ABL protein is formed that 
functions as a constitutively activated tyrosine kinase 1,2,6. Although BCR-ABL kinase 
inhibitors are highly effective in treating chronic phase CML patients 40,48,201, they do not 
efficiently kill LSCs 62,63. Thus, new therapeutic strategies need to be developed. Because 
LSCs share many properties with normal HSCs, such as self-renewal, pluripotency and 
signaling 65,89,90, it is important to develop therapies that only disturb the functions of 
LSCs but not normal HSCs.  
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In this study, we identify Blk, a Src family kinase, as a key regulator in CML 
LSCs. We show that Blk functions as a tumor suppressor in LSCs without affecting 
normal HSCs and mediates its inhibitory effect through a pathway involving an upstream 
regulator, Pax5, and a downstream effector, p27.  
 
Results 
Blk has a tumor suppressor function in the induction of CML by BCR-ABL 
LSCs in CML are insensitive to BCR-ABL inhibitors 62-64, suggesting that 
although some genes are activated or inactivated by BCR-ABL in LSCs, their expression 
is not affected by these inhibitors, i.e. their expression is BCR-ABL dependent but kinase 
independent. To identify genes regulated by BCR-ABL in LSCs, we compared gene 
expression profiles between normal LSK cells (Lin-Sca-1+c-Kit+) and LSCs (BCR-ABL-
expressing LSK) by DNA microarray as decribed previously85. We found that the Blk 
gene was down-regulated in LSCs, and, unexpectedly, this down-regulation was not 
significantly reversed by imatinib treatment (Fig. 1A). Real-time RT-PCR confirmed the 
down-regulation of Blk by BCR-ABL and the inability of imatinib to restore Blk 
expression in LSCs (Fig. 1B). Knockdown of BCR-ABL expression by an shRNA 
restored Blk expression in leukemia cells (Fig. S1A, B), suggesting that BCR-ABL 
down-regulates Blk in a kinase activity-independent manner. 
The expression results raised the possibility that Blk suppresses CML 
development. To test this idea, we first studied the role of Blk in CML development 
using Blk homozygous knockout (Blk-/-) mice, which as expected did not express Blk 
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(Fig. S2A). If Blk suppresses CML development, we expect to observe accelerated 
disease development in the absence of Blk. Fig. 1C shows that recipients of BCR-ABL-
transduced bone marrow cells (5x105 cells per recipient mouse) from 5-FU-treated Blk-/- 
donor mice developed CML and died significantly faster than did recipients of BCR-
ABL-transduced WT bone marrow cells. Acceleration of CML due to Blk deficiency was 
more evident when a lower number of cells (1x105 cells) were transplanted. The 
accelerated disease phenotype correlated with a higher percentage and number of Gr-1+ 
myeloid leukemia cells in peripheral blood (Fig. 1D, E), and with more severe infiltration 
of leukemic cells in the spleen (Fig. 1F). The lack of Blk did not affect BCR-ABL 
retroviral transduction efficiency (Fig. S2B) or homing of normal (Fig. S2C) and BCR-
ABL-transduced (Fig. S2D) cells to bone marrow after transplantation. 
To further demonstrate the tumor suppressor activity of Blk in CML development, 
we overexpressed Blk in donor bone marrow cells by transducing the cells with retrovirus 
expressing both BCR-ABL and Blk (Fig. S3). We found that overexpression of Blk 
significantly increased survival of CML mice (Fig. 1G), which correlated with a lower 
percentage of Gr-1+ myeloid cells in peripheral blood (Fig. 1H) and decreased infiltration 
of leukemic cells in the spleen and lung (Fig. 1I, J).  
To determine whether Blk inhibits the progression of CML disease, we first 
induced CML and then transduced bone marrow cells, which contain established 
leukemic cells, with empty vector (MSCV-IRES-hCD4) or Blk (MSCV-Blk-IRES-
hCD4). After sorting hCD4+ cells by magnetic-activated cell sorting (MACS), we 
normalized and transplanted an equal number of GFP+hCD4+ cells into recipient mice 
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(Fig. 1K), and monitored leukemia cell proliferation. We observed that the percentages 
of GFP+hCD4+ leukemia cells in the two groups were initially similar, but Blk-expressing 
leukemia cells gradually decreased with time (Fig. 1K), indicating that Blk also inhibits 
progression of CML. Collectively, these results demonstrate that Blk strongly suppresses 
BCR-ABL-induced CML.  
Suppression of LSCs in CML mice by Blk raised the possibility that restoration of 
Blk expression could synergize with a BCR-ABL kinase inhibitor in the treatment of 
CML. To test this idea, we induced CML in mice with BCR-ABL or BCR-ABL-Blk, and 
treated these mice with a placebo or imatinib. Either overexpression of Blk or imatinib 
treatment prolonged survival, as expected, but overexpression of Blk in combination of 
imatinib was much more effective, with about 40% of CML mice surviving longer than 
130 days (Fig. 1L). This therapeutic effect correlated with lower white blood cell counts 
(Fig. 1M) and with the disappearance of leukemic cells (Fig. 1N).  
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Figure 1. Blk suppresses the induction of CML by BCR-ABL. (A) Microarray 
analysis showing expression of the Blk gene in LSCs of CML mice and upon imatinib 
treatment. Results are given as mean ± SEM. (B) Real-time RT-PCR analysis of Blk 
expression in BCR-ABL-transduced LSCs from CML mice compared to GFP vector-
transduced normal stem cells. Results are given as mean ± SEM. (C) Kaplan-Meier 
survival curves for recipients of BCR-ABL-transduced bone marrow cells from WT (n=7) 
or Blk-/- (n=8) donor mice. (D) The percentage of GFP+Gr-1+ cells in peripheral blood of 
recipients of BCR-ABL-transduced bone marrow cells from WT or Blk-/- donor mice at 
day 11 after BMT. (P<0.002)  (E) The total number of GFP+Gr-1+ cells in peripheral 
blood of recipients of BCR-ABL-transduced bone marrow cells from WT or Blk-/- donor 
mice at days 8, 11, and 14 after BMT. *P<0.05 (F) Spleen weight in recipients of BCR-
ABL-transduced Blk-/- and WT bone marrow cells at day 11 after BMT. Results are given 
as mean ± SEM. (G) Kaplan-Meier survival curves for recipients of BCR-ABL (n=10) or 
BCR-ABL-Blk (n=10) transduced bone marrow cells. (H) The percentage of GFP+Gr-1+ 
cells in peripheral blood of recipients of BCR-ABL- or BCR-ABL-Blk-transduced donor 
bone marrow cells at day 15 after BMT. (P<0.001)  (I) Gross appearance of the lungs and 
spleens of BCR-ABL- or BCR-ABL-Blk-transduced donor bone marrow cells at day 15 
after BMT. (J) Photomicrographs of haematoxylin and eosin-stained lung and spleen 
sections from recipients of BCR-ABL- or BCR-ABL-Blk-transduced bone marrow cells 
(Scale bar = 100µm). (K) Leukemia cell growth in recipient mice transplanted with equal 
numbers of GFP+hCD4+ cells. Results are given as mean ± SEM. (L) Kaplan-Meier 
survival curves for recipients of BCR-ABL (n=7) or BCR-ABL-Blk (n=7) transduced 
bone marrow cells treated with a placebo or imatinib (P=0.0001). (M) Total number of 
white blood cells in peripheral blood of recipients of BCR-ABL- or BCR-ABL-Blk-
transduced bone marrow cells at 1 week after the treatment with a placebo or imatinib. 
Results are given as mean ± SEM. (N) FACS analysis showing the percentage of GFP+ 
leukemia cells in recipients of BCR-ABL-Blk-transduced bone marrow cells at 8 weeks 
after imatinib treatment.  
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Figure 1. Blk suppresses the induction of CML by BCR-ABL. 
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Blk suppresses LSCs 
The down-regulation of Blk by BCR-ABL in LSCs and the ability of Blk to 
suppress CML development prompted us to test whether Blk suppresses proliferation of 
LSCs. Fig. 2A shows that the percentages of total LSCs and long-term (CD34-) or short-
term (CD34+) LSCs (LT-LSCs or ST-LSCs, respectively) in bone marrow of recipients of 
BCR-ABL-transduced Blk-/- donor bone marrow cells were significantly higher than 
those in bone marrow of recipients of BCR-ABL-transduced WT donor bone marrow 
cells, indicating that Blk suppresses proliferation of LSCs. By contrast, Blk deficiency 
did not significantly alter the percentages of the myeloid progenitors CMP (common 
myeloid progenitor, Lin-Sca-1-Kit+CD34+FcyRII/IIIlo), GMP (granulocyte-macrophage 
progenitor, Lin-Sca-1-Kit+CD34+FcyRII/IIIhi), and MEP (megakaryocyte-erythroid 
progenitor, Lin-Sca-1-Kit+CD34-FcyRII/IIIlo) in bone marrow of CML mice (Fig. 2A).  
To confirm the inhibitory effect of Blk on LSCs, we tested whether Blk 
overexpression caused a reduction of LSCs in CML mice. We transduced bone marrow 
cells with BCR-ABL or BCR-ABL-Blk to induce CML, followed by transplantation into 
recipient mice. We observed that the percentages and numbers of total LSCs, LT-LSCs 
and ST-LSCs were significantly lower in recipients of BCR-ABL-Blk-transduced bone 
marrow cells than in recipients of BCR-ABL-transduced bone marrow cells (Fig. 2B), 
indicating that Blk suppressed proliferation of LSCs. To verify the ectopic expression of 
Blk, we sorted LSCs by FACS, isolated total RNA for RT-RCR analysis, and found that 
Blk expression was increased from an undetectable level in LSCs to a level close to that 
of endogenous Blk in normal HSCs (Fig. 2C). To further demonstrate the inhibitory 
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effect of Blk on LSCs, we tested their ability to transfer disease to secondary recipient 
mice. Bone marrow cells were transduced with BCR-ABL or BCR-ABL-Blk to induce 
primary CML, and then bone marrow cells were isolated from these CML mice and 
transferred into secondary recipient mice. Fig. 2D shows that Blk overexpression caused 
a significant delay of CML development in the secondary recipients (Fig. 2D), providing 
further evidence that Blk suppresses proliferation of LSCs. Consistently, in vitro colony-
forming assay showed that Blk-/- LSCs generated much more colonies than WT LSCs; 
however, Blk-expressing LSCs gave rise to less colonies than WT LSCs (Fig. S4). 
To more rigorously evaluate the inhibitory effect of Blk on LSC function, we 
examined whether Blk reduces the ability of LSCs to repopulate. LSCs were sorted by 
FACS from bone marrow of mice with primary CML induced by transplantation with 
BCR-ABL-transduced CD45.2 or BCR-ABL-Blk-transduced CD45.1 donor bone 
marrow cells. The sorted CD45.2 and CD45.1 LSCs were mixed in a 1:1 ratio, and 
transplanted into lethally irradiated recipient mice to induce secondary CML. At days 14, 
23 and 28 after transplantation, fewer than 5% of GFP+Gr-1+ cells in peripheral blood of 
the mice were CD45.1 leukemia cells that overexpressed Blk, whereas greater than 75%-
80% of GFP+Gr-1+ cells were CD45.2 leukemia cells that did not overexpress Blk (Fig. 
2E). Consistent with these results, at day 28 after transplantation, the percentage of 
GFP+Gr-1+ CD45.1 leukemia cells that overexpressed Blk was very low (Fig. 2E). The 
suppression of LSCs by Blk is explained, at least in part, by inhibition of cell cycle 
progression, as there were significantly fewer LSCs that overexpressed Blk in the 
S+G2M phase of the cell cycle compared to LSCs that did not overexpress Blk (Fig. 2F). 
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In addition, we observed increased apoptosis in LSCs from recipients of BCR-ABL-Blk-
transduced bone marrow cells (Fig. 2G), suggesting that Blk also inhibits proliferation 
and induces apoptosis of LSCs. 
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Figure 2. Blk suppresses LSCs. (A) The percentages of total LSCs (GFP+LS+K+), long-
term (LT)-LSCs (GFP+LS+K+CD34-), short-term (ST)-LSCs (GFP+LS+K+CD34+), CMP 
(GFP+LS-K+CD34+FcyRII/IIIlo), GMP (GFP+LS-K+CD34+FcyRII/IIIhi), and MEP 
(GFP+LS-K+CD34-FcyRII/IIIlo) in bone marrow of recipients of BCR-ABL-transduced 
Blk-/- donor bone marrow cells (n=9) were compared with those in bone marrow of 
recipients of BCR-ABL-transduced WT donor bone marrow cells (n=5) at day 11 after 
BMT. Mean values (± SEM) are shown. (B) The percentages and numbers of total LSCs, 
LT-LSCs and ST-LSCs in bone marrow of recipients of BCR-ABL- or BCR-ABL-Blk-
transduced bone marrow cells were analyzed at day 15 after BMT. Mean values (± SEM) 
are shown (n=5). (C) RT-PCR analysis of expression of Blk, BCR-ABL, and GFP in 
LSCs. Bone marrow cells transduced with retrovirus expressing GFP alone (vector), 
BCR-ABL/GFP, or BCR-ABL/Blk/GFP were transplanted into recipient mice to induce 
CML. 2 weeks after BMT, LSCs were sorted by FACS from bone marrow of the mice for 
isolation of total RNA for RT-PCR analysis. (D) Kaplan-Meier survival curves for 
secondary CML mice. Bone marrow cells from primary CML mice induced by BCR-ABL 
or BCR-ABL-Blk were collected at day 15 after BMT, and equal number of the cells from 
each group were transplanted into lethally irradiated secondary recipient mice (n=10 for 
each group). (E) Competitive repopulation assay. 103 sorted-LSCs from bone marrow of 
primary CML mice induced by transplanting BCR-ABL-transduced CD45.2 or BCR-
ABL-Blk-transduced CD45.1 donor bone marrow cells were mixed at 1:1 ratio, followed 
by transplantation into lethally irradiated recipients mice. The percentages of BCR-ABL-
Blk expressing (CD45.1) cells in peripheral blood and bone marrow were compared with 
those of BCR-ABL-expressing (CD45.2) cells at 2, 3, and 4 weeks after BMT (n=3 for 
each time point). (F) The cell cycle analysis of LSCs from bone marrow of CML mice 
induced by BCR-ABL or BCR-ABL-Blk (n=5 for each group). Bone marrow cells were 
stained with Hoechst Blue, and DNA contents in the S+G2M phase of the cell cycle in 
LSCs were examined by FACS (P<0.05). (G) Percentage of apoptotic GFP+Lin-Sca-1+c-
Kit+ cells in bone marrow from CML mice at day 14 after BMT. Mean values (± SEM) 
are shown.  
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Figure 2. Blk suppresses LSCs. 
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Blk does not suppress normal hematopoietic stem cells 
The finding that Blk suppresses proliferation and induces apoptosis of LSCs 
prompted us to ask whether Blk has a similar effect on normal HSCs. We examined the 
effect of Blk on normal hematopoiesis and HSCs. Fig. 3A-C show that the percentages of 
total LSK, LT-HSCs, ST-HSCs, CMP and MEP in bone marrow of Blk-/- and WT mice 
were similar, although the percentage of GMP was higher in Blk-/- (0.19%) than in WT 
(0.12%) mice. Notably, however, there was no significant difference in more mature 
myeloid cells (Gr-1+Mac-1+) in bone marrow of Blk-/- and WT mice (Fig. 3D). We also 
found that Blk deficiency did not affect cell cycle progression (Fig. 3E) or apoptosis 
(Fig. 3F) of LSK cells. These results indicate that Blk does not suppress normal HSCs or 
hematopoiesis. To examine whether Blk deficiency affects the function of normal HSCs, 
we performed a competitive repopulation assay. 2x105 bone marrow cells from WT or 
Blk-/- mice (CD45.2) were transplanted into each lethally irradiated WT recipient 
(CD45.1) along with an equal number of WT competitor cells (CD45.1). The lineage 
contribution of WT or Blk-/- cells in recipient mice was evaluated at 8, 12 and 16 weeks 
after transplantation. We observed similar percentages of donor-derived myeloid (Gr-1+ 
and Mac-1+) and T lymphoid cells (CD4+ and CD8+) (Fig. 3G), indicating that Blk did 
not affect the function of normal HSCs. Although Blk deficiency affected the levels of B 
cells (B220+) (Fig. 3G), this effect is likely due to the known role of Blk in B cell 
development 154. We also performed colony-forming assay to examine the effect of Blk 
on progenitor cell function in vitro using sorted LSK cells from Blk-/- and WT mice bone 
marrow. Similar numbers and types of colonies were formed in the presence and absence 
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of Blk (Fig. 3H). Further, we analyzed the abilities of WT and Blk-/- bone marrow cells to 
rescue recipient mice from lethal irradiation. Fig. 3I shows that there was no significant 
difference in the ability of WT and Blk-/- bone marrow cells to rescue lethally irradiated 
mice.  
To provide additional evidence for the role of Blk in regulation of the function of 
HSCs, we tested whether overexpression of Blk suppresses proliferation of HSCs. We 
transduced bone marrow cells from WT mice with Blk-GFP or GFP retrovirus, followed 
by transplantation into recipient mice (Fig. 3J). The lineage contribution of GFP or Blk-
GFP cells in recipient mice was evaluated at 8, 12 and 16 weeks after transplantation. 
The percentages of mature myeloid cells (GFP+Gr-1+/Mac-1+), B-lymphoid cells 
(GFP+B220+), and T cells (GFP+CD3e+) in peripheral blood of recipients of Blk-GFP- or 
GFP-transduced marrow cells were similar (Fig. 3J), and the percentages of GFP+LSK 
cells in bone marrow of recipients of Blk-GFP- or GFP-transduced marrow cells at 16 
weeks after transplantation were also similar (Fig. 3K). In addition, there was no 
significant difference in cell cycle progression between Blk-GFP- and GFP-transduced 
bone marrow cells (Fig. 3L). Next, we conducted an in vivo limiting dilution analysis. 16 
weeks after transplantation, GFP+LSK cells were sorted from recipients of Blk-GFP or 
GFP transduced marrow cells, and were injected into secondary recipients at different 
doses (10, 50, 100 or 500 cells). After 12 weeks, we analyzed the GFP+ cells. Poisson 
statistics showed no significant difference in the frequency of long-term repopulation 
ability among control and Blk-transduced cells (Fig. 3M). These results indicate that Blk 
overexpression does not affect the long-term repopulation activity of HSCs. 
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Figure 3 Blk does not inhibit hematopoiesis or normal HSCs. (A-C) FACS analysis of 
HSCs, CMP, GMP and MEP cell populations in bone marrow of WT (n=3) or Blk-/- (n=4) 
mice. (B) The percentages of LSK, LT-HSCs, and ST-HSCs in bone marrow of WT or 
Blk-/- mice. (C) The percentages of CMP, GMP, and MEP cells in bone marrow of WT 
(n=3) or Blk-/- (n=4) mice. (D) The percentages of myeloid (Gr-1+Mac-1+) and lymphoid 
(B220+IgM+) cells in bone marrow of WT or Blk-/- mice. (E) Cell cycle analysis of LSK 
cells in bone marrow of WT or Blk-/- mice. (F) Apoptosis analysis of bone marrow cells 
and LSK cells from WT (n=3) or Blk-/- (n=4) through staining with Annexin V and 
7AAD. (G) Competitive repopulation assay.  FACS analysis showed donor contribution 
of different cell lineages in recipient mice at 8, 12 and 16 weeks after transplantation. * 
P<0.05 (H) Colony forming assay showed equivalent colony numbers and types between 
WT and Blk-/- group. (I) Irradiation rescue assay. Three doses (1x105, 5x105, 2.5x104) of 
WT or Blk-/- BM cells were injected into lethally irradiated recipients, and survival curves 
for these three groups were compared. (J) In vivo long-term reconstitution analysis. 
FACS analysis showed the lineage contribution in peripheral blood from recipients of Blk 
and vector transduced bone marrow cells at 8, 12, 16 weeks after transplantation. (K) The 
percentages of LSK cells in the GFP+ population of bone marrow from recipients of 
vector and Blk transduced BM cells at16 weeks after transplantation. (L) Cell cycle 
analysis of LSK cells from bone marrow of recipients transplanted with GFP or Blk/GFP 
transduced bone marrow cells. (P=0.86 for G0-G1; P=0.2 for S+G2M). (M) In vivo 
limiting dilution analysis. 16 weeks after BMT, GFP+LSK cells were sorted from 
recipients of Blk-GFP or GFP transduced marrow cells, and were injected into secondary 
recipients in different doses (10, 50, 100 or 500 cells per mouse). After 12 weeks, the 
GFP+ cells were examined by FACS. Poisson statistics showed no significant difference 
in the frequency of long-term repopulation among control and Blk-transduced cells. 
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Figure 3. Blk does not inhibit hematopoiesis or normal HSCs. 
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Pax5 is an upstream regulator of Blk in LSCs 
We next studied the underlying mechanisms by which Blk has an inhibitory effect 
on LSCs but not normal HSCs. Pax5 is known to bind to the Blk promoter and stimulate 
Blk expression 202. We therefore considered the possibility that the down-regulation of 
Blk expression by BCR-ABL in LSCs is mediated through Pax5. In support of this idea, 
we found that BCR-ABL markedly down-regulated Pax5 expression in LSCs (Fig. 4A).  
To test whether Pax5 suppresses proliferation of LSCs and CML development, we 
generated a retroviral construct that co-expressed BCR-ABL and Pax5 (Fig. 4B). We 
transduced bone marrow cells with BCR-ABL or BCR-ABL-Pax5, followed by 
transplantation into recipient mice. Fourteen days later, bone marrow cells from CML 
mice were analyzed for the percentages and numbers of LSCs. The results of Fig. 4C 
show that Pax5 overexpression caused a marked decrease in total, LT- and ST-LSCs. We 
next compared survival between the two transplantation groups. All recipients of BCR-
ABL-transduced bone marrow cells died of CML within 3 weeks, whereas fewer than 
20% of the recipients of BCR-ABL-Pax5-transduced bone marrow cells developed CML 
and died (Fig. 4D), which correlated with lower, gradually decreased percentages of 
myeloid leukemia cells in peripheral blood during the course of the disease (Fig. 4E), and 
with less severe splenomegaly and leukemic cell infiltration in the spleen and lung (Fig. 
4F). We also found that ectopically expressed Pax5 caused an increase of Blk expression 
in LSCs (Fig. 4G), supporting the idea that Pax5 functions upstream of Blk to mediate the 
down-regulation of Blk by BCR-ABL. To further test this idea, we transduced bone 
marrow cells from Blk-/- or WT mice with BCR-ABL-Pax5 or BCR-ABL alone, followed 
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by transplantation into recipient mice. If Pax5 is upstream of Blk, the delay of CML 
development by Pax5 should be prevented in the absence of Blk. We found that compared  
to the accelerated CML development in recipients of Blk-/- bone marrow cells transduced 
by BCR-ABL alone (Fig. 4H), recipients of Blk-/- bone marrow cells transduced with 
BCR-ABL-Pax5 died of CML much more slowly, although these mice developed CML 
significantly faster than recipients of BCR-ABL-Pax5-transduced WT bone marrow cells. 
These results suggest that Blk is one but not only the downstream functional target gene 
of Pax5 in LSCs. 
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Figure 4 Pax5 is an upstream partner of Blk in LSCs. (A) Real time RT-PCR analysis 
showing expression of Pax5 in LSCs as compared to normal HSCs. Results are given as 
mean ± s.e.m. (B) Western blot analysis showing expression of Pax5 and BCR-ABL in 
293T cells transfected with BCR-ABL and BCR-ABL-Pax5. (C) FACS analysis of the 
numbers of total LSCs, LT-LSCs, and ST-LSCs from recipients of BCR-ABL- or BCR-
ABL-Pax5-transduced BM cells. Results are given as mean ± s.e.m. (D) Kaplan-Meier 
survival curves for recipients of BCR-ABL- (n=7) or BCR-ABL-Pax5- (n=6) transduced 
bone marrow cells. (E) FACS analysis showing the percentages of GFP+Gr-1+ cells in 
peripheral blood of recipients of BCR-ABL- or BCR-ABL-Pax5-transduced bone 
marrow cells at days 11, 14, 17, 30, and 40 after BMT, and gradual disappearance of 
GFP+Gr-1+ cells in peripheral blood of recipients of BCR-ABL-Pax5-transduced bone 
marrow cells but not in recipients of BCR-ABL-transduced bone marrow cells. (F) Gross 
appearance of the lungs and spleens of recipients of BCR-ABL- or BCR-ABL-Pax5-
transduced donor bone marrow cells at day 14 after BMT. (G) Real time RT-PCR 
analysis monitoring Blk expression in LSCs from bone marrow of recipients of BCR-
ABL- and BCR-ABL-Pax5-transduced bone marrow cells. Bone marrow cells from mice 
with CML induced by BCR-ABL or BCR-ABL-Pax5 were cultured under stem cell 
conditions for 6 days, and LSCs were sorted by FACS for isolation of total RNA for real 
time PCR analysis. (H) Kaplan-Meier survival curves for recipients of BCR-ABL- or 
BCR-ABL-Pax5-transduced WT or Blk-/- bone marrow cells.  
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Figure 4 Pax5 is an upstream partner of Blk in LSCs. 
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c-Myc and EBF1 mediate down-regulation of Pax5 by BCR-ABL 
We next studied how BCR-ABL down-regulates Pax5 expression. Previous 
studies have shown that BCR-ABL induces c-Myc expression 203-205, and analysis of the 
Pax5 promoter region revealed a consensus c-Myc binding motif at -312 basepairs 
upstream of the transcription start site (Fig. S5A). ChIP analysis demonstrated that c-Myc 
directly bound to this region, but not to a region further upstream (Fig. 5A). Therefore, 
we investigated whether BCR-ABL down-regulates Pax5 through c-Myc using a 
luciferase assay for monitoring Pax5 promoter activity. Fig. 5B shows that expression of 
c-Myc caused a reduction of Pax5 promoter activity in a dose dependent manner in 
NIH3T3 cells, indicating that c-Myc suppresses Pax5 expression at the transcriptional 
level. In addition, we mutated the c-Myc binding site in the Pax5 promoter, and found 
that the suppression of luciferase activity by c-Myc was markedly rescued (Fig. 5C). 
These data indicate that c-Myc directly binds to and suppresses Pax5 expression at the 
transcriptional level. To determine whether c-Myc down-regulates Pax5 expression in 
HSCs, we transduced bone marrow cells with a retrovirus expressing c-Myc (Fig. S5B) 
or, as a control, Pax5. Real time RT-PCR analysis showed that c-Myc significantly 
inhibited expression of Pax5 and Blk in LSK cells (Fig. 5D and 5E), whereas Pax5 
dramatically enhanced Blk expression in these cells (Fig. 5E). These results indicate that 
the down-regulation of Pax5 by BCR-ABL is mediated by c-Myc.  
Previous studies have suggested that the transcription factor EBF1 binds to the 
Pax5 promoter and stimulates Pax5 expression 206,207, and our microarray results 
indicated that EBF1 was significantly downregulated in LSCs (Fig. S6). To investigate 
   
97 
the role of EBF1, we conducted a ChIP analysis and found that EBF1 directly bound to 
Pax5 promoter within a region from -1638 to -1647 (Fig. 5F), consistent with previous 
results 206,207. Using a Pax5 promoter-luciferase reporter, we found that expression of 
EBF1 increased luciferase activity (Fig. 5G). Because interferon regulatory factor 8 
(IRF8) is known to regulate expression of EBF1 and Pax5 208,209, we also tested whether 
IRF8 regulates Pax5 expression by itself or synergistically with EBF1. However, IRF8 
had no effect on Pax5 promoter activity (Fig. 5G). We mutated the EBF1 binding site in 
the Pax5 promoter, and found that the increased luciferase activity by EBF1 was 
markedly inhibited (Fig. 5H). It remained possible that c-Myc also down-regulates EBF1 
expression resulting in decreased Pax5 expression. Therefore, we asked whether BCR-
ABL and c-Myc down-regulate EBF1 expression in LSCs. Real time RT-PCR analysis 
showed that BCR-ABL down-regulated EBF1 expression in LSCs (Fig. 5I), and c-Myc 
down-regulated EBF1 expression in LSK cells (Fig. 5J). Thus, down-regulation of Pax5 
by BCR-ABL is mediated by c-Myc and EBF1.  
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Figure 5 c-Myc and EBF1 regulate Pax5 expression. (A) ChIP assay showed c-Myc 
directly bound to the Pax5 promoter. Results were shown as mean ± s.e.m. (B) A Pax5 
promoter luciferase reporter construct was cotransfected with empty vector or c-Myc 
plasmid into NIH3T3 cells. Cell extracts were analyzed for luciferase activity. Results 
were shown as mean ± s.e.m.. (C) Luciferase assay showed mutant c-Myc binding site in 
the Pax5 promoter restored the luciferase activity. Results were shown as mean ± s.e.m. 
(D and E) Real time RT-PCR analysis monitoring Pax5 and Blk expression in c-Myc-
expressing or Pax5-expressing LSK cells. Results were shown as mean ± s.e.m. (F) ChIP 
assay showed EBF1 directly bind to the Pax5 promoter. Results were shown as mean ± 
s.e.m. (G) A Pax5 promoter luciferase reporter construct was cotransfected with empty 
vector, EBF1, or IRF8 plasmids into NIH3T3 cells. Cell extracts were analyzed for 
luciferase activity. Results were shown as mean ± s.e.m. (H) Luciferase assay showed 
mutant EBF1 binding site in the Pax5 promoter rescued the luciferase activity. Results 
were shown as mean ± s.e.m. (I) Real time RT-PCR analysis monitoring EBF1 
expression by BCR-ABL in LSCs as compared to normal HSCs. Results are given as 
mean ± s.e.m. (J) Real time RT-PCR analysis monitoring EBF1 expression in c-Myc-
expressing LSK cells. Results are given as mean ± s.e.m. 
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Figure 5 c-Myc and EBF1 regulate Pax5 expression 
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p27 functions downstream of Blk to suppress proliferation of LSCs  
Next, we attempted to identify genes required for Blk to suppress LSC 
proliferation and CML development. The mammalian cyclin-dependent kinase inhibitor 
(CDKI) p27 is a negative cell cycle regulator that blocks the G1 to S phase transition 210. 
BCR-ABL down-regulates p27 expression through multiple mechanisms 211-214. Because 
Blk inhibits cell cycle progression of LSCs, we considered the possibility that Blk 
functions through p27. To test this idea, we first compared the levels of p27 in 293T cells 
transfected with BCR-ABL alone or with both BCR-ABL and Blk. We found that BCR-
ABL down-regulated p27 and Blk restored the level of p27 expression (Fig. 6A). The 
inhibition of Skp2 by Blk was confirmed by real time RT-PCR (Fig. S7A). Notably, 
BCR-ABL and Blk did not alter the levels of other cell cycle regulators such as p21 and 
Cdk2 (Fig. 6A).  
To confirm that BCR-ABL functions through Blk to reduce p27 expression, we 
transduced WT or Blk-/- bone marrow cells with BCR-ABL. We found that p27 
expression was significantly lower in the absence of Blk (Fig. 6B and Fig. S7B). 
Conversely, we overexpressed Blk in LSCs both to verify that Blk increases p27 
expression and to identify other Blk target genes. Toward this end, bone marrow cells 
were transduced with GFP, BCR-ABL-GFP or BCR-ABL-Blk-GFP, followed by 
transplantation into recipient mice. Fourteen days after transplantation, bone marrow cells 
were isolated and LSCs cells were sorted by FACS for isolation of total RNA for DNA 
microarray analysis. We found that BCR-ABL down-regulated p27 expression, which 
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was reversed by Blk overexpression (Fig. 6C). We also identified many other genes that 
were significantly up- or down-regulated by Blk in LSCs (Table S1 and S2).  
We next tested whether p27 could suppress LSC proliferation and CML 
development. We transduced WT or p27-/- bone marrow cells with BCR-ABL, followed 
by transplantation of a relatively small number of transduced cells (1x105 cells per 
recipient). After 14 days, bone marrow cells from CML mice were analyzed for the 
number of LSCs. Fig. 6D shows that p27 deficiency caused a marked increase in total, 
LT- and ST-LSCs. Significantly, only 20% of recipients of BCR-ABL-transduced WT 
bone marrow cells died by 60 days after transplantation, whereas 90% of recipients of 
BCR-ABL-transduced p27-/- bone marrow cells died by 45 days after the transplantation 
(Fig. 6E). This accelerated CML development in the absence of p27 correlated with a 
higher percentage and number of myeloid leukemia cells in peripheral blood (Fig. 6F,G).  
The regulation of p27 by Blk in cell cycle progression was further demonstrated 
in cultured bone marrow cells from CML mice. Consistent with the results in 293T cells, 
Blk overexpression increased expression of p27 but not CDK2 and Cyclin E (Fig. S7C). 
Collectively, these results indicate that p27 functions downstream of Blk to suppress LSC 
proliferation and CML development. By contrast, although an elevated p27 expression 
was found in Blk-expressing HSCs (Fig. S7D), the percentage of HSCs were similar in 
bone marrow of mice receiving control and Blk-transduced marrow cells (Fig. 3G), 
indicating that p27 does not suppress proliferation of normal HSCs.  
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Figure 6. p27 is a downstream partner of Blk in LSCs. (A) Western blot analysis of 
the expression of p27, p21, Cdk2 and Skp2 in 293T cells after transfection with BCR-
ABL, Blk or BCR-ABL-Blk. (B) Western blot analysis monitoring p27 expression. BCR-
ABL-transduced bone marrow cells from WT or Blk-/- mice were grown in Whitlock-
Witte culture for 7 days, and protein lysates were isolated for comparing p27 expression 
regulated by BCR-ABL in the presence and absence of BCR-ABL by Western blotting. 
(C) Microarray analysis showing p27 expression in vector-, BCR-ABL- and BCR-ABL-
Blk-transduced LSCs. Mean values (± SEM) are shown. (D) The total numbers of total 
LSCs, LT-LSCs, and ST-LSCs in bone marrow of recipients of BCR-ABL-transduced 
p27-/- (n=4) and BCR-ABL-transduced WT (n=3) donor bone marrow cells at day 14 
after BMT. Mean values (± SEM) are shown. (*P<0.05) (E) Kaplan-Meier survival 
curves for recipients of BCR-ABL-transduced bone marrow cells from WT or p27-/- 
donor mice (P=0.02; n=8 for each group). (F) FACS analysis showing the percentages of 
GFP+Gr-1+ cells in peripheral blood of recipients of BCR-ABL-transduced bone marrow 
cells from WT or p27-/- donor mice at day 12 after BMT. (P<0.02) (G) The total numbers 
of GFP+Gr-1+ cells in peripheral blood of recipients BCR-ABL-transduced bone marrow 
cells from WT or p27-/- donor mice at days 12 and 16 after BMT. Mean values (± SEM) 
are shown.  
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Figure 6. p27 is a downstream partner of Blk in LSCs. 
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Suppression of CML does not require Blk kinase activity  
To determine whether Blk kinase activity was required for suppression of CML 
we analyzed three Blk mutants: deletion of the entire kinase domain (ΔTk), K263E, and 
Y383F (Fig. 7A). The K263E mutation causes a loss of Blk kinase activity, and the 
Y383F mutation reduces Blk autophosphorylation 215. We cloned these three Blk mutants 
into the BCR-ABL retroviral construct. As expected, following transfection in 293T cells, 
all three Blk mutants were expressed (Fig. 7B,C), and kinase activity of Blk-K263E was 
almost completely lost and autophosphorylation of Blk-Y383F was significantly reduced 
(Fig. 7B). To test the effect of the three Blk mutants on BCR-ABL-induced CML 
development, we transduced bone marrow cells with BCR-ABL, BCR-ABL-Blk, BCR-
ABL-Blk(ΔTk), BCR-ABL-Blk-K263E, or BCR-ABL-Blk-Y383F, which had similar 
viral titers (Fig.e S8A, B). The transduced bone marrow cells were transplanted into 
recipient mice to induce CML. We found that recipients of bone marrow cells transduced 
with BCR-ABL-Blk(ΔTk) or BCR-ABL alone developed CML similarly, as shown by 
survival (Fig. 7D) and infiltration of leukemic cells into the lung and spleen (Fig. 7E). 
Thus, the kinase domain of Blk is required for suppression of CML development. 
Surprisingly, in recipients of BCR-ABL-Blk-K263E- and BCR-ABL-Blk-Y383F-
transduced bone marrow cells CML development was also suppressed (Fig. 7F), which 
correlated with lower numbers of white blood cells (Fig. 7G). Thus, Blk suppresses CML 
development through a kinase-independent mechanism.  
The results from several previous studies raised the possibility that the ability of 
Blk to stimulate p27 expression involves the S-phase kinase associated protein 2 (Skp2). 
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For example, p27 levels are inversely correlated with Skp2 expression 216; BCR-ABL 
stimulates cell cycle progression by promoting Skp2-mediated degradation of p27 211; 
and Skp2 is required for BCR-ABL induced myeloproliferative disease 217. Fig. 7H 
shows that Blk prevented BCR-ABL-induced Skp2 expression, which was dependent on 
the Blk kinase domain.  
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Figure 7. The inhibitory effect of Blk on CML does not require Blk kinase activity. 
(A) Schematic structures of Blk mutants. SH, Src-homology; TK, tyrosine kinase. (B) 
Western blot analysis monitoring the phosphorylation status of Blk-K263E, and the 
reduced phosphorylation level of Blk-Y383F, as compared to that of WT Blk. (C) 
Western blot analysis monitoring expression of Blk, Blk∆Tk, and BCR-ABL in 293T 
cells. (D) Kaplan-Meier survival curves for recipients of BCR-ABL-, BCR-ABL-Blk-, or 
BCR-ABL-Blk∆Tk-transduced bone marrow cells (n=8 for each group). (E) Gross 
appearance of the lungs and spleens of recipients of BCR-ABL-, BCR-ABL-Blk- or 
BCR-ABL-Blk∆Tk-transduced bone marrow cells at 14 days after BMT. (F) Kaplan-
Meier survival curves for recipients of BCR-ABL- (n=11), BCR-ABL-Blk- (n=15), 
BCR-ABL-Blk-K263E- (n=14) or BCR-ABL-Blk-Y383F- (n=9) transduced bone 
marrow cells. (G) The total number of white blood cells in peripheral blood of recipients 
of BCR-ABL-, BCR-ABL-Blk-, BCR-ABL-Blk-K263E- or BCR-ABL-Blk-Y383F-
transduced bone marrow cells at days 10, 14 and 17 after BMT (*P<0.006). (H) Western 
blot analysis indicated that Blk but not the truncated Blk∆Tk, down-regulated Skp2 
expression. 
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Figure 7. The inhibitory effect of Blk on CML does not require Blk kinase activity.  
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Blk functions as tumor suppressor in human CML cells 
The results described above prompted us to investigate whether Blk has a 
comparable tumor suppressor function in human CML cells. In the first series of 
experiments we asked whether Blk expression was lost in human cells expressing BCR-
ABL and during CML development. Fig. 8A showed that Blk expression was 
substantially lower in bone marrow cells from human CML patients compared to normal 
human bone marrow cells. Consistent with our results, we analyzed a publicly available 
gene expression profiling database of human CML bulk CD34+ cells218, and found that 
Blk expression was markedly down-regulated in the majority of CML patients in chronic 
phase, accelerated phase and blast crisis (Fig. 8B). Next, we transduced human cord 
blood CD34+ cells with BCR-ABL and measured Blk expression. Fig. 8C showed that 
BCR-ABL significantly lowered Blk expression and this effect was not reversed by 
imatinib. Consistently, through analyzing another public microarray data of human CML 
CD34+CD38- cells219, we also found that Blk expression did not changed by imatinib 
treatment in CML CD34+CD38- cells  (Fig. 8D). We further asked whether Blk 
expression in quiescent and dividing CD34+ cells was downregulated in a public database 
of human CML quiescent stem/progenitor cells220. As expected, both quiescent and 
dividing CD34+ cells from CML patients showed dramatically lower Blk expression than 
that in normal quiescent and dividing CD34+ cells (Fig. 8E); interestingly, Blk expression 
was significantly lower in quiescent population than dividing cells from CML patients 
but not normal control (Fig. 8E). Together, the above data suggest that Blk might play 
tumor suppressive role in human CML stem cells.  
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In a second set of experiments, we tried to determine the functional effect of Blk 
on human CML stem/progenitor cells.  To be able to infect quiescent cells, we used a 
lentivirus vector to express Blk (Fig. 8F). We found that Blk overexpression inhibited 
CML CD34+CD38- stem cells entry into cell cycle (Fig. 8G). We also performed a 
colony-formation assay, which provides an assessment of progenitor function221. and 
found that Blk overexpression inhibited the colony-forming ability of human CML but 
not normal bone marrow cells (Fig. 8H). We also found that Blk expression inhibited the 
colony-forming ability of BCR-ABL-transduced human cord blood CD34+ cells (Fig. 8I). 
Furthermore, we found that overexpression of Blk induced the apoptosis of CML 
stem/progenitor cells (Fig. S9). To determine whether Blk inhibits proliferation of human 
CML cells, we transduced BCR-ABL+ human K562 cells with a retrovirus co-expressing 
Blk and GFP or, as a control, GFP alone. Fig. 8J showed that Blk-expressing K562 cells 
grew significantly more slowly than cells that did not express Blk. Collectively, the 
results presented in Figure 8 demonstrate that Blk functions as a tumor suppressor in 
human CML stem/progenitor cells.  
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Figure 8 Blk functions as tumor suppressor in human CML cells. (A) Real-time RT-
PCR analysis was performed to detect Blk expression in bone marrow cells from CML 
patients and normal human bone marrow cells. (P<0.0001). (B) Blk expression in human 
CML samples. Microarray analysis of expression of Blk in bone marrow and peripheral 
blood CD34+ cells from 42 chronic (green), 17 accelerated (blue) and 31 blast crisis 
phase (red) CML patients. (C) Real-time RT-PCR analysis monitoring Blk expression in 
BCR-ABL-transduced human CD34+ cord blood progenitor cells. CD34+ cells from 
human cord blood were transduced with BCR-ABL retrovirus. Blk expression was 
determined by RT-PCR analysis using sorted BCR-ABL-expressing CD34+ cells. BCR-
ABL-transduced CD34+ cells were also treated by imatinib (1 µM) for 24 hours. Imatinib 
treatment did not rescue the down-regulation of Blk expression. (P<0.001; ns, no 
significance. Mean values (± s.e.m) are shown. (D) Blk expression in human CML 
CD34+CD38- cells did not affect by imatinib treatment. (n=3) (E) The expression of Blk 
in normal and CML quiescent and dividing stem/progenitor cells from public microarray. 
(F) Real-time RT-PCR analysis of Blk expression in primary chronic phase bone marrow 
cells from CML patients transduced with either an empty lentivirus (pLenti-puro) or virus 
expressing Blk (pLenti-Blk-puro). (P=0.0015). (G) FACS analysis showed Blk inhibited 
CML CD34+CD38- cells proliferation. (H) Blk overexpression inhibited colony-forming 
ability of human CML bone marrow cells but not normal cells. Equal numbers of human 
CML bone marrow cells transduced with empty or Blk expressing lentivirus were plated 
in cytokine-supplemented methylcellulose in the presence of puromycin. (P=0.01). (I) 
Blk overexpression inhibited colony-forming ability of BCR-ABL-expressing CD34+ 
cells. CD34+ cells from human cord blood were co-transduced BCR-ABL-GFP-
expressing retrovirus and either an empty lentivirus or lentivirus expressing Blk, and 
colony-forming assay were performed in cytokine-supplemented methylcellulose in the 
presence of puromycin. (P=0.01) (J) Growth curves of FACS sorted human K562 cells 
after transduction with retrovirus expressing Blk-GFP or GFP alone. (K) Molecular 
model of the Blk pathway in LSCs.  
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Figure 8. Blk functions as tumor suppressor in human CML cells 
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Discussion 
In this study we have shown that Blk functions as a tumor suppressor in CML 
through a pathway that is summarized in Fig. 8K and discussed below. Consistent with 
this tumor suppressor function, Blk expression is down-regulated by BCR-ABL in both 
mouse and human hematopoietic cells, and in bone marrow cells from CML patients. Of 
particular significance, expression profiling experiments indicate that Blk expression is 
markedly down-regulated in LSCs from the majority of CML patients in chronic phase, 
accelerated phase and blast crisis. Thus, suppression of Blk expression begins at an early 
stage of CML and is maintained throughout the course of disease. 
 Although imatinib and other BCR-ABL kinase inhibitors can induce a complete 
cytogenetic response in the majority of CML patients in chronic phase, they are incapable 
of eradicating LSCs 61-63. We show that Blk markedly suppresses proliferation of LSCs 
without affecting normal HSCs or hematopoiesis. Thus, the Blk pathway identified here 
provides a selective target for eradicating LSCs and treating CML. For example, BCR-
ABL down-regulates Blk expression to efficiently induce CML, and restoration of Blk 
expression or up-regulation of other genes in the Blk pathway, such as Pax5 and p27, 
could be used to treat CML. Our results demonstrate the feasibility and effectiveness of 
specifically targeting cancer stem cells.  
The strategy of selectively targeting LSCs contrasts sharply with other therapeutic 
approaches to inhibit the function of genes that have essential roles in both LSCs and 
normal HSCs 91,92,110,222,223. For example, the Wnt signaling pathway has been shown to 
be critical in the regulation of hematopoietic stem and progenitor cell function 222,223, and 
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deletion of the β-catenin gene causes a profound defect in LSCs and subsequent induction 
of CML by BCR-ABL 91,224. In addition, inhibition of the hedgehog pathway impairs 
both LSCs and normal HSCs 92,110. 
The finding that Blk functions as a tumor suppressor role is somewhat unexpected 
because other Src family kinases have been found to promote leukemogenesis 86,145,146,151. 
Paradoxically, Blk promotes normal B cell development by cooperating with other Src 
family members.  Pax5, which we show functions upstream of Blk, is also required for 
normal B cell development 225,226. Deletions and mutations of Pax5 have been indentified 
in human acute lymphoid leukemia 227,228, suggestive of a tumor suppressor function.  
 Pax5 mediates down-regulation of Blk by BCR-ABL through c-Myc. We also 
show that p27 mediates the inhibitory effect of Blk on LSCs, although it is likely that 
there are other downstream Blk target genes. Mechanistically, we show that Blk up-
regulates p27 through downregulation of Skp2. We have previously shown that LSCs in 
CML are also positively regulated by the Alox5 gene, which is up-regulated by BCR-
ABL 85. Our unpublished data suggest that Blk regulates Alox5 in LSCs, and it will be 
important to further elucidate the functional relationship between Blk and Alox5 in LSCs. 
We found that Blk and p27 do not suppress proliferation of normal HSCs. 
Consistent with our results, a previous study found that p27 has no effect on the number 
and self-renewal ability of HSCs229. Although a ten-fold overexpression of Pax5 
modestly inhibited normal HSCs (data not shown), we believe that restoration of Pax5 
expression to a normal endogenous level in HSCs would not significantly inhibit 
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proliferation. In contrast to the modest effect of Pax5 on HSCs, Pax5 overexpression 
strongly inhibited proliferation of LSCs and CML development.  
Blk is a tyrosine kinase but unexpectedly we found that Blk tumor suppressor 
function is not dependent upon its kinase activity. Thus, when a Src kinase inhibitor, such 
as dasatinib, is used to treat CML, it will not inhibit Blk tumor suppressor activity. 
Down-regulation of Blk by BCR-ABL is not reversed following inhibition of BCR-ABL 
kinase activity, which is consistent with the inability of imatinib to kill LSCs. 
Importantly, we show that Blk inhibits proliferation of human CML stem cells, providing 
a rationale for targeting LSCs by restoration of the Blk pathway.  
 
Material and methods 
Samples. Cord blood mononuclear cells were isolated by Ficoll-Hypaque density 
gradient centrifugation. CD34+ cells were enriched using the MACS CD34 progenitor kit 
(Miltenyi Biotec). Transduction of cord blood CD34+ cells were performed as described 
previously 230. Six human CML bone marrow samples contained greater than 97% (in 
average) of leukemia cells based on the karytyping results for the t(9;22) translocation. 
This result is supported by the FISH analysis of the chimeric BCR-ABL oncogene in the 
cells. Human bone marrow CML cells were cultured in Iscoves Modified Dulbecco 
medium (Sigma) supplemented with a serum substitute (BIT; StemCell), 40µg/mL low-
density lipoproteins, 100ng/mL recombinant human Flt3-ligand, 100ng/mL steel factor, 
20ng/mL recombinant human interleukin-3 (IL-3), IL-6, and granulocyte-colony-
stimulating factor 231. For CML stem cell proliferation assay, sorted human CML CD34+ 
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cells were transduced with vector or Blk expressing lentivirus, and labeled with 1µM 
carboxyfluorescein diacetate succinimidyl ester (CFSE), and cultured for 4 days in vitro. 
Mice. Blk-/-  mice were kindly provided by Dr. Alexander Tarakhovsky (Rockefeller 
University). p27-/-, C57BL/6J-CD45.1, C57BL/6J-CD45.2 mice were obtained from The 
Jackson Laboratory. All mice were in C57BL/6J background 
Cell culture. K562 cells were obtained from ATCC, and maintained in RPMI 1640 plus 
10% fetal bovine serum (FBS). 293T cells were cultured in DMEM median plus 10% 
FBS. 
Generation of retrovirus and lentivirus Stocks. The retroviral constructs MSCV-IRES-
GFP, MSCV-BCR-ABL-IRES-GFP, MSCV-Blk-IRES-GFP, MSCV-BCR-ABL-IRES-
Blk-IRES-GFP, and MSCV-BCR-ABL-IRES-Pax5-IRES-GFP were used to generate 
high-titer, helper-free, replication-defective ecotropic virus stock by transient transfection 
of 293T cells as previously described 23. Lentiviral vector (pLenti-Puro) was a kind gift 
from Dr. Eric Campaus (University of Massachusetts Medical School). Lentiviral 
particles were produced by cotransfection of 293T cells with pLP1, pLP2, VSV-G and 
empty vector or pLenti-hBlk-Puro. Lentiviral shRNA vector pLKO.1 were from 
OpenBiosystems. The targeted BCR-ABL sequences are as follows: sense 5’-
ctgaccaactcgtgtgtgaaa-3’, antisense 5’-tttcacacacgagttggtcag-3’. 
Bone marrow transduction/transplantation. 8 to 12 week-old C57BL/6 mice were 
used for bone marrow transduction/transplantation. Retroviral transduction and 
transplantation of mouse bone marrow cells for inducing CML by BCR-ABL had been 
described previously 23,86,232.  
   
116 
Flow cytometry analysis. For stem cell analysis, bone marrow cells were suspended in 
staining medium (Hank’s Balanced Salt Solution (HBSS) with 2% heat-inactivated calf 
serum), and incubated with biotin-labeled lineage antibody cocktail containing a mixture 
of antibodies against CD3, CD4, CD8, B220, Gr-1, Mac-1 and Ter119. After washing, 
the fluorochrome-labeled secondary antibody (APC-Cy7-conjugated Streptavidin) for 
recognizing biotin and PE-conjugated c-Kit and APC-conjugated Sca-1 antibodies were 
added to the cells. Long-term and short-term LSCs were distinguished by the CD34 
antibody. LSCs were analyzed by FACS. All these antibodies were purchased from 
eBioscience. 
Leukemia stem cell culture. For mouse leukemia stem cell culture, bone marrow cells 
isolated from CML mice were cultured in vitro in the presence of stemspan SFEM, SCF, 
IGF-2, TPO, heparin, and α-FGF as reported previously for culturing hematopoietic stem 
cells 232. 
In Vitro methylcellulose colony formation assay. Human CML cells or BCR-ABL 
transformed human cord blood CD34+ cells were transduced with vector or Blk lentivirus 
and cultured in methylcellulose medium containing 2.5µg/mL puromycin for selection 
(Methocult GF H4435; Stem Cell Technologies). Colonies were counted under 
microscope after 7 days.  
Chromatin immunoprecipitation. ChIP assays were performed. Briefly, 3x107 ENU or 
BaF3 cells were incubated with 1% formaldehyde for 10 min at room temperature before 
crosslinking was quenched by addition of 0.125 M glycine. Cells were collected by 
centrifugation and lysed in lysis buffer containing 50mM Tris-HCl (pH 8.0), 10 mM 
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EDTA, 0.5% SDS, proteinase inhibitors and phosphatase inhibitors. The cells suspension 
was sonicated  seven times for 10s each with 2-min intervals on ice using a Misonix 
Sonicator 3000 at output 8. Sonicated chromatin was then incubated at 4oC overnight 
with 5 µg of the appropriate antibody: α-c-Myc (Santa Cruz), α-EBF1 (Avaon). 
Immunoprecipitated DNA was amplified by real-time PCR using the following primers: 
myc-chip-for (5’-gacgtgtctggggacatcttg-3’), myc-chip-rev (5’-gtccgaaggcaccgtgaaatg), 
EBF1-chip-for (5’-actacggagactacttggtgg), and EBF1-chip-rev (5’- 
caccggacatcgcaaattcac) 
Luciferase reporter assays. 2x105 NIH3T3 cells were seeded in six-well plates 24h 
before transfection. 1 µg of the Pax5 promoter luciferase reporter plasmid (pGL3-Pax5), 
kindly provided by Dr. Kathryn Calame (Columbia University), was cotransfected with 
various amounts of EBF1, IRF8, c-Myc, or control vectors, into NIH3T3 cells by the 
calcium phosphate method. 48h after transfection, cells were harvested and lucifease 
activity was determined using the Dual-Lucifease Reporter Assay system (Promega). 
DNA microarray and data analysis. Bone marrow cells were isolated from CML mice 
14 days after the induction of the disease. BCR-ABL-expressing or BCR-ABL/Blk-
expressing (transduced with the BCR-ABL-GFP or BCR-ABL-Blk-GFP, respectively) 
GFP+Lin-c-Kit+Sca-1+ cells (representing LSCs) were stored by FACS directly into 
RNAlater (Ambion) and homogenized in RLT Buffer (RNeasy Micro Kit) (Qiagen). 
Total RNA was isolated by following the protocol for the RNeasy Micro Kit. RNA was 
amplified, labeled, and approximately 2.0µg of fragmented and biotin-labeled cDNA was 
then hybridized onto Mouse Genome 430 2.0 microarray (Affymetrix). Relative fold 
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change (RFC) of a gene between BCR-ABL-expressing or BCR-ABL/Blk-expressing 
LSCs was calculated using the formula: RFC = (sign(D) + (D == 0)) * 2abs(D). The log2 of 
the RFC value for the gene was shown. The detailed analysis of the microarray 
experiment and data were described in the Supplemental Information and the microarray 
data was deposited into GEO database (GSE36096). The expression of Blk gene in 
human CML cells, quiescent and dividing CML CD34+ cells, and CD34+CD38- CML 
stem cells treated with imatinib were analyzed independently in publicly available 
microarray data sets including GSE4170 for human CML bulk CD34+ cells, GSE 
GSE24739 for quiescent (G0) and dividing (G1) CML leukemia stem cells, and 
GSE20876 for CML CD34+CD38- leukemia stem cells with/without imatinib treatment. 
The probe-level raw intensity data were normalized and summarized into probes-set level 
data using Probe Logarithmic Intensity Error (PLIER) method. The BLK gene expression 
were extracted and further re-normalized at probe-set level by a set of suitable reference 
genes, the significance of changes between relevant groups was assessed by moderated t-
test. 
Immunoprecipitation, western blotting and antibodies. Protein lysates were prepared 
by lysing cells in RIPA buffer containing 25mM TrisHCl, 150mM NaCl, 1%NP-40, 1% 
sodium deoxycholate, 0.1% SDS. Blk was immunoprecipitated with anti-Blk antibody 
and blotted with anti-phospho-tyrosine (p-Tyr) antibody. Antibodies against c-Abl, Blk, 
p-Tyr, Pax5, p27, p21, CDK2, Skp2, c-Myc and beta-actin were purchased from Santa 
Cruz Biotechnology.  
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Real time-PCR. Total RNA was isolated from GFP+LK+S+ bone marrow cells from mice 
using the RNeasy Mini kit (Qiagen). cDNA was synthesized using the Ovation-Pico 
cDNA synthesis method. All real time PCR reactions were done using the Applied 
Biosystems 7500. 25µL reaction system was composed of 12.5µL SYBR Green, 2.5µL 
20uM primer mixture, 10ng cDNA and nuclease-free water. All experiments were 
performed in triplicate. ß-actin was the internal control. The following are specific primer 
sequences: Pax5 sense: gtacagcagccccccaatc; antisense: accttcatccctcttgcgttt; Blk sense: 
tgtggtcaccagagagcccattta; antisense: tgtcaatctgccttggaagggaca; EBF1 sense: 
tgcagatctggttgaagccctgta; antisense: atccctgcatggaccgaagtgtta; Skp2 sense: 
aaacctttgtgggtggctctg; antisense: cttaagtcgaggcggatgag; BCR sense: 
cgtgtgtgaaactccagactgtca; ABL antisense: cttcagcggccagtagcatct; Actin sense: 
atggaatcctgtggcatcca; antisense: cgctcaggaggagcaatgat. 
Statistical analysis. Results are given as mean ± s.e.m. Statistical analysis was 
performed by Students’s t test for all column statistis. For survival curves, p values were 
obtained using a Log-rank test. 
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Figure S1. Knockdown BCR-ABL expression restores Blk expression. (A) Western 
blot analysis showed marked decrease of BCR-ABL expression after lentivirus shRNA 
infection. (B)Real time RT-PCR analysis showed increased Blk expression in leukemia 
cells after knockdown of BCR-ABL. 
 
 
 
Figure S2. Blk deletion does not affect the transfection efficiency and homing ability 
of bone marrow cells. (A) Detection of Blk Expression in Bone Marrow Cells of WT 
and Blk-/- Mice by western blotting. (B) Blk does not affect the retroviral transduction 
efficiency of bone marrow cells. Bone marrow cells from 5-FU treated WT or Blk-/- mice 
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were transduced with BCR-ABL-GFP, and the percentages of GFP+ cells before BMT 
were analyzed by FACS. (C) Homing assay of WT or Blk-/- bone marrow cells. 6×106 
WT or Blk-/- bone marrow cells (CD45.2) were transplanted into lethally irradiated 
recipients (CD45.1) and the donor-derived bone marrow cells (CD45.2) were detected by 
FACS in 3 hours after BMT. Mean values (± SEM) are shown. (D) WT or Blk-/- bone 
marrow cells transduced with BCR-ABL retrovirus were cultured for 6 days. Equal 
number of GFP+ cells were transplanted into each lethally irradiated recipient mice, and 
the percentages of GFP+ cells in bone marrow of recipients were analyzed 3 hours after 
BMT (n=4). Mean values (± SEM) are shown.  
 
 
 
 
 
Figure S3. Functional testing of BCR-ABL and Blk Retroviruses in 3T3 Cells. 3T3 
cells were transduced with retrovirus (1:2 or 1:8 dilution) expressing BCR-ABL-GFP, 
Blk-GFP, or BCR-ABL-Blk. Expression of BCR-ABL and Blk proteins were detected by 
Western blotting 
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Figure S4. Blk suppress colony forming ability of LSCs. LSCs from CML mice which 
received BCR-ABL transduced WT and Blk-/- boe marrow cells or received BCR-ABL-
Blk transduced WT bone marrow cells were plated in methycellulose medium for colony 
culture. Compared with WT LSCs, Blk-/- LSCs generated more colonies, and Blk 
overexpression caused less colonies.   
 
 
Figure S5. The c-myc binding site in the Pax5 promoter. (A) The sequence of c-Myc 
binding site in the Pax5 promoter is completely conserved in mouse and human. (B) 
Western blot analysis showed c-Myc expression. Pax5 overexpression has a modest 
effect on normal HSCs and Pax5 promoter has c-myc binding site. 
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Figure S6. EBF1 expression was down-regulated in BCR-ABL expressing LSCs. 
Microarray analysis showing EBF1expression in vector- and BCR-ABL-transduced 
LSCs. Mean values (± s.e.m) are shown. p<0.05. 
 
 
Figure S7. Blk affects the expression of Skp2 and p27. (A) Real time RT-PCR analysis 
showed Blk inhibited the induction of Skp2 expression by BCR-ABL. (B) p27 was down-
regulated in myeloid leukemia cells. Myeloid leukemia cells were sorted from the spleen 
of CML mice receiving BCR-ABL transduced WT or Blk-/- bone marrow cells two weeks 
after CML induction, and p27 levels in the cells were detected by Western blotting. (C) 
Western blot analysis showed that Blk induced expression of p27 and p53 expression but 
not CDK2 and cyclin E. in bone marrow cells from CML mice which were cultured for 4 
days in vitro under the stem cell culture conditions. (D) Real-time RT-PCR data showed 
a significant upregulation of p27 in sorted Blk-expressing LSK cells. Mean values (± 
SEM) are shown (P<0.01). 
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Figure S8. Normalization of the retrovirus titers of BCR-ABL, BCR-ABL-Blk, 
BCR-ABL-Blk-K263E, BCR-ABL-Blk-Y383F, and BCR-ABL-Blk∆TK. (A and B) 
NIH3T3 cells were infected with retroviruses, and 48h later, the levels of BCR-ABL 
proteins were analyzed by western blotting. 
 
Figure S9. Blk expression induces apoptosis of CML stem cells. Lin-CD34+ cells from 
CML patients were sorted and infected with Blk lentivirus. After puromycin selection, 
FACS analysis showed increased apoptosis in the presence of Blk. 
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Table S1. List of up-regulated genes (P ≤ 0.05) 
Symbol Gene name Relative 
fold change 
Igkv19-93 immunoglobulin kappa chain variable 19-93 2.89 
Myo1h myosin 1H 2.1 
Ufsp1 UFM1-specific peptidase 1 2.07 
Them4 thioesterase superfamily member 4 1.92 
Igl-V2 Immunoglobulin lambda chain, variable 2 1.89 
Clec9a C-type lectin domain family 9, member a 1.88 
Cldn22 claudin 22 1.78 
Rab1b RAB1B, member RAS oncogene family 1.78 
Gnrh1 gonadotropin releasing hormone 1 1.77 
Tsga14 testis specific gene A14 1.75 
Plekho2 pleckstrin homology domain containing, family O member 2 1.73 
Hist1h2ak histone cluster 1, H2ak 1.73 
Cyb5d1 cytochrome b5 domain containing 1 1.72 
Prl7c1 prolactin family 7, subfamily c, member 1 1.7 
Zfp459 zinc finger protein 459 1.66 
Kcnrg potassium channel regulator 1.65 
Cmtm3 CKLF-like MARVEL transmembrane domain containing 3 1.65 
Gcet2 germinal center expressed transcript 2 1.62 
Olfr43 olfactory receptor 43 1.62 
Rfc5 replication factor C (activator 1) 5 1.6 
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Table S2 List of down-regulated genes (P ≤ 0.05) 
Symbol Gene name 
Relative 
fold change 
Khdc1a KH homology domain containing 1A 4.40 
Il1f9 Interleukin 1 family, member 9 2.78 
Ublcp1 ubiquitin-like domain containing CTD phosphatase 1 2.48 
Lcn2 lipocalin 2 2.39 
Scrn3 secernin 3 2.26 
Fabp4 fatty acid binding protein 4, adipocyte 2.21 
Trem3 triggering receptor expressed on myeloid cells 3 2.17 
Chi3l3 chitinase 3-like 3 2.17 
Dhrs7 dehydrogenase/reductase (SDR family) member 7 2.16 
Gldc glycine decarboxylase 2.10 
S100a5 S100 calcium binding protein A5 2.08 
Ifitm6 interferon induced transmembrane protein 6 2.06 
Clec4d C-type lectin domain family 4, member d 2.03 
Serpina3f serine (or cysteine) peptidase inhibitor, clade A, member 3F 1.97 
Nrg4 Neuregulin 4 1.95 
Hdc histidine decarboxylase 1.94 
Bank1 B-cell scaffold protein with ankyrin repeats 1 1.89 
Mt1 metallothionein 1 1.84 
Il6 Interleukin 6 1.83 
Gem GTP binding protein (gene overexpressed in skeletal muscle) 1.81 
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CHAPTER IV 
Scd1 plays a tumor suppressive role in survival of leukemia stem cells  
and the development of chronic myeloid leukemia 
 
The work described in the chapter has been published (Zhang et al., Mol. Cell. Biol. 2012 
32:1776-1787) 
 
Abstract 
Chronic myeloid leukemia (CML) is derived from a stem cell and it is widely 
accepted that the existence of leukemia stem cells (LSCs) is one of the major reasons for 
the relapse of CML treated with kinase inhibitors. Key to eradicating LSCs is to identify 
genes that play a critical role in survival regulation of these stem cells. Using BCR-ABL-
induced CML mouse model, here we show that expression of the stearoyl-CoA 
desaturase 1 (Scd1) gene is down-regulated in LSCs and that Scd1 plays a tumor 
suppressive role in LSCs with no effect on the function of normal hematopoietic stem 
cells (HSCs). Deletion of Scd1 causes acceleration of CML development and conversely 
overexpression of Scd1 delays CML development. In addition, using genetic approaches, 
we show that Pten, p53 and Bcl2 are regulated by Scd1 in LSCs.  Furthermore, we find 
that induction of Scd1 expression by a PPARγ agonist suppresses LSCs and delays CML 
development. Our results demonstrate a critical role for Scd1 in functional regulation of 
LSCs, providing a new anti-LSC strategy through enhancing Scd1 activity.  
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Introduction 
Leukemia stem cells (LSCs) are defined as transformed hematopoietic stem cell 
or progenitors that have acquired unlimited self-renewal ability. It is generally accepted 
that eradication of LSCs is required for effectively treating and eventually curing the 
diseases. Chronic myeloid leukemia (CML) is believed to originate from a hematopoietic 
stem cell (HSC) harboring Philadelphia chromosome formed through a reciprocal 
translocation between chromosomes 9 and 22. Human CML is induced by the BCR-ABL 
oncogene that produces the chimeric BCR-ABL protein functioning as a constitutively 
activated tyrosine kinase in leukemogenesis 1,2,6. Although BCR-ABL kinase inhibitors 
are highly effective in treating chronic phase CML patients 39, they do not completely 
eradicate LSCs39,62,63,201. Therefore, there is an urgent need for developing anti-LSC 
strategies, and this approach relies on identification of critical target genes in LSCs.  
Accumulating evidence shows a close relationship between cancer and 
metabolism 233. Cancer cells display changes in fatty acid metabolism234, which is 
associated with modulations of expression and activity of lipogenic enzymes.  One such 
an enzyme is stearoyl-CoA desaturase (Scd). Scd is an endoplasmic reticulum enzyme, 
belonging to a family of ∆9-fatty acid desaturase isoforms. Scd1 catalyzes the 
biosynthesis of monounsaturated fatty acids (MUFA) from saturated fatty acids (SFA), 
which are the most abundant fatty acids present in mammalian organisms 157. Scd1 
expression is detected in almost all tissues with a predominant expression in liver, and is 
involved in regulating metabolic pathways related to preadipocyte differentiation, insulin 
sensitivity, metabolism, and tumorigenesis 157,164-167. A recent study indicates that 
   
129 
inhibition of Scd1 impairs lung cancer cell proliferation, survival and invasiveness 165, 
suggesting that Scd1 plays a supporting role in lung cancer cells. Another study shows 
that the level of Scd1 expression correlates with predisposition to liver carcinogenesis 166. 
However, the role of Scd1 in leukemogenesis and hematopoiesis remains unknown, 
although it is suggested that fatty acid metabolism plays a role in leukemogenesis and 
hematopoiesis 170,171, In this study, using BCR-ABL induced chronic myeloid leukemia 
mouse model, we found that expression of the Scd1 gene was down-regulated in LSCs 
and deletion of Scd1 accelerated CML development through affecting the function of 
LSCs but not normal HSCs, suggesting that Scd1 plays a tumor suppressive role in BCR-
ABL leukemogenesis. Our study provides a new strategy for targeting LSCs by 
enhancing the Scd1 function.  
 
Results 
Scd1 plays a tumor suppressive role in CML development 
BCR-ABL-expressing HSCs (GFP+Lin-Sca-1+c-Kit+ cells) in mice function as 
LSCs 63. We analyzed the results from our previously published DNA microarray study 
(GEO submission: GSE10912), in which we compared the gene expression profiles 
between LSCs and normal HSCs. We found that expression of the Scd1 gene was 
dramatically lower in BCR-ABL-expressing LSCs as compared to normal HSCs (Fig. 
1A), and this down-regulation of Scd1 in LSCs was confirmed by real time RT-PCR (Fig. 
1B). Furthermore, we analyzed a publicly available gene expression profiling database of 
human CML stem cells 218, and found that Scd1 expression was markedly down-regulated 
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in the majority of CML patients in chronic phase and blast crisis (Fig. 1C).  These results 
suggest that Scd1 plays a tumor suppressive role in CML development. To test this idea, 
we first investigated whether Scd1 deficiency causes acceleration of CML development 
using Scd1 homozygous knockout (Scd1-/-) mice. We transduced bone marrow cells from 
5-FU-treated wild type (WT) or Scd1-/- mice with the BCR-ABL-GFP retrovirus, followed 
by transplanting the transduced cells into lethally irradiated recipient mice to induce 
CML. We found that recipients of BCR-ABL-transduced Scd1-/- bone marrow cells 
developed and died of CML significantly faster than did recipients of BCR-ABL-
transduced WT bone marrow cells (Fig. 1D). The accelerated CML development in the 
absence of Scd1 correlated with a higher percentage and total numbers of GFP+Gr-1+ 
myeloid leukemia cells in peripheral blood (Fig. 1E, F), and with more severe 
splenomegaly and lung hemorrhage (Fig. 1G). Histological examination showed more 
extensive infiltration of leukemia cells in the lung and spleen of CML mice receiving 
BCR-ABL-transduced Scd1-/- bone marrow cells (Fig. 1H). Because increased homing of 
donor bone marrow cells could lead to accelerated CML development, we compared the 
homing ability of Scd1-/- bone marrow cells with WT bone marrow cells 3 hours after the 
transplantation of the cells into recipient mice. We found that the percentages of donor-
derived WT and Scd1-/- bone marrow cells in recipient mice were similar (Fig. 1I), 
indicating that Scd1 deficiency does not significantly alter the homing ability of bone 
marrow cells. 
Reversely, we overexpressed Scd1 in donor bone marrow cells by transducing the 
cells with retrovirus expressing both BCR-ABL and Scd1 (Fig. 1J) to examine whether 
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enforced expression of Scd1 causes a delay of CML development. We did observe that 
Scd1 overexpression caused a significant delay of CML development in secondary 
recipients of bone marrow cells from the primary CML mice (Fig. 1K). This delayed 
CML development correlated with lower percentages of myeloid cells in peripheral blood 
of the mice (Fig. 1L). Together, these results indicate that Scd1 plays an inhibitory role in 
CML development. 
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Figure 1. Scd1 plays a tumor suppressive role in CML development. (A) Microarray 
analysis showed that Scd1 expression was down-regulated in BCR-ABL-expressing 
LSCs as compared to normal stem cells that did not express BCR-ABL. (B) Real time 
RT-PCR analysis showed that Scd1 expression was down-regulated in LSCs. The 
expression data were normalized to β-actin expression and shown as mean±s.e.m. (n=3; 
*, P<0.05). (C) Scd expression in human CML samples. Microarray analysis showed 
expression of Scd1 in CD34+ bone marrow and peripheral blood (PB) cells from 42 
chronic (green), and 31 blast crisis phase (red) CML patients. (D) Kaplan-Meier survival 
curve for recipients of BCR-ABL-transduced WT or Scd1-/- bone marrow cells (n=7-8 
mice per group; p<0.005). (E) The percentage of GFP+Gr-1+ cells in peripheral blood of 
recipients of BCR-ABL-transduced bone marrow cells from WT or Scd1-/- donor mice at 
day 14 after bone marrow transplantation (BMT). (F) Total number of GFP+Gr-1+ 
leukemia cells in PB of recipients of BCR-ABL-transduced WT or Scd1-/- bone marrow 
cells. (G) Gross appearance of the lungs and spleens from mice receiving BCR-ABL-
transduced WT or Scd1-/- bone marrow cells at day 14 after BMT. (H) Hematoxylin/eosin 
staining of tissue sections from the lungs and spleens of mice receiving BCR-ABL-
transduced WT or Scd1-/- bone marrow cells at day 14 after BMT (Scale bar: 50 µm). (I) 
The loss of Scd1 does not affect the homing ability of bone marrow cells. 6×106 bone 
marrow cells from WT or Scd1-/- mice (CD45.2) were transplanted into lethally irradiated 
recipient mice (CD45.1). The donor-derived bone marrow cells (CD45.2) were detected 
by FACS in 3 hours after BMT. (J) Western blot analysis showed expression of Scd1 and 
BCR-ABL in 293T cells transfected with BCR-ABL-Scd1. (K) Kaplan-Meier survival 
curve for secondary recipients of equal number of bone marrow cells from primary CML 
mice receiving BCR-ABL- or BCR-ABL-Scd1-transduced WT bone marrow cells. (n=14-
16 mice per group; p<0.0001). (L) The percentages of myeloid cells (Gr-1+Mac-1+) in 
peripheral blood of secondary recipients of bone marrow cells from primary CML mice 
receiving BCR-ABL- or BCR-ABL-Scd1-transduced WT bone marrow cells.at day 9, 12, 
16, and 28 after BMT. 
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Figure 1. Scd1 plays a tumor suppressive role in CML development. 
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Scd1 deletion does affect the development of BCR-ABL induced B-ALL 
We also tested whether Scd1 is required for BCR-ABL induced B-ALL. We first 
assessed Scd expression in human B-ALL using a publicly microarray dataset (GSE5314) 
of 37 BCR-ABL-positive (21 of p190BCR-ABL and 16 of p210BCR-ABL) and 17 BCR-ABL-
negative adult ALL235. We did not observe significant difference in Scd expression 
between BCR-ABL-positive ALL and BCR-ABL-negative ALL and between p190BCR-
ABL-positive and p210BCR-ABL-positive ALL (Fig. 2A). These data suggest that Scd 
expression may not be relevant to BCR-ABL in ALL. Consistent with this idea, 
recipients of WT or Scd1-/- bone marrow cells transduced with BCR-ABL retrovirus  
developed and died of ALL with similar disease latency and survival (Fig. 2B), 
correlating with similar numbers and percentages of GFP+B220+ leukemia cells in 
peripheral blood of the two groups of B-ALL mice (Fig. 2C, D). These results indicate 
that Scd1 is dispensable for BCR-ABL induced B-ALL. 
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Figure 2. Scd1 does not suppress B-ALL induced by BCR-ABL. (A) Microarray 
analysis showing Scd expression in human B-ALL samples from 37 BCR-ABL-positive 
[21 of p190BCR-ABL (green) and 16 of p210BCR-ABL (red)] and 17 BCR-ABL-negative 
(blue) adult patients. (B) Kaplan-Meier survival curve for recipients receiving BCR-ABL-
transduced WT or Scd1-/- bone marrow cells. Both groups of mice developed and died of 
ALL with similar disease latency (n=8 mice per group). (C) The total number of 
GFP+B220+ cells in PB of recipients of BCR-ABL-transduced WT or Scd1-/- bone marrow 
cells. (D) FACS analysis showed no difference in the percentages of GFP+B220+ cells in 
PB of recipients of BCR-ABL-transduced WT or Scd1-/- bone marrow cells.  
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Figure 2. Scd1 does not suppress B-ALL induced by BCR-ABL 
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Scd1 suppresses LSCs 
The tumor suppressive effect of Scd1 on CML development could be caused by 
affecting LSCs. To test this possibility, we first examined whether deletion of Scd1 
causes an increase of LSCs in bone marrow of CML mice. Two weeks after CML 
induction using BCR-ABL transduced WT or Scd1-/- bone marrow cells, we analyzed 
bone marrow cells from CML mice by FACS (Fig. 3A). We found that the percentages 
and numbers of total LSCs and long-term (LT) (GFP+Lin-c-Kit+Sca-1+ CD34-) or short-
term (ST) (GFP+Lin-c-Kit+Sca-1+ CD34+) LSCs were significantly higher in recipients of 
BCR-ABL-transduced Scd1-/- bone marrow cells than in recipients of BCR-ABL-
transduced WT bone marrow cells (Fig. 3A). We also cultured bone marrow cells from 
CML mice in vitro for 7 days under the stem cell culture conditions 232, and found that 
the percentage and number of Scd1-/- LSCs were significantly higher than those of WT 
LSCs (Fig. 3B).  
To investigate whether Scd1 affects self-renewal of LSCs, we carried out an in 
vitro serial replating assay to examine the ability of LSCs to form progenitor colonies. 
We sorted LSCs from recipients of BCR-ABL-transduced WT or Scd1-/- bone marrow 
cells, and plated the cells in vitro for colony formation. We observed that Scd1-/- LSCs 
formed significantly higher numbers of colonies compared to WT LSCs (Fig. 3C). To 
determine whether deletion of Scd1 causes an increase in LSC function in vivo, we mixed 
BCR-ABL-transduced WT (CD45.1) and Scd1-/- (CD45.2) bone marrow cells in a 1:1 
ratio, and transplanted into lethally irradiated mice. At days 8 and 11 after CML 
induction, FACS analysis showed much higher percentages of CD45.2+ leukemia cells in 
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peripheral blood, as compared to the percentages of CD45.1+ leukemia cells (Fig. 3D). 
To further confirm this result, LSCs were sorted by FACS from bone marrow of primary 
CML mice receiving BCR-ABL-transduced WT (CD45.1) or Scd1-/- (CD45.2) bone 
marrow cells, mixed in a 1:1 ratio, and then transplanted into secondary recipient mice. 
Eight weeks later, more than 75% of GFP+Gr-1+ leukemia cells in peripheral blood were 
CD45.2+ (Fig. 3E), indicating that Scd1-/- LSCs grew predominantly over WT LSCs to 
induce CML in recipient mice. Together, these results demonstrate that Scd1 suppresses 
the function of LSCs. 
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Figure 3. Scd1 suppresses LSCs.  (A) Bone marrow cells from recipients of BCR-ABL-
transduced WT or Scd1-/- bone marrow cells were analyzed by FACS at day 14 after 
BMT. The percentages and numbers of total LSCs, LT-LSCs, ST-LSCs, in bone marrow 
of recipients of BCR-ABL-transduced Scd1-/- donor bone marrow cells were dramatically 
higher as compared to those in bone marrow of recipients of BCR-ABL-transduced WT 
donor bone marrow cells. (n=4-7 mice per group). Data are representative of one of four 
independent experiments, and mean values (± s.e.m) are shown (*, P<0.05). (B) Loss of 
Scd1 promotes survival of LSCs in vitro. Bone marrow cells from recipients of BCR-ABL 
transduced WT or Scd1-/- bone marrow cells were cultured for 6 days under the in vitro 
stem cell culture conditions. The total number and percentage of LSCs were analyzed by 
FACS. (C) Loss of Scd1 increased the colony-forming ability of LSCs. The sorted 
GFP+Lin-Sca-1+c-Kit+ cells from CML mice were plated into methycellulose media, and 
the numbers of colonies were counted. The cells from colonies were serially replated. 
Data are representative of one of two independent experiments. Mean values (± s.e.m) are 
shown (**, P<0.01; ***, P<0.001). (D) Equal number of BCR-ABL-transduced bone 
marrow cells from WT (CD45.1) or Scd1-/- (CD45.2) mice were mixed well and 
transplanted into lethally irradiated WT mice (CD45.2). At day 8 and 11 after BMT, 
FACS analysis gated in GFP+ cell population showed that the percentages of leukemia 
cells from Scd1-/- mice (CD45.2) were dramatically higher than those from WT mice 
(CD45.1). Mean values (± s.e.m) are shown (**P<0.01; **8P<0.001). (E) Competitive 
repopulation assay showed that loss of Scd1 increased engraftment of LSCs. 103 sorted 
LSCs from bone marrow of primary CML mice induced by transplanting BCR-ABL-
transduced Scd1-/- bone marrow cells (CD45.2) and BCR-ABL- transduced WT bone 
marrow cells (CD45.1) were mixed at 1:1 ratio, followed by transplantation into lethally 
irradiated recipients mice. The percentages of CD45.2 cells in GFP+ cell population from 
PB were compared with those of CD45.2 cells at 8 weeks after BMT (n=3; ***, 
P<0.0001).  
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Figure 3. Scd1 suppresses LSCs.   
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Scd1 deletion inhibits apoptosis but not cell cycle of LSCs 
To explore cellular mechanisms by which Scd1 regulates LSC function, we 
investigated whether Scd1 suppresses LSCs through affecting cell cycle progression or 
apoptosis. We analyzed LSCs from the bone marrow and spleen of CML mice, and we 
did not observe a significant difference in the percentages of LSCs in the S-G2-M phase 
of the cell cycle in the presence and absence of Scd1 (Fig. 4A). However, the percentages 
of apoptotic LSCs (Annexin V+) were significantly lower in the absence than in the 
presence of Scd1 (Fig. 4B), indicating Scd1 suppresses LSCs through reducing their 
survival. To study the molecular mechanisms by which Scd1 suppresses LSCs and 
attenuates CML development, we compared expression of Pten, p53 and Bcl-2 in WT 
and Scd1-/- leukemia progenitor cells and LSCs. We found that Scd1 deficiency caused a 
decreased expression of Pten and p53 and an increased expression of Bcl-2 in LSCs (Fig. 
4C) and in GFP+Lin- leukemia progenitor cells (Fig. 4D). Consistently, when we 
overexpressed Scd1 in LSCs, we found that Scd1 overexpression induced expression of 
Pten and p53 and reduced expression of Bcl-2 in LSCs (Fig. 4E). To examine functional 
significance of these genes in LSCs, we constructed the BCR-ABL-Pten-GFP retroviral 
construct to allow co-expression of BCR-ABL, Pten and GFP in the same cells187. We 
transduced bone marrow cells from WT or Scd1-/- mice with BCR-ABL-Pten-GFP 
retrovirus, and transplanted into lethally irradiated recipient mice. Recipients of BCR-
ABL transduced Scd1-/- bone marrow cells displayed higher percentage and number of 
leukemia cells in peripheral blood compared to recipients of BCR-ABL transduced WT 
bone marrow cells, whereas recipients of BCR-ABL-Pten transduced WT and Scd1-/- bone 
   
142 
marrow cells showed a lower number of leukemia cells (Fig. 4F, G). These results 
indicate that Pten functions downstream of Scd1 to suppress CML development . To 
further confirm the effect of Pten on Scd1-/- LSCs, we conducted a colony-forming assay, 
and found that Pten suppressed colony formation of Scd1-/- LSCs  (Fig. 4H).  
Using the colony-forming assay, we also examined the function of Bcl2 and p53 
through lentiviral shRNA mediated knockdown of Bcl2 and p53 in Scd1-/- LSCs and 
Scd1-expressing LSCs, respectively. Western blotting analysis showed that lentiviral 
shRNA markedly reduced the expression level of Bcl2 and p53 (Fig. 4I). Because Scd1 
deficiency caused a higher level of  Bcl2 expression in Scd1-/- LSCs (Fig. 4C), we 
assumed that Bcl2 knockdown would reverse the phenotype of Scd1-/- LSCs. As 
expected, we found that Scd1-/- LSCs with Bcl2 knockdown gave rise to less colonies 
compared to control Scd1-/- LSCs without Bcl2 knockdown (Fig. 4J), indicating that Bcl2 
also mediates the function of Scd1 in LSCs. Furthermore, we knocked down p53 in Scd1-
expressing LSCs and observed increased number of colonies (Fig. 4K), although the 
increase was not statistically significant, suggesting that p53 plays a minor role 
downstream of Scd1 in LSCs.  
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Figure 4. Scd1 deletion promotes survival but not cell cycle progression of LSCs. (A) 
The cell cycle analysis showed comparable percentage of cycling LSCs from the bone 
marrow and spleen of CML mice receiving BCR-ABL-transduced WT and Scd1-/- bone 
marrow cells. Data shown are a representative experiment from three independent 
experiments, with 4-7 mice per group in each experiment. Mean values (± s.e.m) are 
shown (NS, no significance). (B) Apoptotic analysis of LSCs from the bone marrow and 
spleen of CML mice receiving BCR-ABL-transduced wild type or Scd1-/- bone marrow 
cells. Data shown are a representative experiment from three independent experiments, 
with 4-7 mice per group in each experiment. Mean values (± s.e.m) are shown (*, P<0.05; 
**, P<0.01). (C and D) Real time RT-PCR analysis of expression of Pten, p53, and Bcl-2 
in the sorted WT or Scd1-/- LSCs and progenitor cells from CML mice. Representative 
data from two independent experiments are shown. Mean values (± s.e.m) are shown (*, 
P<0.05; **, P<0.01). (E) Real time RT-PCR analysis showed that Scd1 up-regulated 
expression of Pten and p53 and down-regulated expression of Bcl-2 in LSCs. Bone 
marrow cells from 5-FU pretreated mice were co-transduced with MSCV-BCR-ABL-GFP 
and MSCV-Scd1-hCD4 or MSCV-hCD4. 14 days after BMT, Scd1-overexpressing LSCs 
(hCD4+GFP+Lin-Sca-1+c-Kit+) or control LSCs were sorted for extracting total RNA for 
real time PCR analysis. Representative data from two independent experiments are 
shown. Mean values (± s.e.m) are shown (*, P<0.05; **, P<0.01). (F) FACS analysis 
showing the total numbers of leukemia cells in PB of recipients of BCR-ABL or BCR-
ABL-Pten transduced WT and Scd1-/- bone marrow cells at Day 14 after BMT. 
Representative data from two independent experiments are shown. Mean values (± s.e.m) 
are shown (**, P<0.01; ***, P<0.001). (G) FACS analysis showing the percentages of 
leukemia cells in PB of recipients of BCR-ABL or BCR-ABL-Pten transduced WT and 
Scd1-/- bone marrow cells at Day 14 after BMT. (H) Colony-forming assay showed that 
Pten overexpression reduced colony-forming ability of Scd1-/- LSCs. Representative data 
from two independent experiments are shown. Mean values (± s.e.m) are shown (**, 
P<0.01; ***, P<0.001).  (I) (I) Western blotting analysis of Bcl2 and p53 expression after 
lentivirus shRNA mediated knockdown. (J) Colony-forming assay. CML bone marrow 
cells from recipients of BCR-ABL transduced WT and Scd1-/- bone marrow cells were 
infected with shRNA-Bcl2 or control lentivirus and cultured in the presence of 
puromycin for 48 hours. Equal numbers of infected cells were plated into methycellulose 
media. Representative data from two independent experiments are shown. Mean values 
(± s.e.m) are shown (**, P<0.01). (K) Colony-forming assay. CML bone marrow cells 
from recipients of BCR-ABL or BCR-ABL-Scd1 transduced WT bone marrow cells were 
infected with shRNA-p53 or control lentivirus and cultured in the presence of puromycin 
for 48 hours. Equal numbers of infected cells were plated into methycellulose media. 
Representative data from two independent experiments are shown. Mean values (± s.e.m) 
are shown (**, P<0.01; NS, no significance). 
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Scd1 regulates Pten, p53 and Bcl2 transcription and mRNA stability  
To examine whether Scd1 regulates expression of Pten, p53, and Bcl2 at a 
transcriptional or post-transcriptional level, we first performed chromatin 
immunoprecipitation of RNA Pol-II using WT and Scd1-/- leukemia cells and found that 
the enrichments of Pol-II in the promoters of Pten and p53 were significant higher in the 
WT leukemia cells than those in the Scd1-/- leukemia cells (Fig. 5A, B). We also found 
that the enrichment of Pol-II in the promoter of Bcl2 was lower in the WT leukemia cells 
than that in the Scd1-/- leukemia cells (Fig. 5C). These data suggest that Scd1 deletion 
reduces the transcription of Pten and p53 and induces Bcl2 transcription. We tested 
whether Scd1 affects mRNA stability of Pten, p53 and Bcl2. Leukemia cells from WT 
and Scd1-/- CML mice were treated with actinomycin D (5µg/mL) to block the 
transcription, and total RNA was subsequently harvested at various time points and the 
mRNA half-life for Pten, p53, or Bcl2 was examined by RT-PCR. We found that the 
mRNA half-life for Pten and p53 was similar in WT and Scd1-/- leukemia cells, but the 
mRNA half-life for Bcl2 was markedly increased in Scd1-/- leukemia cells (Fig. 5D). 
These results indicate that Scd1 regulates expression of Pten and p53 only at the 
transcriptional level, but regulates expression of Bcl2 through affecting both transcription 
and mRNA stability. 
To further study the functional relationship between Scd1 and Pten/p53, we 
examined Akt phosphorylation in Scd1-/- leukemia cells, because a published study 
showed an increased Akt activity in Scd1-/- cells 173. We found that the level of Akt 
phosphorylation level was elevated in Scd1-/- leukemia cells (Fig. 5E). Therefore, we 
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Figure 4. Scd1 deletion promotes survival but not cell cycle progression of LSCs. 
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asked further whether Akt pathway is involved in the regulation of Pten and p53 by Scd1. 
We treated Scd1-/- CML leukemia cells with Akt inhibitor triciribine, and found that 
inhibition of Akt activity partially reversed expression of Pten but not p53 (Fig. 5F, G). 
Inhibition of PI3K/mTOR pathway by the dual inhibitor PI103 reversed expression of 
both Pten and p53 (Fig. 5F, G). However, inhibition of MAPK activity by the inhibitor 
SB203580 did not have an effect on expression of either Pten or p53 (Fig. 5F, G). These 
results suggest that the PI3K/Akt but not MAPK pathway mediates the regulation of Pten 
and p53 by Scd1 .   
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Figure 5. Scd1 regulates Pten, p53 and Bcl2 transcription and mRNA stability. (A 
and B) Pol-II ChIP analysis showed the accumulation of polymerase II in the promoters 
of Pten and p53 of WT but not Scd1-/- leukemia cells. (C) Pol-II ChIP analysis showed 
the accumulation of polymerase II in the promoter of Bcl2 of Scd1-/- but not WT 
`leukemia cells. (D) Decay time course of the mRNA levels for Pten, p53 and Bcl2 in 
WT and Scd1-/- leukemia cells. (E) Western blot analysis showed Akt phosphorylation in 
WT and Scd1-/- leukemia progenitor cells. (F) Real time RT-PCR assay for Pten 
expression in Scd1-/- leukemia cells treated with PI103, triciribine and SB203580. 
Representative data from two independent experiments are shown. Mean values (± s.e.m) 
are shown (*, P<0.05; **, P<0.01). (G) Real time RT-PCR assay for p53 expression in 
Scd1-/- leukemia cells treated with PI103, triciribine and SB203580. Representative data 
from two independent experiments are shown. Mean values (± s.e.m) are shown (*, 
P<0.05; **, P<0.01) 
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Figure 5. Scd1 regulates Pten, p53 and Bcl2 transcription and mRNA stability 
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Induction of Scd1 expression inhibits LSCs and attenuates CML development 
The tumor suppressive role of Scd1 in CML development prompted us to test 
whether upregulation of Scd1 expression delays CML development. It has been shown 
that the PPARγ agonists, rosiglitazone and pioglitazone, induce Scd1 expression, and this 
Scd1 upregulation is blocked by PPARγ antagonists in vitro and in vivo 236,237. Therefore, 
we treated bone marrow cells from CML mice with rosiglitazone for 6 days in vitro, and 
found that Scd1 expression was significantly induced in LSCs (Fig. 6A), accompanied by 
a dramatic decrease in the numbers of LSCs (Fig. 6B). To test the effect of rosiglitazone 
on CML development, we treated CML with a placebo, imatinib alone, rosiglitazone 
alone, and the two agents in combination. Although treatment with rosiglitazone alone 
did not prolong the survival of CML mice, combined treatment with rosiglitazone and 
imatinib synergized and more significantly prolonged survival of CML mice than did 
imatinib alone (Fig. 6C). This therapeutic effect by rosiglitazone and imatinib correlated 
with much lower numbers of GFP+Gr-1+ myeloid leukemia cells (Fig. 6D) and increased 
apoptosis (Fig. 6E) of leukemia cells in peripheral blood. Because Scd1 overexpression 
induced expression of Pten and p53 in LSCs (Fig. 4E), we tested whether rosiglitazone 
treatment affects Pten and p53 expression. We observed higher levels of Pten and p53 
expression in LSCs after rosiglitazone treatment (Fig. 6F). We also treated human CML 
cell line K562 with rosiglitazone for 24 hours, and found that rosiglitazone treatment 
induced expression of Pten, p53 and Scd1 but decreased expression of Bcl2 (Fig. 6G). 
To confirm the requirement of Scd1 for the effect of rosiglitazone in suppressing 
leukemia development, we cultured bone marrow cells from recipients of BCR-ABL 
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transduced WT and Scd1-/- bone marrow cells in vitro under the stem cell culture 
conditions in the presence of rosiglitazone. We found that rosiglitazone treatment caused 
a marked decrease (up to 55%) of WT LSCs (Fig. 6H). In contrast, rosiglitazone 
treatment only caused a modest decrease in the percentage of Scd1-/- LSCs (25% 
decrease) (Fig. 6H), indicating that rosiglitazone regulates LSCs through Scd1. 
Additionally, we compared the impact of rosiglitazone on the colony-forming ability 
between WT and Scd1-/- LSCs. Since Scd1-/- LSCs had an increased colony-forming 
ability (Fig. 3C), we normalized the colony number in the control group (DMSO) to 
100%, and showed that the deletion of Scd1 caused a slight reduction in colony formation 
after rosiglitazone treatment (Fig. 6I), further demonstrating that that the inhibitory effect 
of rosiglitazone on LSCs is mediated through induction of Scd1 expression..  
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Figure 6. Induction of Scd1 expression suppresses LSCs and attenuates CML 
development. (A) Real time RT-PCR showed the induction of Scd1 expression by 
rosiglitazone in LSCs. Bone marrow cells from primary CML mice were treated with 
rosiglitazone in vitro for 7 days, and LSCs were sorted by FACS and total RNA was 
isolated for RT-PCR analysis. Representative data from two independent experiments are 
shown. Mean values (± s.e.m) are shown (***, P<0.001). (B) Bone marrow cells from 
primary CML mice were treated with rosiglitazone in vitro for 7 days, and the number of 
LSCs was decreased upon rosiglitazone treatment. (C) Kaplan-Meier survival curve for 
CML mice treated with a placebo, rosiglitazone alone, imatinib alone, or both 
rosiglitazone and imatinib.(n=6-12 mice per group; P=0.009). (D) The total numbers of 
leukemia cells in PB of CML mice treated with a placebo, rosiglitazone alone, imatinib 
alone, or both rosiglitazone and imatinib were analyzed at day 4, 8, 14, 21, 28 and 35 
after initiation of the treatments.  Results are representatives of two independent 
experiments. (E) FACS analysis of the percentages of apoptotic leukemia cells in PB of 
CML mice treated with imatinib alone (n=5), or both rosiglitazone and imatinib (n=5) for 
8 weeks. Mean values (± s.e.m) are shown (*, P<0.05). (F) Rosiglitazone treatment 
induced expression of Pten and p53 in LSCs in vitro. Mean values (± s.e.m) are shown 
(**P<0.01; ***P<0.001). (G) Western blot analysis showed the regulation of expression 
of Pten, p53, Bcl2 and Scd1 by rosiglitazone in human K562 cells. (H) The percentages 
of WT and Scd1-/- LSCs cultured in vitro in the presence of rosiglitazone. (I) Scd1 
deletion reduced the inhibitory effect of rosiglitazone on colony formation of LSCs. Bone 
marrow cells from recipients of BCR-ABL transduced WT and Scd1-/- bone marrow cells 
were plated in methycellulose media in the presence of rosiglitazone. Note that the 
colony forming unit for the cells treated with DMSO was defined as 100%. 
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Figure 6. Induction of Scd1 expression suppresses LSCs and attenuates CML 
development 
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Scd1 mediates the inhibitory effect of imatinib on CML development 
 To investigate whether Scd1 synergizes with imatinib in delaying CML 
development, we first analyzed our LSC microarray data and found that imatinib 
treatment induced Scd1 expression in LSCs (Fig. 7A). We next treated leukemia cells 
with imatinib in vitro under the stem cell culture conditions, and found that treatment 
with imatinib or rosiglitazone alone caused an increase in Scd1 expression, and treatment 
with both drugs further induced Scd1 expression (Fig. 7B). Furthermore,, we treated 
recipients of BCR-ABL transduced WT and Scd1-/- bone marrow cells with imatinib, and 
found that upon imatinib treatment, survival of recipients of BCR-ABL transduced WT 
bone marrow cells was significantly longer than recipients of BCR-ABL transduced Scd1-
/- bone marrow cells (Fig. 7C), consistent with a lower percentage of leukemia cells in the 
presence of Scd1 (Fig. 7D).  
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Figure 7. Scd1 mediates the inhibitory effect of imatinib on CML development. (A) 
Microarray analysis showed that imatinib treatment induced Scd1 expression in LSCs. 
(B) Real time RT-PCR showed that imatinib treatment induced Scd1 expression in 
leukemia cells. (*, P<0.05). (C) Kaplan-Meier survival curve for imatinib treated 
recipients of BCR-ABL transduced WT and Scd1-/- bone marrow cells (n=5-8 mice per 
group; P=0.002). (D) FACS analysis showed the percentages of leukemia cells in PB of 
recipients of BCR-ABL transduced WT and Scd1-/- bone marrow cells at day 4, 7 and 20 
after imatinib treatment. 
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Figure 7. Scd1 mediates the inhibitory effect of imatinib on CML development 
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Scd1 does not affect normal HSCs 
Scd1 is a suppressor of LSCs in CML mice (Figure 3), we wondered whether this 
inhibitory effect is specific to LSCs with no effect on normal HSCs. We analyzed non-
BCR-ABL-expressing (GFP-) HSCs (GFP-Lin-c-Kit+Sca-1+), LT- (GFP-Lin-c-Kit+Sca-
1+CD34-) and ST- (GFP-Lin-c-Kit+Sca-1+CD34+) HSCs in CML mice receiving BCR-
ABL-transduced WT or Scd1-/- bone marrow cells. We did not observe any significant 
differences in the percentages and numbers of these cell populations between the two 
groups (Fig. 8A). This result suggests that Scd1 does not suppress normal HSCs. To 
confirm this observation, we directly analyzed HSCs and progenitors in bone marrow of 
WT and Scd1-/- mice. We found that the percentages of total HSCs (Lin-Sca-1+c-Kit+), 
LT-HSCs (Lin-Sca-1+c-Kit+CD34- Flk-2-), ST-HSCs (Lin-Sca-1+c-Kit+CD34+ Flk-2-), 
and MPP (Lin-Sca-1+c-Kit+CD34+ Flk-2+) in bone marrow of Scd1-/- mice were similar to 
those in WT mice (Fig. 8B). Although the percentage of GMP (Lin-Sca-1+c-
Kit+CD34+FcyRII/IIIhi) was modestly higher in Scd1-/- mice than that in WT mice, the 
percentages of CMP (Lin-Sca-1+c-Kit+CD34+FcyRII/IIIlo) and MEP (Lin-Sca-1+c-
Kit+CD34-FcyRII/IIIlo) in bone marrow were similar between Scd1-/- and WT mice (Fig. 
8B).  In addition, Scd1-/- mice had a normal distribution of mature myeloid cells (Gr-
1+Mac-1+) and B lymphoid cells (B220+) (Fig. 8C).  
To determine whether Scd1 affects the self-renewal capacity of HSCs, we did a 
competitive repopulation assay. 2 x 105 bone marrow cells from WT (CD45.2) or Scd1-/- 
(CD45.2) mice were transplanted into lethally irradiated CD45.1 mice along with equal 
number of WT CD45.1 competitor bone marrow cells. Analysis of these chimeric mice 
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was done by FACS during 1-4 months after the bone marrow transplantation. We found 
that the percentages of WT and Scd1-/- donor-derived myeloid cells (Gr-1+, Mac-1+), B 
cells (B220+), and T cells (CD3e+) in peripheral blood were similar at 4 and 8 weeks after 
BMT; however the percentage of Scd1-/- donor-derived myeloid cells  at 12 and 16 
weeks, and the percentages of Scd1-/- donor-derived B and T cells at 16 weeks were 
slightly higher than those of WT donor-derived cells (Fig. 8D), although the difference 
was not statistically significant. At 16 weeks, we directly compared the percentages of 
donor-derived WT and Scd1-/- HSCs in bone marrow, and we did not observe a 
significant difference (Fig. 8E). Together, these results indicate that Scd1 does not affect 
the function of normal HSCs. 
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Figure 8. Scd1 deficiency does not affect the function of normal HSCs. (A) The total 
numbers and percentages of HSCs (GFP- Lin-c-Kit+Sca-1+), LT-HSCs (GFP- Lin-c-
Kit+Sca-1+CD34-), and ST-HSCs (GFP- Lin-c-Kit+Sca-1+CD34+) in the GFP- cell 
population of recipients of BCR-ABL transduced WT and Scd1-/- bone marrow cells were 
compared. (NS, non significance) (B) The percentages of normal stem cells and 
progenitors from WT and Scd1-/- bone marrow (n=4) were compared. HSC: Lin-c-
Kit+Sca-1+; LT-HSC: Lin-c-Kit+Sca-1+CD34-Flk-2-; ST-HSC: Lin-c-Kit+Sca-
1+CD34+Flk-2-; MPP: Lin-c-Kit+Sca-1+CD34+Flk-2+; Progenitor:  Lin-c-Kit+Sca-1-; 
CMP: Lin-c-Kit+Sca-1-CD34+FcγRII/IIIlo; GMP: Lin-c-Kit+Sca-1-CD34+FcγRII/IIIhi; 
MEP: Lin-c-Kit+Sca-1-CD34-FcγRII/IIIlo. (C) The percentages of myeloid (Gr-1+) and B 
cells (B220+) in bone marrow of WT and Scd1-/- mice were compared. Mean values (± 
s.e.m) are shown. (D) Competitive repopulation assay for the effect of Scd1 on normal 
HSCs. FACS analysis of the percentage of donor-derived (CD45.2) myeloid (Gr-1+, Mac-
1+), B cells (B220+), T cells (CD3e+) in PB of recipients of normal bone marrow cells 
from WT and Scd1-/- mice. (E) FACS analysis of the donor-derived (CD45.2+) HSCs in 
the bone marrow of recipients of WT and Scd1-/- mice. (n=8 mice per group) Mean values 
(± s.e.m) are shown. 
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Figure 8. Scd1 deficiency does not affect the function of normal HSCs 
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Discussion 
Our study supports a critical role for Scd1 in CML development through 
specifically regulating LSCs but not normal HSCs. In our previously published study, we 
identified another lipid-metabolic gene, arachidonate 5-lipoxygenase (Alox5), required 
for functional regulation of LSCs but not normal HSCs 85. Our identification of Scd1 in 
this study strengthens the feasibility to specifically target LSCs in the treatment of CML.  
Although dysregulated expression of Scd1 has been observed in several human 
cancers 238, to our knowledge this study provides the first evidence for the role of Scd1 in 
hematopoiesis and leukemogenesis. Previous data indicated Scd1 regulated cancer cell 
proliferation and survival. Knockdown Scd1 by siRNA significantly reduced the survival 
of multiple human tumor cell lines 239. In contrast, in this study, we find that Scd1 plays a 
tumor suppressive role in LSCs through regulating apoptosis of LSCs. This indicates that 
Scd1 plays different roles in different cancers. Additionally, while CML development 
was accelerated in the loss of Scd1, the development of Ph+ B-ALL could be unimpaired. 
It is known that CML is a stem cell disease while the cell of origin for ALL is a 
committed B cell progenitor 23. Therefore, the distinct roles of Scd1 in different leukemia 
subtypes suggest that Scd1 acts in a cell type-specific manner. 
With respect to the molecular basis for the functional regulation of LSCs by Scd1, 
we show that Scd1 deficiency results in dysregulated expression of apoptosis-related 
genes, including decreased expression of Pten and p53, and increased expression of Bcl-
2, which is consistent with the observation from other groups showing that Scd1 
deficiency reduces cardiac apoptosis in ob/ob mice due to increased expression of 
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antiapoptotic factor Bcl-2 240. In addition, we also show that treatment with PPARγ 
agonist induces the apoptosis of leukemia cells, which is associated with a higher 
expression of Scd1, Pten and p53. A recent study showed that unsaturated fatty acid 
affected Pten expression in hepatoma cells through regulating microRNA mediated Pten 
mRNA stability, which depends on the mTOR and NF-κB pathways 241. Our results show 
that Scd1 regulates Pten, p53 and Bcl2 at the transcriptional and/or post-transcriptional 
level. However, detailed mechanisms by which Scd1 regulates expression of Pten, p53 
and Bcl2 need to be further investigated in the future. 
 
Material and methods 
Mice. Scd1-/-, C57BL/6J-CD45.1, and C57BL/6J-CD45.2 mice were obtained from mice 
were purchased from The Jackson Laboratory. All mice were in C57BL/6J background, 
and were bred and maintained in a temperature- and humidity-controlled environment 
and given unrestricted access to 6% chow diet and acidified water. 
Generation of retrovirus stocks. The retroviral constructs MSCV-IRES-GFP, MSCV-
BCR-ABL-IRES-GFP, MSCV-BCR-ABL-IRES-Scd1, MSCV-Scd1-IRES-humanCD4 
MSCV-BCR-ABL-IRES-Pten-IRES-GFP were used to generate high-titer, helper-free, 
replication-defective ecotropic virus stock by transient transfection of 293T cells as 
previously described 23.  
Lentiviral transduction and shRNA-mediated knockdown of p53 and Bcl2. 
Lentiviral shRNA vector pLKO.1 were purchased from OpenBiosystems. Sequences of 
p53 and Bcl2 shRNA were as follows: shRNA-p53: sense 5’- ccagtctacttcccgccataa-3’: 
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shRNA-p53 antisense 5’-ttatggcgggaagtagactgg-3’; shRNA-Bcl2 sense 5’-
cgtgatgaagtacatacatta -3’; shRNA-Bcl2 antisense 5’-taatgtatgtacttcatcacg-3’. For 
transduction of shRNAs, bone marrow cells from CML mice were transfected with 
lentiviral shRNA, and 24 hours later, were selected under puromycin (2.5µg/ml) for 48 
hours to enrich shRNA-expressing cells. 
Bone marrow transduction/transplantation. 8 to 12 week-old C57BL/6 mice were 
used for bone marrow transduction/transplantation. Retroviral transduction and 
transplantation of mouse bone marrow cells for inducing CML and B-ALL by BCR-ABL 
had been described previously 23,86,232. Diseased mice were evaluated by flow cytometric, 
histopathological and molecular analyses. For secondary transplantation, equal number of 
bone marrow cells from primary CML mice was transplanted into lethally irradiated 
recipient mice. For drug treatment, rosiglitazone (GlaxoSmithKline) and imatinib 
(Novartis) were given orally in a volume of less than 0.3 mL by gavage (100mg/kg, twice 
a day for rosiglitazone, and 100mg/kg, twice a day for imatinib) beginning at 8 days after 
BMT, and continuing until the morbidity or death of the mice with leukemia.   
Flow cytometry analysis. Hematopoietic cells were collected from bone marrow and 
peripheral blood of CML mice for FACS analysis. For stem cell analysis, five mice from 
each experimental group were sacrificed at day 14 after BMT to collect bone marrow 
cells. Red blood cells (RBCs) were depleted using RBC lysis buffer (containing NH4Cl, 
KHCO3, and EDTA). To stain the cells with antibodies, bone marrow cells were 
suspended in staining medium (Hank’s Balanced Salt Solution (HBSS) with 2% heat-
inactivated calf serum), and incubated with biotin-labeled lineage antibody cocktail 
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containing a mixture of antibodies against CD3, CD4, CD8, B220, Gr-1, Mac-1 and 
Ter119 at 4oC for 15 min. After washing, the fluorochrome-labeled secondary antibody 
(APC-Cy7-conjugated Streptavidin) for recognizing biotin and PE-conjugated c-Kit and 
APC-conjugated Sca-1 antibodies were added to the cells for 15min at 4oC in the dark. 
Long-term and short-term LSCs were distinguished by the CD34 antibody. CML stem 
cell population (GFP+Lin-c-Kit+Sca-1+) was analyzed by FACS. All these antibodies 
were purchased from eBioscience. 
         Cell cycle analysis of LSCs was performed by staining cells with antibodies in 
combination with Hoechst 33342 for 90 min at 37oC, followed by flow cytometry 
analysis. To analyze apoptosis of bone marrow cells, the cells were stained with Annexin 
V (eBioscience) for 15 min at room temperature. 7AAD was added before flow 
cytometry analysis. 
Leukemia stem cell culture. For mouse leukemia stem cell culture, bone marrow cells 
isolated from CML mice were cultured in vitro in the presence of stemspan SFEM, SCF, 
IGF-2, TPO, heparin, and α-FGF as reported previously for culture of hematopoietic stem 
cells. For in vitro treatment, rosiglitazone (Cayman Chemical) was dissolved in DMSO.  
In vitro methylcellulose colony formation assay.  
LSCs (GFP+Lin-Sca-1+c-Kit+) from bone marrow of CML mice receiving BCR-ABL-
transduced WT or Scd1-/- bone marrow cells were sorted by FACS, and were cultured in 
methylcellulose medium (Methocult GF M3434; Stem Cell Technologies) at 37oC in 
humidified air for 7 days. Colonies were counted under microscope. 
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Chromatin immunoprecipitation of RNA Polymerase II. ChIP assays were performed 
as previously described (Sheng et al., 2009).  Briefly, 3x107 leukemia cells from WT and 
Scd1-/- CML mice were incubated with 1% formaldehyde for 10 min at room temperature 
before crosslinking was quenched by addition of 0.125 M glycine. Cells were collected 
by centrifugation and lysed in lysis buffer containing 50mM Tris-HCl (pH 8.0), 10 mM 
EDTA, 0.5% SDS, proteinase inhibitors and phosphatase inhibitors. The cells suspension 
was sonicated  seven times for 10s each with 2-min intervals on ice using a Misonix 
Sonicator 3000 at output 8. Sonicated chromatin was then incubated at 4oC overnight 
with 5 µg polymerases II antibody (Avaon). Immunoprecipitated DNA was amplified by 
real-time PCR using the following primers: Pten promoter-sense (5’-cgggactctttgtgcactg-
3’), Pten promoter-antisense (5’-gcggctcaactctcaaactt-3’), p53 promoter-sense (5’-
aacagtggcggtccacttac-3’), and p53 promoter-antisense (5’-gggacttgcagagtcaggat-3’), Bcl2 
promoter-sense (5’- ccggcggagaatgaagtaa-3’), and Bcl2 promoter-antisense (5’-
cgcaccctttctcctcct-3’). 
Real time RT-PCR. Total RNA was isolated from GFP+Lin-Sca-1+c-Kit+ bone marrow 
cells from mice using the RNeasy Mini kit (Qiagen, CA). cDNA was synthesized using 
the Ovation-Pico cDNA synthesis method. All real time PCR reactions were done using 
the Applied Biosystems 7500. 25µL reaction system was composed of 12.5µL SYBR 
Green, 2.5µL 20uM primer mixture, 10ng cDNA and nuclease-free water. All 
experiments were performed in triplicate. Beta-actin was used as the internal control. The 
primer sequences were listed as following: Scd1: sense: 5’-ttcttacacgaccaccacca-3’; 
antisense: 5’-gcaggagggaaccagtatga-3’; Pten: sense: 5’-acaccgccaaatttaactgc-3’; 
   
165 
antisense: 5’-tacaccagtccgtccctttc-3’; p53: sense: 5’-agagaccgccgtacagaaga-3’; antisense: 
5’-ctggtagcatgggcatccttt-3’; Bcl2: sense: 5’-ctggcttcttctccttccag-3’; ansisense: 5’- 
gacggtagcgacgagaggaag-3’; ß-actin: sense: 5’-atggaatcctgtggcatcca-3’; antisense: 5’- 
cgctcaggaggagcaatgat-3’.  
Statistical analysis. Results are given as mean ± s.e.m. Statistical analysis was 
performed by Students’s t test. For survival curves, p values were obtained using a Log-
rank test. 
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CHAPTER V  
FINAL SUMMARY AND DISCUSSION 
 
Studies on CML from the identification of the first cancer-associated 
chromosomal abnormality (Ph+) to the subsequent development of TKIs that inhibit 
BCR-ABL kinase activity in CML have served as a paradigm for cancer research and 
therapy. Although TKIs have achieved great success in the treatment of CML patients, of 
which 87% of chronic phrase CML patients treated with imatinib as initial therapy show 
a complete cytogenetic response after 5 years of follow-up43, resistance to TKI and the 
subsequent disease relapse have been frequently observed in patients upon 
discontinuation of this therapy, especially in patients with advanced-stage disease59,61,242. 
Two major reasons for the development of resistance are generally agreed. The first 
reason is the mutations in the BCR-ABL kinase domain that lead to the change of the 
BCR-ABL kinase domain conformation, thereby blocking the inhibition of BCR-ABL 
kinase activity by TKIs. Studies on the structure and dynamics of c-ABL/BCR-ABL, 
along with the development of computational biology, have led to the development of 
alternative strategies to target other BCR-ABL motifs. In this regard, several inhibitors 
have been developed. A highly selective non-ATP competitive inhibitor of BCR-ABL, 
GNF-2/5, which can target the C-terminal myristoyl pocket of ABL, was identified 
through a high-throughput screen54,55. DCC-2036, which regulates the conformational 
control inhibition and potently inhibits both unphosphorylated and phosphorylated ABL1 
through inducing an inactive conformation, exhibits efficacy against the T315I mutant in 
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vivo56. An engineered protein 7c12, which disrupts the SH2-kinase domain interface, 
inhibits BCR-ABL kinase activity and leukemogenesis243. As these motifs are remote 
from the kinase domain and would be unaffected by kinase mutations that confer the 
ability of TKI-resistance, BCR-ABL bearing mutations in the kinase domain exhibit 
higher sensitivity to these inhibitors. This approach helps to overcome drug resistance 
resulting from BCR-ABL kinase domain mutations.  
The second reason for the development of resistance to TKIs and subsequent 
disease relapse is the existence of a rare population of LSCs resistant to TKIs. It has been 
shown that LSCs in CML are insensitive to imatinib62, and cannot be eliminated 
completely by TKIs in CML mice and patients63,64. Eradication of LSCs appears to be 
extremely difficult, calling for a greater understanding of the biology of LSCs. Studies 
from our group and others have revealed that LSCs of CML form a hierarchy similar to 
that seen in normal hematopoiesis, in which a rare stem cell population with limitless 
self-renewal potential gives rise to progenies that lack such potential33,63. However, we 
hypothesize that LSCs possess biological features that are different from those of HSCs 
and are critical for their malignant characteristics. Therefore, based on these concerns, in 
my thesis work, using BCR-ABL-induced CML as a disease model for LSCs, I attempted 
to understand the molecular mechanisms of LSC maintenance by comparing the gene 
expression profiling of normal HSCs and LSCs. I found that the HIF1α signaling 
pathway positively regulates the self-renewal of LSCs. I also identified two novel 
negative regulators, Blk and Scd1, which play tumor suppressor roles in LSCs. 
 
The positive regulatory pathway---HIF1α in LSCs 
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In this part of my work, I found that the HIF1α signaling pathway is active in 
BCR-ABL-expressing LSCs compared to normal HSCs. Recent studies showed that 
HIF1α plays an important role in cancer progression by activating the transcriptional 
programs necessary for maintaining the ability of self-renewal and multipotency of 
cancer stem cells in glioma and lymphoma94,126-128.  In this part of our work, we provided 
the first evidence of an essential role for HIF1α in regulating self-renewal of LSCs of 
CML. We demonstrated a loss of colony-forming potential and a failure to induce CML 
disease in the secondary recipients by HIF1α-/- LSCs. Therefore HIF1α signaling joins 
the ranks of the positive regulatory pathways in LSC maintenance, which include Wnt/β-
catenin, hedgehog, FoxO and Bcl6 pathways.  
Another exciting finding in this part of the work is that LSCs of CML are more 
dependent on HIF1α activity than HSCs, which is based on the following evidence we 
observed. First, deletion of HIF1α results in a more significant reduction of the self-
renewal ability of LSCs, as we observed that compared to wild type LSCs, HIF1α -/- 
LSCs gave rise to less colonies in all three serial replating. However, compared to WT 
HSCs, HIF1α -/- HSCs generated similar numbers of colonies in the 1st and 2nd plating. 
Second, deficiency of HIF1α induced apoptosis of LSCs but not HSCs. Finally, HIF1α-/- 
LSCs but not HSCs displayed lower expression levels of the HIF1α targets VEGF and 
GLUT1, and microarray analysis also showed significant changes of HIF1α target genes 
in HIF1α-/- LSCs compared to HIF1α-/- HSCs. Given the observation that enhanced 
HIF1α expression and undetectable levels of pVHL were found in cancer stem cells of 
   
169 
lymphoma, it is possible that leukemia stem cells require higher levels of HIF1α for their 
maintenance than normal stem cells, thereby making them more sensitive to HIF1α 
inhibition94,244. Together, these findings make it possible to effectively target LSCs with 
less harm to their normal stem cell counterparts.  
However, several important questions need to be addressed in the future.  
1) How does HIF1α regulate the expression of p16Ink4a and p19Arf? It is known 
that p16Ink4a and p19Arf are encoded by the INK4-ARF locus, and these locus genes are 
epigenetically silenced in HSCs but become active upon exposure to oncogenic stress, 
thereby inducing cell senescence or apoptosis245. INK4-ARF deletions frequently occur in 
Ph+ ALL, and Arf gene loss enhances oncogenicity and attenuates responsiveness to 
imatinib in a mouse model of BCR-ABL-induced ALL246,247. We found that HIF1α 
deletion induced a tumor suppressor response in LSCs through induction of expression of 
p16Ink4a and p19Arf. We also showed that knockdown of p16Ink4a and p19Arf rescued the 
defective colony-forming ability of HIF1α -/- LSCs. It is still unclear how HIF1α mediates 
expression of p16Ink4a and p19Arf. Through analyzing the promoter sequences of p16Ink4a 
and p19Arf, we did not find the HIF-responsive element (HRE) that mediates the binding 
of HIF1α to its targets, suggesting that HIF1α does not directly regulate p16Ink4a and 
p19Arf. Therefore, there must be a mediator which links HIF1α with p16Ink4a/p19Arf. It is 
well known that the INK4-ARF locus is repressed by members of the Polycomb group 
(PcG), including Bmi1248. Bmi1-/- MEFs exhibit accumulation of p15Ink4b, p16Ink4a and 
p19Arf 249. Conversely, overexpression of Bmi1 represses the expression of p16Ink4a and 
p19Arf in HSCs, thereby rescuing the defective reconstitution ability of HSCs caused by 
   
170 
HIF1α deficiency 181. Together, these data suggest that Bmi1 might mediate the 
regulation of p16Ink4a and p19Arf by HIF1α in LSCs. Therefore, it will be helpful to 
examine whether HIF1α deletion down-regulates Bmi1 expression in LSCs, although a 
previous study showed that overexpression of HIF1α, or exposure to hypoxic conditions, 
up-regulated Bmi1 mRNA and protein levels in tumor-initiating cells of head and neck 
squamous cell carcinoma250.  
2) The efficiencies and effects of echinomycin or other HIF1α inhibitors, such as 
PX-478251, on LSCs of CML need to be investigated. Although CSCs in lymphoma 
exhibit high sensitivity to the HIF1α inhibitor, echinomycin94, it is unknown whether 
echinomycin has the same effect on CML LSCs. These studies will be investigated using 
our CML mouse model and primary CML cells from human patients.  
3) What are the functions of other targets of the HIF1α pathway in LSCs? Further 
analyzing the gene expression profiling of HIF1α-/- LSCs will be helpful to answer this 
question. Additionally, we observed a lower expression level of Alox5, which is required 
for CML LSCs85, in HIF1α-/- LSCs, suggesting that Alox5 might be one of the 
downstream genes of HIF1α. Therefore the relationship between Alox5 and HIF1α will 
need to be examined through biochemical analysis, such as the luciferase assay, ChIP, 
and biological assays, such as the colony forming assay.  
4) It will be of interest to investigate how a hypoxic environment affects LSCs, 
given the critical role of HIF1α in mediating the effect of hypoxia on normal 
hematopoiesis178,180. The interaction between HSCs and the bone marrow niche, which is 
considered as a relatively hypoxic microenvironment, is critical for the maintenance of 
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normal HSC quiescence. A recent study revealed that HSCs are hypoxic in the niche and 
display a higher expression of HIF1α181. Accumulating evidence indicates that LSCs 
occupy and receive important signals from the microenvironment252. However, many 
fundamental questions remain to be examined. For example, do LSCs and their normal 
counterparts require different expression levels of HIF1α for their self-renewal? What is 
the role of HIF2α in mediating hypoxia influence on LSCs? Therefore, it is reasonable to 
consider hypoxia as a signal provided by the bone marrow niche for LSC maintenance, 
and it is necessary to investigate the molecular mechanisms of how hypoxia regulates 
LSCs in the future. 
 
The negative regulatory pathways----Blk and Scd1 in LSCs  
 
Our strategy is to identify key regulators that have essential roles in LSCs but not 
their normal stem cell counterparts. In this part of my work, Blk and Scd1 were chosen 
for further functional study based on our comparison of the gene expression profiling of 
LSCs and HSCs. We found both Blk and Scd1 are significantly down-regulated in CML 
LSCs, which is consistent with the results of a microarray on human CML showing that 
Blk and Scd1 expression are markedly down-regulated in the majority of CML patients in 
the chronic phase, accelerated phase and blast crisis. Additionally, we identified that both 
Blk and Scd1 function as tumor suppressors in CML through their effects on the 
proliferation and apoptosis of LSCs. The roles of the classic negative regulatory 
pathways, such as p53 and Pten, have been investigated121,253. We have shown that 
deletion of Pten accelerates CML development; conversely, enforced expression of Pten 
markedly delays the development CML121. We further proved that Pten affects the 
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reconstitution ability of CML LSCs via regulating the cell cycle and apoptosis of LSCs. 
In this part of the thesis, our findings reveal that Blk and Scd1 represent two novel 
negative regulators for CML LSCs, thereby contributing to understanding the genetic 
basis and underlying biology of CML LSCs.  
Most importantly, in this part of my work, we found that both Blk and Scd1 
specifically affect CML LSCs but do not markedly affect normal hematopoiesis. 
Compared to wild type mice, Blk-/- or Scd1-/- mice display similar percentages of different 
stem cell populations including long term and short term HSCs. A series of functional 
assays, such as a competitive repopulation assay and rescue assay were performed to 
assess the functions of  Blk-/- or Scd1-/- HSCs in normal hematopoiesis. We found that 
deletion of Blk or Scd1 did not obviously affect the function of normal HSCs. Given their 
critical role in CML LSCs, thereby affecting the development of CML, we are confident 
to propose that Blk and Scd1 are unique regulators of CML LSCs but not their normal 
stem cell counterparts. Interestingly, using high-throughput screening, Weinberg and 
colleagues identified specific inhibitors of epithelial CSCs131, implying the existence of 
molecular pathways specific to CSCs that could serve as effective and selective 
therapeutic targets. In our lab, we identified the Alox5 gene as an important regulatory 
gene in LSCs but not normal HSCs85 and showed that Alox5 deficiency impaired CML 
development by blocking stem cell differentiation. Therefore, the findings in this part of 
my work strengthen the feasibility of specifically targeting LSCs in the treatment of 
CML.  
   
173 
The major issue in CML biology is to understand why LSCs are insensitive to 
TKI monotherapy. Another exciting finding in this thesis might provide the molecular 
mechanism for the insensitivity of LSCs to TKI. We found that the down-regulation of 
Blk is independent of BCR-ABL kinase activity, shown by the finding that imatinib 
treatment failed to restore the down-regulation of Blk in LSCs. On the one hand, this 
finding in here is in line with our previous data showing that Src family kinases are 
independent of BCR-ABL kinase activity, as inhibition of BCR-ABL kinase activity 
cannot affect the activation of Src kinases by BCR-ABL86. This finding confirms the idea 
we proposed previously that there is BCR-ABL kinase activity-independent pathways in 
LSCs254. On the other hand, considering the recent studies demonstrating that human 
CML stem cells do not depend on BCR-ABL activity for their survival 64,84, the study in 
this part suggests that the BCR-ABL kinase independent pathways are common 
phenomena in CML stem cells, and provides the explanation of how TKIs cannot 
eliminate CML LSCs. This suggests that TKI therapy alone is not enough for curing 
CML. In our lab, we identified several genes, such as Alox5 and Tph1, which are 
independent of BCR-ABL kinase activity85. Therefore, from a therapeutic standpoint, the 
work described in this part of the thesis provides the rationale for the alternative 
strategies that are developed to target these kinase independent pathways for eliminating 
CML LSCs.  
However, several important questions remain to be answered.  
1) What is the underlying mechanism by which Blk suppressed LSCs? Although 
we have shown that p27 mediates the inhibitory effect of Blk on LSCs, it is likely that 
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there are other downstream Blk target genes. For example, we observed that 
overexpression of Blk markedly increased the apoptosis of LSCs, implying that Blk 
might regulate the apoptotic pathways. Therefore, it is important to investigate whether 
the apoptotic related genes (such as p53 and Bcl2) mediate the function of Blk in LSCs.   
2) Regarding Scd1, it remains unclear how BCR-ABL inhibits Scd1 expression. 
As it is known that Scd1 expression is regulated by several transcriptional factor, 
including SREBP-1c, PPAR, and LXR, it is important to investigate whether these 
factors mediate the downregulation of Scd1 in LSCs.  
3) The detailed mechanisms of how Scd1 suppresses CML development via 
affecting the function of LSCs need to be investigated further. How does Scd1 influence 
the expression of Pten, p53, and Bcl2? What is the mediator between Scd1 and Pten, p53 
or Bcl2? Do other pathways, excluding Pten, p53 and Bcl2, mediate the effect of Scd1 on 
LSCs? For example, a previous study showed that deletion of Scd1 activates the insulin 
signaling pathway173. On the other hand, BCR-ABL activates IGF-1 signaling, and 
blocking this pathway with small molecule drugs or shRNA decreases proliferation and 
enhances apoptosis of leukemia cells255. Therefore, it is reasonable to assess whether the 
insulin pathway is responsible for the effect of Scd1 on LSCs.   
4) The mechanism by which a PPARγ agonist inhibits LSCs is unclear. PPARs 
are ligand-binding transcription factors belonging to the nuclear receptor family. PPARs 
are involved in regulating lipid metabolism, cell growth and survival. It has been shown 
that activation of the PPAR pathway with a dual α and γ ligand TZD18 induces apoptosis 
and inhibits proliferation of human CML cells 256,257. Although rosiglitazone synergized 
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with imatinib to delay CML development, rosiglitazone alone failed to do so. One 
possibility is that rosiglitazone alone is not effective enough to prevent lung 
hemorrhages, a major cause of death of CML mice. Another possibility is that the level of 
Scd1 induced by rosiglitazone is not high enough to delay CML development. PPAR 
agonists are anti-inflammatory agents as they inhibit expression of several 
proinflammatory cytokines and most chemokines 258. The role of anti-inflammatory 
agents on LSCs is supported by our previous study showing that the anti-inflammatory 
drug Zileuton that inhibits the function of Alox5 gene and prolongs survival of CML 
mice85. Therefore, it is reasonable to hypothesize that the Alox5 inhibitor may synergize 
with PPAR agonists in the elimination of LSC. The in vitro/in vivo treatment assay can be 
used to observe if a deeper response can be predicted.  
 
Strategy for targeting LSCs---- combination therapy 
 
Targeting leukemia stem cells has become a common proposal for curing CML. 
Taken together, based on the findings in this thesis, I propose that combination therapy of 
TKI with drugs that target the key regulators of LSCs will be the promising and 
effectively therapeutic strategy for CML treatment (Figure 1). Several lines of evidence 
indicate that inactivation of key pathways for CML stem cell maintenance could 
contribute to CML therapy. Pharmacological blockade of Hedgehog signaling by 
cyclopamine92,110, inhibition of the TGFβ-FoxO pathway by Ly364947, inactivation of 
Bcl6 by the retro-inverso Bcl6 peptide inhibitor RI-BPI, or inhibition of Alox5 by 
zilueton, impair CML development by suppressing LSCs. Similarly, inhibition of the 
HIF1α pathway by echinomycin would effectively eliminate LSCs. Interestingly, given 
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the specific roles of Blk and Scd1 in CML LSCs, either restoration of Blk expression, or 
enhancement of Scd1 activity, provides an attractive strategy for specifically targeting 
LSCs in CML. 
 
 
Figure 1. The combination of inhibiting BCR-ABL by TKIs and targeting key 
regulators of LSCs in CML treatment. TKI treatment plus inhibition of positive 
pathways, or restoration the expression of negative regulators could effectively target 
LSCs for curing CML. 
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